🏷

Classifications

Harrison's Part

🔗

Mappings

MONDO

MONDO:0007739 Huntington disease

Orphanet lists MONDO:0007739 as an exact cross-reference for the ORPHA:399 Huntington disease record.

📘

Definitions

1

Orphanet Huntington disease definition

Orphanet defines Huntington disease as a rare central nervous system neurodegenerative disorder characterized by choreatic movements, psychiatric and behavioral disturbances, and dementia.

CASE_DEFINITION

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia."

Orphanet's definition supports the entry's high-level disease framing and cardinal clinical domains.

👪

Inheritance

1

Autosomal Dominant HP:0000006

HD follows autosomal dominant inheritance with complete penetrance at 40+ CAG repeats. Reduced penetrance occurs with 36-39 repeats. Anticipation is observed, particularly with paternal transmission due to meiotic instability of the CAG repeat.

Autosomal dominant inheritance Penetrance: COMPLETE

Parent-of-origin effect: Strong paternal transmission bias for large intergenerational expansions. Male meiotic instability of the CAG tract drives anticipation, and the effect is most extreme in juvenile-onset HD, where the mutant HTT allele is paternally inherited in roughly 80% of cases.

Show evidence (4 references)

PMID:31045518 SUPPORT Human Clinical

"Where data were available, the median age of onset was 9 years, 52% were female, the mutant HTT allele was transmitted paternally in 80% of cases, and the median CAG repeat length was 64."

Quantifies the paternal transmission bias and median repeat length recorded in parent_of_origin_effect, pooled across 285 juvenile-onset cases.

PMID:20301482 SUPPORT Human Clinical

"Expansion and contraction of CAG repeat length can occur with maternal or paternal transmission; however, expansion occurs far more commonly in paternal transmission and contraction occurs more commonly in maternal transmission."

GeneReviews, the authoritative expert clinical reference for HD, corroborates the directional parent-of-origin asymmetry recorded here: expansion is paternally biased while contraction is maternally biased. This is the general-HD statement underlying the more extreme ~80% paternal transmission seen specifically in juvenile-onset cases.

PMID:41233526 SUPPORT Human Clinical

"Huntington disease is a fatal, inherited, neurodegenerative disease caused by a CAG repeat expansion in the huntingtin gene (HTT), resulting in a toxic polyglutamine tract in the huntingtin protein."

Confirms HD is an inherited disorder caused by CAG repeat expansion in HTT.

+ 1 more reference

◆

Subtypes

3

Adult-onset Huntington Disease

Classical form with onset typically between ages 30-50, CAG repeat length 36-55, characterized by chorea, cognitive decline, and psychiatric symptoms.

Juvenile-Onset Huntington Disease MONDO:0016621

approximately 1-5% of clinically manifest Huntington disease cases HTT hgnc:4851

Juvenile-onset Huntington disease (JHD/JOHD) is defined by motor symptom onset at or before age 20 and accounts for roughly 1-5% of manifest HD. It is driven by the longest CAG expansions - repeat length is usually above 55, around half of cases carry 60 or more repeats, and childhood-onset cases can exceed 80 - which arise by anticipation, most often through paternal transmission (about 80% of cases). The motor phenotype inverts that of adult-onset disease: chorea is uncommon early, while rigidity, axial bradykinesia, dystonia, dysarthria and gait disturbance dominate, and epilepsy, ataxia, spasticity and developmental regression are JHD-specific features. Presentation is frequently non-motor first (behavioural disturbance, declining school performance), which drives misdiagnosis and diagnostic delay. Progression is faster and disease duration shorter than in adult-onset HD. Terminology note: this subtype is historically called the "Westphal variant", but the European Huntington Disease Network JHD working group advises against that usage because the hypokinetic-rigid Westphal phenotype also occurs in adult-onset HD and so is not specific to juvenile onset. The term is retained here only as a synonym, and the preferred label is juvenile-onset HD.

Show evidence (6 references)

PMID:31045518 SUPPORT Human Clinical

"Juvenile-onset Huntington's disease (JHD) is defined by onset at the age of 20 or younger and represents approximately 5% of all HD cases."

Establishes the age-at-onset boundary and the approximate share of HD cases that define this subtype.

PMID:39121132 SUPPORT Human Clinical

"Juvenile-onset Huntington's disease (JHD) represents 1-5% of Huntington's disease (HD) patients, with onset before the age of 21."

Supports the 1-5% subtype frequency band recorded in subtype_frequency.

PMID:38669553 SUPPORT Human Clinical

"Repeat length in JHD is usually > 55 and caused by anticipation, usually via paternal transmission."

European Huntington Disease Network JHD working group review supporting the repeat-length range, anticipation, and paternal transmission bias.

+ 3 more references

Late-Onset Huntington Disease

Onset over 60 years of age, accounting for roughly 4.4-11.5% of individuals with HD, and often with a slower, milder course than the typical fourth-decade onset.

Show evidence (2 references)

PMID:28671137 SUPPORT Other

"BACKGROUND: Although the typical age of onset for Huntington's disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age)."

Defines late-onset HD as onset over 60 years of age, occurring in 4.4-11.5% of individuals with HD, supporting the corrected subtype description.

PMID:17390259 REFUTE Other

"Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment."

Refutes any characterization of late onset as beginning after age 50; HD most typically manifests between ages 35 and 45, so the late-onset subtype is best defined by onset over 60 rather than over 50.

◈

Mechanistic Hypotheses

5

Toxic Gain-of-Function (Polyglutamine Aggregation)

canonical_toxic_gain_of_function CANONICAL

Evidence balance 6 support

The expanded polyglutamine tract in mutant huntingtin confers a toxic gain-of-function through protein misfolding, oligomerization, and aggregation into inclusion bodies. This is the widely accepted primary disease mechanism, with polyQ expansion beyond the pathogenic threshold (~36 repeats) driving neurodegeneration predominantly in the striatum.

Retained as CANONICAL. The 2026 openscientist hypothesis-search report (kb/hypotheses/Huntingtons_Disease/canonical_toxic_gain_of_function) reviewed 81 papers and found the gain-of-function model robustly validated, but identified three critical refinements: (1) **somatic CAG repeat instability** driven by MMR genes (MSH3, MSH2, PMS1, MLH1, FAN1) is an upstream amplifier that expands repeats far beyond the inherited length in vulnerable striatal MSNs — inherited repeat length is necessary but not sufficient for toxicity; (2) gain-of-function operates alongside **loss of normal HTT function** (aggregates sequester wild-type HTT) rather than independently; (3) RNA-level toxicity from expanded CAG repeats is an additional pathogenic layer independent of protein aggregation. The first-generation HTT-lowering trials' disappointing results also signal that simple mHTT removal is insufficient and reinforce the multi-layered model.

Show evidence (6 references)

PMID:22180703 SUPPORT Other

"It is caused by expansion of a polyglutamine tract within the N-terminal domain of the Huntingtin protein. The mutation confers a toxic gain-of-function phenotype, resulting in neurodegeneration that is most severe in the striatum."

Explicitly names the toxic gain-of-function phenotype as the consequence of polyQ expansion and links it to striatal neurodegeneration.

PMID:25336039 SUPPORT Other

"The mutational expansion of polyglutamine beyond a critical length produces a toxic gain of function in huntingtin and results in neuronal death. In the course of the disease, expanded huntingtin is proteolyzed, becomes abnormally folded, and accumulates in oligomers, fibrils, and microscopic inclusions."

Directly states the toxic gain-of-function framing and details the aggregation cascade from proteolysis through misfolding to inclusion body formation.

PMID:41233526 SUPPORT Other

"These findings point to somatic CAG repeat expansions"

Major review reframes HD pathogenesis: somatic CAG repeat expansion driven by DNA repair (MMR) gene activity is now recognized as a rate-limiting upstream process that determines disease onset and progression — qualifying the simple gain-of-function model with a necessary upstream-amplifier step.

+ 3 more references

Transcriptional Dysregulation

canonical_transcriptional_dysregulation CANONICAL

Evidence balance 8 support

Mutant huntingtin disrupts transcriptional regulation by sequestering key transcription factors and co-activators (Sp1, CBP, REST/NRSF), leading to widespread downregulation of neuronal survival genes including BDNF. This is a canonical downstream mechanistic layer in HD, linking mutant huntingtin protein interactions to loss of neuronal maintenance programs.

Pathograph links

Transcriptional Dysregulation -> Mitochondrial Dysfunction INDIRECT KNOWN INTERMEDIATES Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure. Intermediates: reduced PGC-1alpha activity; impaired mitochondrial biogenesis and antioxidant defense

Show evidence (8 references)

PMID:11839795 SUPPORT Model Organism

"In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin."

In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.

PMID:11839795 SUPPORT In Vitro

"Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells."

Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.

PMID:11264541 SUPPORT In Vitro

"We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain."

HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.

+ 5 more references

Mitochondrial Dysfunction and Bioenergetic Failure

canonical_mitochondrial_bioenergetic_failure CANONICAL

Evidence balance 3 support

Mutant huntingtin impairs mitochondrial function through reduced oxidative phosphorylation complex activity, disrupted calcium homeostasis, and transcriptional repression of PGC-1alpha. This is a canonical convergent mechanism in HD that links transcriptional dysregulation and mutant huntingtin stress to bioenergetic failure, oxidative damage, and neuronal death, particularly in energy-demanding striatal medium spiny neurons.

Retained as CANONICAL but reframed as a **downstream convergent mediator** rather than an independent initiating event. The 2026 openscientist hypothesis-search report (kb/hypotheses/Huntingtons_Disease/canonical_mitochondrial_bioenergetic_failure) reviewed 76 papers and identified three refinements: (1) the transcriptional-repression-of-PGC-1α pathway (PMID:17018277) is the strongest mechanistic link, validated by genetic and rescue experiments; (2) the "direct mHTT-mitochondria interaction" model is challenged by isolated-mitochondria studies, shifting emphasis toward indirect transcription-mediated mechanisms; (3) GWAS overwhelmingly implicate DNA-repair/somatic-expansion genes — not mitochondrial genes — as rate-limiting modifiers, positioning mitochondrial dysfunction as a downstream amplifier rather than an upstream driver. Failed clinical trials of mitochondrial-targeting agents (CoQ10, creatine) are consistent with this reframing. Bioenergetic failure critically synergizes with NMDAR-mediated excitotoxicity through ATP loss and Mg²⁺-block removal, creating a feedforward loop in energy-demanding striatal MSNs.

Pathograph links

Transcriptional Dysregulation -> Mitochondrial Dysfunction INDIRECT KNOWN INTERMEDIATES Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure. Intermediates: reduced PGC-1alpha activity; impaired mitochondrial biogenesis and antioxidant defense

Show evidence (3 references)

PMID:17018277 SUPPORT Model Organism

"mutant huntingtin causes disruption of mitochondrial function by inhibiting expression of PGC-1alpha"

Identifies PGC-1α transcriptional repression as the strongest mechanistic link from mHTT to mitochondrial dysfunction. PGC-1α KO crossbred with HD KI exacerbates striatal neurodegeneration; PGC-1α restoration via lentivirus is neuroprotective in HD mice — direct causal validation of the canonical pathway.

PMID:19622387 SUPPORT Other

"Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death."

Frames mitochondrial dysfunction as a key pathogenic mechanism linking compromised energy metabolism and oxidative damage to neuronal death.

PMID:23602910 SUPPORT Other

"There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma..."

Links PGC-1alpha impairment to mitochondrial dysfunction in HD, connecting transcriptional dysregulation of mitochondrial biogenesis genes to bioenergetic failure.

NMDA Receptor-Mediated Excitotoxicity

alternative_excitotoxicity ALTERNATIVE

Evidence balance 2 support

Historical but still supported superimposed model proposing that mutant huntingtin and corticostriatal circuit dysfunction enhance NMDA receptor-mediated excitotoxicity in striatal medium spiny neurons. This hypothesis is best viewed as a selective-vulnerability amplifier rather than the sole initiating lesion.

Show evidence (2 references)

PMID:17188796 SUPPORT Other

"Many lines of evidence support a role for neuronal damage arising as a result of excessive activation of glutamate receptors by excitatory amino acids in the pathogenesis of Huntington disease. The N-methyl-d-aspartate subclass of ionotropic glutamate receptors (NMDARs) is more selective and..."

Comprehensive review establishing NMDAR-mediated excitotoxicity as a key pathogenic mechanism in HD with evidence from human tissue, animal models, and cell-based systems.

PMID:19279257 SUPPORT Model Organism

"This is the first direct in vivo evidence of NR2B-NMDAR-mediated excitotoxicity in the context of HD. Our results are consistent with previous suggestions that direct and/or indirect interactions of mutant huntingtin with NMDARs are a proximate cause of neurodegeneration in HD."

Provides the first direct in vivo genetic evidence for the excitotoxicity hypothesis by showing exacerbated striatal neurodegeneration when NR2B-NMDAR subunits are overexpressed in an HD mouse model.

Double-Strand Break Accumulation as an Expansion-Independent Driver

dsb_expansion_independent_driver EMERGING

Evidence balance 6 support

Genome-wide DNA double-strand breaks (DSBs) are a driver of HD neuropathology that is mechanistically separable from somatic CAG expansion. On this model the two forms of DNA damage coexist but act through distinct routes: site-specific CAG tract lengthening is driven by active mismatch repair, whereas DSBs arise genome-wide from mutant huntingtin-mediated suppression of non-homologous end joining acting on a background where oxidation converts base excision repair single-strand break intermediates into double-strand breaks. Three observations support separability. (1) DSBs accumulate in zQ175/MSH3(-/-) mice, which cannot somatically expand their allele, alongside the same transcriptional dysfunction seen in expansion-competent zQ175. (2) Pharmacological suppression of DSBs with the mitochondria-targeted antioxidant XJB-5-131 rescues striatal neuron loss and motor performance in HdhQ(150/150) mice while leaving somatic tract length substantially unchanged. (3) Geometry - the CAG tract is under 1e-7 of the genome, so most breaks fall outside it, and Ku70/Ku80 limits end-joining length changes inside it to a few nucleotides, so break burden and tract length are largely decoupled. The therapeutic implication is that expansion suppression and DSB suppression are independent targets that may need to be combined.

Recorded as EMERGING rather than CANONICAL or ALTERNATIVE. It does not displace the canonical toxic gain-of-function or somatic-expansion models; it adds a parallel arm. Four caveats a curator should preserve. (a) All primary evidence is mouse and, in HdhQ(150/150), male only. (b) The DSBR deficit is measured as delayed clearance of radiation-induced breaks rather than as endogenous repair kinetics. (c) XJB-5-131 suppresses DSB formation upstream via mitochondrial reactive oxygen species; it does not restore end joining, so the rescue shows that break burden matters, not that NHEJ was repaired. (d) No DSBR or NHEJ gene has emerged from human HD GWAS, which the authors attribute to breaks being randomly distributed and NHEJ being reduced rather than absent - this remains an unresolved human/model discrepancy, recorded as the HUMAN_MODEL_MISMATCH discussion mismatch_hd_dsbr_absent_from_human_gwas.

Pathograph links

HTT CAG Repeat Expansion -> mHTT Suppression of Non-Homologous End Joining INDIRECT KNOWN INTERMEDIATES The inherited disease-length tract produces mutant huntingtin that associates with the Ku70-Ku80 end-joining machinery and inhibits double-strand break repair early, before somatic expansion begins. Intermediates: mutant huntingtin protein interaction with the Ku70-Ku80 heterodimer

Mitochondrial Dysfunction -> Oxidative Single-Strand to Double-Strand Break Conversion DIRECT Mitochondrial reactive oxygen species raise the endogenous base-damage load, increasing base excision repair single-strand break intermediates and their conversion to double-strand breaks. This is the edge targeted by the mitochondria-directed antioxidant XJB-5-131.

mHTT Suppression of Non-Homologous End Joining -> Genome-Wide Double Strand Break Accumulation DIRECT Inefficient end joining leaves double-strand breaks unrepaired, so break burden rises across the genome with age.

Oxidative Single-Strand to Double-Strand Break Conversion -> Genome-Wide Double Strand Break Accumulation DIRECT Oxidation-driven conversion of BER single-strand break intermediates supplies the double-strand breaks that inefficient end joining then fails to clear.

Genome-Wide Double Strand Break Accumulation -> Medium Spiny Neuron Degeneration INDIRECT KNOWN INTERMEDIATES As break burden rises, the risk grows that an unrepaired double-strand break terminates transcription of a gene required for neuronal survival. Suppressing double-strand breaks pharmacologically reverses striatal neuron loss without altering tract length. Intermediates: unrepaired breaks in essential genes terminating transcription

Genome-Wide Double Strand Break Accumulation -> Transcriptional Dysregulation INDIRECT UNKNOWN INTERMEDIATES Error-prone end joining introduces somatic nucleotide variants at repair junctions, and unrepaired breaks interrupt transcription, both of which are proposed to contribute to the transcriptional pathology. Double-strand breaks and transcriptional dysfunction rise together in animals that cannot somatically expand their allele, but the causal direction between them was not tested. Intermediates: error-prone non-homologous end joining generating somatic nucleotide variants; transcription blockade at unrepaired breaks

Show evidence (6 references)

PMID:42091595 SUPPORT Model Organism

"We propose that CAG expansion and DSBs promote downstream neuronal pathology as separable drivers."

States the hypothesis in the authors' own terms.

PMID:42091595 SUPPORT Model Organism

"DSBs and transcriptional dysfunction occur in animals that cannot somatically expand their inherited allele."

The zQ175/MSH3(-/-) separation-of-function result - double-strand breaks and transcriptional pathology without any somatic expansion.

PMID:42091595 SUPPORT Model Organism

"Conversely, suppression of DSBs is sufficient to reverse neuropathology even when somatic expansion is active."

The interventional arm - rescue of neuropathology by suppressing breaks while expansion continues.

+ 3 more references

?

Discussions and Knowledge Gaps

5

Does the somatic-CAG-expansion therapeutic rationale, which underpins MSH3- and FAN1-directed programmes in adult-onset HD, still apply in the juvenile repeat range, where the inherited allele may already exceed the pathogenic threshold and further somatic expansion may be dispensable for pathogenesis?

HUMAN MODEL MISMATCH OPEN mismatch_jhd_somatic_expansion_dispensable_at_juvenile_repeat_lengths

Attached to

pathophysiology#Somatic CAG Repeat Expansion pathophysiology#Juvenile-Range CAG Expansion pathophysiology#Mutant Huntingtin Protein Aggregation

In the zQ175 knock-in model, whose approximately 185-CAG allele sits in the juvenile/pediatric rather than adult range, complete Msh3 ablation abolished somatic expansion throughout brain and periphery and 50% reduction slowed it - yet neither striatal nuclear huntingtin aggregation nor the dysregulated striatal transcriptional profile improved. This is the opposite of the result obtained when Msh3 is ablated in knock-in models carrying shorter, adult-range repeats, where the intervention is beneficial. The authors' own translational argument is that human repeats of comparable size cause onset before age 2, so somatic expansion in brain cannot be required for pathogenesis at these lengths. The mismatch is therefore two-sided and specifically juvenile. Model-to-human: the negative result is a mouse result, and no trial of somatic-instability-directed therapy has been run in children with juvenile-onset HD - they are excluded from most HD trials, so the human counterpart of this experiment does not exist. Human-to-model: the repeat length at which the benefit of somatic-expansion suppression disappears is unknown in humans, because the trajectory of somatic expansion in mutation-carrier brain has not been measured. Until that threshold is located, an MSH3- or FAN1-directed agent validated in adult-onset HD must not be assumed to transfer to juvenile-onset patients, and the practical implication the authors draw - treat as early as possible, before the threshold is crossed - is itself untested in this group. This discussion deliberately does not resolve the general somatic-expansion gap recorded in gap_hd_somatic_expansion_threshold_rescue; it is the juvenile-range special case of it, where the sign of the expected effect may differ.

Proposed experiments

Repeat-length-titrated MSH3 suppression in juvenile-range HD neurons

isogenic allelic-series perturbation experiment

exp_jhd_repeat_length_titrated_msh3_suppression

Locate the repeat length at which suppressing somatic expansion stops conferring benefit, using isogenic human striatal neurons spanning the adult-onset through juvenile and highly expanded pediatric ranges. Apply graded MSH3 knockdown to each line, then measure somatic expansion alongside the phenotypes that failed to respond in zQ175 - nuclear huntingtin aggregation and the striatal transcriptional signature - plus survival. The read-out of interest is not whether suppression works at any one length but where in the repeat-length series the dose-response inverts, which is the number needed to decide whether juvenile-onset patients belong in MSH3-directed trials at all.

Model systems

Juvenile-range isogenic hPSC-derived striatal neuron allelic series

Human pluripotent-stem-cell-derived striatal projection neurons carrying an isogenic series of HTT CAG tract lengths that spans the adult-onset, juvenile, and highly expanded pediatric ranges, so repeat length is the only variable distinguishing the lines.

IPSC DERIVED MODEL

Show evidence (3 references)

PMID:38387080 SUPPORT Model Organism

"Ablation of Msh3 prevented somatic expansion throughout the brain and periphery, and reduction of Msh3 by 50% decreased the rate of expansion."

Confirms the intervention worked as intended on its molecular target, so the absent phenotypic benefit is not an efficacy failure.

PMID:38387080 SUPPORT Model Organism

"This had no effect on the deposition of huntingtin aggregation in the nuclei of striatal neurons, nor on the dysregulated striatal transcriptional profile."

The negative result at a juvenile-range repeat length that motivates this mismatch discussion.

PMID:38387080 SUPPORT Model Organism

"It is striking that highly expanded CAG repeats of a similar size in humans cause disease onset before 2 years of age, indicating that somatic CAG repeat expansion in the brain is not required for pathogenesis."

The authors' explicit bridge from the mouse result to human juvenile-onset disease, and the basis for treating this as a translational mismatch rather than a model artefact.

Is somatic HTT CAG expansion past a repeat-length threshold a causal, cell-autonomous trigger for medium spiny neuron degeneration, and can MSH3/FAN1-pathway modulation shift neurons below that threshold without unacceptable DNA-repair toxicity?

KNOWLEDGE GAP OPEN gap_hd_somatic_expansion_threshold_rescue

Attached to

pathophysiology#Somatic CAG Repeat Expansion pathophysiology#Medium Spiny Neuron Degeneration pathophysiology#Mutant Huntingtin Protein Aggregation

Human single-cell data now argue for a long silent phase of somatic repeat growth followed by a high-repeat toxicity threshold. A standardized isogenic striatal-neuron experiment would separate repeat-length threshold, mutant huntingtin proteostasis, and DNA-repair perturbation effects before treating somatic-expansion inhibition as a general disease-modifying strategy.

Proposed experiments

Isogenic hPSC striatal-neuron somatic-expansion threshold assay

isogenic stem-cell perturbation experiment

exp_hd_isogenic_spn_repeat_threshold_modulation

Generate isogenic hPSC-derived striatal projection neuron cultures with defined HTT CAG lengths; induce or monitor somatic expansion over maturation; perturb MSH3 and FAN1 pathway activity; then pair single-cell repeat sizing with neuronal identity, stress, survival, and mutant huntingtin aggregation readouts.

Model systems

Isogenic hPSC-derived striatal projection neuron model

Human pluripotent-stem-cell-derived striatal neuron system carrying controlled HTT CAG tracts so repeat-length distributions can be linked to cell-state and degeneration readouts in the same cells.

IPSC DERIVED MODEL

human NCBITaxon:9606

striatum

medium spiny neuron

Perturbations

HTT CAG tract length series

pathophysiology#HTT CAG Repeat Expansion

Isogenic allelic series spanning reduced-penetrance, typical adult-onset, and high-repeat HTT CAG lengths.

HTT hgnc:4851

MSH3 suppression

pathophysiology#Somatic CAG Repeat Expansion

Genetic or pharmacologic reduction of mismatch-repair activity predicted to slow somatic CAG expansion.

MSH3

FAN1 enhancement

pathophysiology#Somatic CAG Repeat Expansion

FAN1-pathway enhancement to test whether repeat-stabilizing activity can preserve neuronal identity without broad DNA-repair toxicity.

FAN1

Readouts

Single-cell HTT CAG repeat-length distribution

pathophysiology#Somatic CAG Repeat Expansion

Repeat length measured in the same cells used for transcriptomic state assignment.

single-cell repeat-length sequencing long-read sequencing

Direction: POSITIVE

Medium spiny neuron identity and survival

pathophysiology#Medium Spiny Neuron Degeneration

Loss of striatal neuron markers, stress-state induction, and cell-loss readouts interpreted against CAG threshold crossing.

single-cell transcriptomic profiling cell viability assay

Direction: POSITIVE

Mutant huntingtin aggregation burden

pathophysiology#Mutant Huntingtin Protein Aggregation

Aggregation or nuclear-inclusion readout paired to repeat length.

immunofluorescence assay

Direction: POSITIVE

Controls

Isogenic non-expanded HTT neurons

Matched striatal neurons carrying nonpathogenic HTT CAG length.

Sham-edited expanded HTT neurons

Expanded-CAG neurons receiving editing or delivery controls only.

Decision criterion

The threshold model is supported if neurons crossing a prespecified high somatic-repeat range lose striatal identity and viability, and if MSH3 suppression or FAN1 enhancement reduces both threshold crossing and degeneration without broad DNA-damage readouts.

Would support

pathophysiology#Somatic CAG Repeat Expansion pathophysiology#Medium Spiny Neuron Degeneration

Would refute

pathophysiology#Somatic CAG Repeat Expansion

Show evidence (3 references)

PMID:39824182 SUPPORT Human Clinical

"Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect"

Establishes the threshold-like causal question by separating lower somatic expansion from the larger expansions linked to neuronal collapse.

PMID:39824182 SUPPORT Human Clinical

"somatic repeat expansion beyond 150 CAGs causes SPNs to degenerate quickly and asynchronously"

Supports testing whether repeat-stabilizing perturbations can prevent the high-repeat state in a controlled human neuronal model.

+ 1 more reference

Mouse data make mutant-huntingtin suppression of non-homologous end joining an early driver of HD neuropathology, yet no DSBR or NHEJ gene has emerged from human HD onset GWAS, where the modifier signal is dominated by mismatch repair and FAN1. Does impaired double-strand break repair operate in human HD brain, or is this a property of the mouse models?

HUMAN MODEL MISMATCH OPEN mismatch_hd_dsbr_absent_from_human_gwas

Attached to

pathophysiology#mHTT Suppression of Non-Homologous End Joining pathophysiology#Genome-Wide Double Strand Break Accumulation

This is a translational-validity question rather than an absence of evidence: the mouse evidence is direct (huntingtin-Ku70/Ku80 co-immunoprecipitation, pathway-selective repair deficit, delayed break clearance, four concordant break markers), but the corresponding human genetic signal is missing. The authors offer a reconciliation that is plausible and untested - double-strand breaks form at effectively random genomic positions and so vary between patients, and non-homologous end joining in mutant-huntingtin-expressing cells is inefficient rather than absent, so a partial effect may not reach genome-wide significance in onset association studies. Two further considerations cut against dismissing the mismatch. GWAS onset modifiers detect variance in the timing of onset, which need not be the same quantity as the mechanism driving degeneration once the disease-length allele is inherited; and Ligase IV, an NHEJ component, has surfaced in a mouse CRISPR screen as a repressor of CAG expansion, implying that NHEJ genes may act on both axes and confound a simple modifier readout. Until double-strand break burden and end-joining activity are measured directly in human HD brain, the expansion-independent driver arm should be treated as demonstrated in mouse and unconfirmed in human.

Proposed experiments

Quantify double-strand break burden in human HD post-mortem striatum

exp_hd_human_striatal_dsb_burden

Apply the marker panel used in mouse (gamma-H2AX, 53BP1, pKAP-1 with NeuN co-staining, plus neutral comet on dispersed cells) to post-mortem striatum and cerebellum from HD mutation carriers across disease stages and matched controls, testing whether break burden is elevated, striatum-selective and neuron-selective as predicted.

Measure end-joining activity in patient-derived neurons

exp_hd_patient_neuron_repair_landscape

Run multiplexed host-cell reactivation across the five major repair pathways in isogenic patient-derived and CAG-corrected striatal neurons, testing whether the deficit is selective for double-strand break repair as it is in mouse glia and whether it scales with repeat length.

Targeted DSBR gene burden testing in HD onset cohorts

exp_hd_targeted_dsbr_gene_burden

Rather than relying on genome-wide significance, test a pre-specified set of NHEJ and DSBR genes for association with residual age of onset in existing HD GWAS cohorts, which has the power to detect the partial effect the authors predict would be missed by an unbiased scan.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"The site-specific increases in CAG tract length are driven by active mismatch repair (MMR), while DSBs occur genome-wide and are driven by mutant huntingtin-mediated suppression of nonhomologous joining of DNA broken ends."

The mouse claim whose human counterpart is unconfirmed.

Do accumulating double-strand breaks cause the transcriptional dysfunction seen in HD striatal neurons - through error-prone end-joining variants and transcription blockade at unrepaired breaks - or do the two simply arise in parallel from mutant huntingtin?

KNOWLEDGE GAP OPEN gap_hd_dsb_transcriptional_causality

Attached to

pathophysiology#Genome-Wide Double Strand Break Accumulation pathophysiology#Transcriptional Dysregulation

The source study is explicit that this was not tested: double-strand break accumulation was shown to coincide with transcriptional dysfunction in both zQ175 and zQ175/MSH3(-/-) mice regardless of somatic expansion, but no experiment established the causal direction. The authors also note a tension in their own model - transcriptional changes in HD are reproducible between studies, which is difficult to derive from breaks distributed at random across the genome. Their proposed resolution is that repair at preferred sites (clustered single-strand breaks at neuronal gene enhancers, where SAR-seq peaks co-localise with PARP and XRCC1) yields recurrent variants while random breaks elsewhere contribute undetectably. The edge from Genome-Wide Double Strand Break Accumulation to Transcriptional Dysregulation is therefore curated with causal_link_type INDIRECT_UNKNOWN_INTERMEDIATES and PARTIAL evidence.

Proposed experiments

Temporal ordering of break burden and transcriptome change

exp_hd_dsb_transcriptome_time_course

Dense time-course sampling of matched striatal tissue for break markers and RNA-seq in HdhQ(150/150) mice, testing whether break burden rises before the transcriptional signature diverges.

Break suppression as a transcriptome intervention

exp_hd_xjb_transcriptome_endpoint

Repeat the XJB-5-131 late-start regimen with striatal RNA-seq as the primary endpoint, testing whether lowering break burden corrects the transcriptional signature and not only neuron number and motor score.

Map repair junctions against dysregulated genes

exp_hd_repair_junction_mapping

Sequence end-joining repair junctions genome-wide in aged disease striatum and test whether somatic variants are enriched at the regulatory elements of the genes that are transcriptionally dysregulated, as the clustered-SSB hypothesis predicts.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"DSBs and transcriptional dysfunction occur in animals that cannot somatically expand their inherited allele."

Establishes co-occurrence, which is what makes the causal direction an open question rather than a settled edge.

Does XJB-5-131 suppress somatic CAG expansion? Two reports from the same laboratory in the same mouse model disagree.

CONTROVERSY OPEN controversy_hd_xjb_effect_on_somatic_expansion

Attached to

pathophysiology#Somatic CAG Repeat Expansion pathophysiology#Oxidative Single-Strand to Double-Strand Break Conversion

Budworth et al. 2015 reported that XJB-5-131 inhibits lengthening of the repeat tract in HdhQ(150) mice and that this correlated with rescue of motor decline, framing the drug as an expansion suppressor. Polyzos et al. 2026 reports that in congenic HdhQ(150/150) mice the same compound rescues neuropathology with no substantial impact on somatic expansion, and uses that dissociation as a central argument for double-strand breaks being an expansion-independent driver. The two studies differ in zygosity, in the congenic background, and above all in treatment window - early dosing in the 2015 study versus dosing begun at 60 weeks in the 2026 study, by which point most expansion has already occurred. A treatment that slows the rate of expansion would look effective when started early and ineffective when started late, which would reconcile the reports without either being wrong. This matters beyond bookkeeping: if XJB-5-131 does suppress expansion under some regimens, then the late-start experiment is the only one that cleanly separates the two drivers, and the separability argument rests on it alone. Curators should not assert either effect as settled.

Show evidence (2 references)

PMID:26247199 SUPPORT Model Organism

"a pharmacological inhibitor, XJB-5-131, inhibits the lengthening of the repeat tracks, and correlates with rescue of motor decline in these animals"

The 2015 claim that XJB-5-131 inhibits repeat lengthening.

PMID:42091595 SUPPORT Model Organism

"Conversely, suppression of DSBs is sufficient to reverse neuropathology even when somatic expansion is active."

The 2026 position that rescue occurs while somatic expansion continues, which is in tension with XJB-5-131 acting as an expansion suppressor under this regimen.

⚙

Pathophysiology

17

HTT CAG Repeat Expansion

Huntington disease is caused by expansion of a CAG trinucleotide repeat in exon 1 of the HTT gene beyond 36 repeats. The expanded repeat produces a mutant huntingtin protein with an elongated polyglutamine tract that confers a toxic gain of function. Repeat length inversely correlates with age of onset. Normal alleles have 6-26 repeats; intermediate alleles (27-35) can expand in offspring; 36-39 repeats show reduced penetrance; 40+ repeats are fully penetrant.

Double-Strand Break Accumulation as an Expansion-Independent Driver

Downstream

Mutant Huntingtin Protein Aggregation Expanded CAG repeat produces mutant huntingtin with toxic polyglutamine tract that misfolds and aggregates.

Somatic CAG Repeat Expansion Germline CAG repeat undergoes further somatic expansion in post-mitotic striatal neurons, accelerating disease onset.

mHTT Suppression of Non-Homologous End Joining The inherited disease-length tract produces mutant huntingtin that associates with the Ku70-Ku80 end-joining machinery and inhibits double-strand break repair early, before somatic expansion begins.

Uninterrupted CAG Tract Length and Loss of CAA Interruption The inherited expanded allele carries a specific repeat structure, and expanding the tract lengthens the run of uninterrupted CAG in alleles that lack the penultimate CAA interruption. Note the direction of this edge carefully: expansion sets the length of the uninterrupted run, but it does NOT create the loss-of-interruption variant, which is an independently inherited sequence change. This edge connects the allele to its repeat structure; it is not a claim that expansion removes the interruption.

Show evidence (2 references)

PMID:41130308 SUPPORT Human Clinical

"Huntington's Disease (HD) became the first disease mapped to a single chromosome and associated with mutations in the huntingtin (HTT) gene, specifically expansions in the trinucleotide cytosine-adenine-guanine (CAG) within exon 1."

Confirms the causative CAG repeat expansion in HTT exon 1.

PMID:41233526 SUPPORT Human Clinical

"Huntington disease is a fatal, inherited, neurodegenerative disease caused by a CAG repeat expansion in the huntingtin gene (HTT), resulting in a toxic polyglutamine tract in the huntingtin protein."

Confirms the toxic polyglutamine tract from CAG expansion as the primary molecular cause.

Uninterrupted CAG Tract Length and Loss of CAA Interruption

The glutamine-encoding repeat in HTT is normally (CAG)n-CAA-CAG: a penultimate CAA codon interrupts the pure CAG tract while encoding the same glutamine. Because CAA and CAG are synonymous, two alleles can encode an identical polyglutamine length while differing in the length of *uninterrupted* CAG at the DNA level. A loss-of-interruption (LOI) variant that removes the interrupting adenines yields a pure CAG tract and is associated with onset roughly 25 years earlier at matched polyglutamine length, and with increased somatic repeat instability. Conversely, patients retaining or duplicating the CAA interruption have later onset than their polyglutamine length predicts. The determinant of onset is therefore a property of the DNA sequence - its propensity for length instability, and hence its somatic expansion rate - rather than the length of the polyglutamine tract in the protein product. This node is why the KB models CAG tract structure separately from polyglutamine proteotoxicity, and it sits upstream of somatic expansion rather than of protein aggregation.

DNA repeat instability of the uninterrupted CAG tract GO:0035753 ↓ DECREASED

Downstream

Somatic CAG Repeat Expansion A longer uninterrupted CAG tract is more prone to length instability, so it raises the somatic expansion rate - the step through which repeat structure translates into earlier onset.

Show evidence (4 references)

PMID:31398342 SUPPORT Human Clinical

"Variable, glutamine-encoding, CAA interruptions indicate that a property of the uninterrupted HTT CAG repeat sequence, distinct from the length of huntingtin's polyglutamine segment, dictates the rate at which Huntington's disease (HD) develops."

The defining statement that onset is set by the uninterrupted CAG repeat at the DNA level rather than by polyglutamine length in the protein.

PMID:31398342 SUPPORT Human Clinical

"suggesting that the special onset-determining property of the uninterrupted CAG repeat is a propensity for length instability that leads to its somatic expansion"

Identifies the mechanism connecting this node to the next: the onset-determining property of the uninterrupted tract is its instability, acting through somatic expansion.

PMID:31104771 SUPPORT Human Clinical

"this LOI variant is associated with dramatically earlier AOO (average of 25 years) despite the same polyglutamine length as in individuals with the interrupting penultimate CAA codon"

Quantifies the effect and provides the controlled comparison - matched polyglutamine length, differing uninterrupted CAG length, 25-year difference in age of onset.

+ 1 more reference

Somatic CAG Repeat Expansion

Somatic expansion of the CAG repeat in post-mitotic striatal neurons, driven by DNA mismatch repair machinery (particularly MSH3 and FAN1), accelerates disease progression beyond what is predicted by the inherited germline repeat length. This mechanism is now recognized as a key determinant of onset timing and a major therapeutic target. GWAS have identified DNA repair gene variants as the principal genetic modifiers of HD age of onset.

striatal medium spiny neuron CL:1001474

DNA mismatch repair driving somatic expansion GO:0006298

striatum UBERON:0002435

Animal models

zQ175/MSH3(-/-) expansion-incompetent knock-in mouse Mouse fails to recapitulate By design this model does not reproduce somatic CAG expansion - Msh3 ablation prevents it throughout brain and periphery. The negative result is the point of the model, not a shortcoming of it: it is what licenses attributing the residual pathology to an expansion-independent driver.

Downstream

Medium Spiny Neuron Degeneration Somatic expansion in striatal neurons exacerbates local protein toxicity and accelerates neuronal death. Human single-cell data indicate this is threshold-like rather than graded: expansion from 40 to about 150 CAGs has no apparent cell-autonomous effect, while neurons crossing roughly 150 repeats lose neuronal identity and die quickly and asynchronously.

Show evidence (7 references)

PMID:41233526 SUPPORT Human Clinical

"genome-wide association studies have identified genetic modifiers, mostly DNA repair genes, that significantly influence disease onset and progression. These findings point to somatic CAG repeat expansions in affected tissues as a key pathological mechanism."

GWAS studies identify DNA repair gene modifiers influencing onset via somatic CAG expansion.

PMID:33579859 SUPPORT Human Clinical

"Validation of leads including the mismatch repair protein MSH3, and interstrand cross-link repair protein FAN1, suggest the mechanism is driven by somatic CAG instability, which is supported by the protective effect of CAA substitutions in the CAG tract."

Validates MSH3 and FAN1 as key mediators of somatic CAG instability.

PMID:41130308 SUPPORT Human Clinical

"Somatic expansion of the CAG repeat length, beyond the inherited length, has been associated with hastening the onset of symptoms compared to that predicted from the germline length."

Confirms somatic expansion accelerates onset beyond germline prediction.

+ 4 more references

Paternal Germline CAG Repeat Instability and Anticipation

The HTT CAG tract is meiotically unstable, and the largest intergenerational expansions occur during male gametogenesis. Juvenile-onset HD is therefore overwhelmingly a paternally transmitted phenomenon: pooled across juvenile-onset series the mutant allele is inherited from the father in about 80% of cases, and the resulting anticipation is what carries an allele from the adult-onset range in the transmitting parent into the very long juvenile range in the child. This node is the germline counterpart of the somatic instability that operates within an affected individual's own striatal neurons: the same repeat-length-dependent instability acts once in the paternal germline to set the inherited allele, and again post-zygotically in post-mitotic neurons.

loss of fidelity in maintaining the HTT CAG trinucleotide repeat GO:0035753 ↓ DECREASED male meiosis, the cell-division context in which the expansion occurs GO:0007140

Downstream

Juvenile-Range CAG Expansion Male meiotic expansion of the inherited tract is the mechanism by which a juvenile-range allele is generated in the offspring.

Show evidence (3 references)

PMID:38669553 SUPPORT Human Clinical

"Repeat length in JHD is usually > 55 and caused by anticipation, usually via paternal transmission."

Directly attributes the juvenile-range repeat length to anticipation occurring predominantly through paternal transmission.

PMID:31045518 SUPPORT Human Clinical

"Where data were available, the median age of onset was 9 years, 52% were female, the mutant HTT allele was transmitted paternally in 80% of cases, and the median CAG repeat length was 64."

Quantifies the paternal transmission bias across 285 pooled juvenile-onset cases.

PMID:34636452 SUPPORT Human Clinical

"About 80% of JHD patients inherit the repeat expansion via paternal transmission."

Independent review confirming the ~80% paternal transmission figure.

Juvenile-Range CAG Expansion

Age at motor onset in HD is inversely related to CAG repeat length, and juvenile onset sits at the extreme end of that relationship. Repeat length in juvenile-onset HD is usually above 55, roughly half of juvenile cases carry 60 or more repeats, and childhood-onset cases can exceed 80. The dose-response is steeper here than in adult-onset disease: repeat length explains around 60% of onset-age variability in adult-onset HD but up to 84% in juvenile-onset HD, so in this subtype the inherited allele - rather than modifier genes or somatic expansion - is the dominant determinant of when disease begins. The same repeat-length gradient operates within the juvenile group, separating a low-expansion from a high-expansion clinical phenotype.

Genetic context HTT hgnc:4851 allele_type: Expanded CAG trinucleotide repeat, usually >55 and commonly >=60 repeats variant_origin: GERMLINE zygosity: HETEROZYGOUS functional_impact_category: GAIN_OF_FUNCTION

Heterozygous germline HTT CAG expansion in the juvenile range, produced by intergenerational expansion and conferring a toxic polyglutamine gain of function of greater magnitude than the adult-onset range.

Downstream

Mutant Huntingtin Protein Aggregation A longer polyglutamine tract raises the aggregation propensity of mutant huntingtin, so the juvenile-range allele drives the same aggregation mechanism as adult-onset HD but earlier and more severely.

Juvenile-Onset Brain Morphometric Divergence The juvenile-range allele acts on a brain that is still developing, producing a structural phenotype that differs from the adult-onset pattern rather than simply preceding it.

Somatic CAG Repeat Expansion Longer inherited tracts are more somatically unstable, so the juvenile-range allele also enters the somatic expansion cycle from a higher starting length.

Highly Expanded Pediatric HD Cerebral Hypometabolic State SCOPE-RESTRICTED EDGE. This edge does NOT apply across the juvenile range. It is asserted only at the highly expanded pediatric extreme (above 80 CAG repeats), where reduced GLUT-1/GLUT-3, mitochondrial complex II-III and hexokinase-II expression were measured in frontal cortex. In the same study, juvenile-onset samples below that threshold had expression levels resembling adult-onset HD, so the edge must not be read as "juvenile-range expansion causes cerebral hypometabolism". The intervening steps are not established, and the target node is marked PROVISIONAL on an n=2 brain sample.

Show evidence (6 references)

PMID:34636452 SUPPORT Human Clinical

"Age at onset is inversely correlated with CAG repeat length."

States the inverse repeat-length/onset-age relationship on which the juvenile threshold rests.

PMID:34636452 SUPPORT Human Clinical

"In approximately 50% of JHD cases the CAG expansion is ≥60, exceeding 80 repeats in childhood onset."

Provides the juvenile repeat-length distribution and the childhood-onset extreme quoted in this node.

PMID:32825467 SUPPORT Human Clinical

"However, CAG repeat length predicted 84% of the variance in AMO amongst participants from the Kids-JOHD study (p < 0.0001)."

Primary Kids-JOHD analysis establishing that repeat length explains 84% of age-at-motor-onset variance in juvenile-onset HD.

+ 3 more references

Juvenile-Onset Brain Morphometric Divergence

Because the juvenile-range allele is expressed throughout brain development, the structural phenotype of juvenile-onset HD is not simply an accelerated version of the adult-onset pattern. Juvenile-onset patients have substantially reduced intracranial volume - a developmental rather than degenerative signature, since intracranial volume is set by brain growth. After correcting for that smaller cranial vault, the caudate, putamen, globus pallidus, thalamus and cortical white matter are all significantly reduced, while the cerebral cortex is largely spared and the cerebellum is proportionately enlarged. The same striatal-down, cerebellum-up pattern is reproduced in R6/2, zQ175 and HdhQ250 mouse models, whose very long repeats make them better models of juvenile than adult-onset disease. This combination - extrastriatal involvement plus relative cerebellar preservation or enlargement - is the leading structural explanation for why juvenile-onset patients present hypokinetic and rigid rather than choreic. Progression is measurable: striatal volume falls about 4% per year in juvenile-onset patients versus essentially no change in gene-non-expanded controls.

striatum UBERON:0002435 cerebellum UBERON:0002037

Downstream

Medium Spiny Neuron Degeneration Striatal, pallidal and thalamic volume loss in juvenile-onset HD reflects the same medium spiny neuron degeneration seen in adult-onset disease, reached earlier and extending further beyond the striatum.

Show evidence (5 references)

PMID:30971481 SUPPORT Human Clinical

"Participants with JHD had substantially reduced intracranial volumes."

Establishes the reduced intracranial volume that distinguishes the juvenile-onset structural phenotype.

PMID:30971481 SUPPORT Human Clinical

"After controlling for the small intracranial volume size, the volumes of subcortical regions (caudate, putamen, globus pallidus, and thalamus) and of cortical white matter were significantly decreased in patients with JHD."

Specifies which structures are reduced once intracranial volume is accounted for.

PMID:30971481 SUPPORT Human Clinical

"However, the cerebellum was proportionately enlarged in the JHD sample."

Supports the relative cerebellar enlargement that is specific to the juvenile-onset pattern.

+ 2 more references

Highly Expanded Pediatric HD Cerebral Hypometabolic State

A candidate mechanism specific to the most extreme end of the juvenile spectrum. In post-mortem frontal cortex from pediatric HD with highly expanded mutations (HE-PHD, above 80 CAG repeats), the glucose transporters GLUT-1 and GLUT-3 are reduced, as are mitochondrial complexes II-III and hexokinase-II, and the same transporter reduction is seen in patient fibroblasts. Critically, the reduction occurs in cortex WITHOUT evidence of extensive neuronal degeneration, so it is not simply a readout of tissue loss, and the resemblance to GLUT-1 deficiency syndrome offers a mechanistic account of the neurodevelopmental delay and epilepsy seen at these repeat lengths. SCOPE CAVEAT, which curators must preserve: this is NOT a general juvenile-onset HD finding. Juvenile-onset (JOHD) samples in the same study had expression levels consistently different from HE-PHD and similar to adult-onset HD, so the hypometabolic signature segregates with the >80-CAG pediatric subgroup rather than with juvenile onset as such. The study is also very small (brain n=2 HE-PHD, n=3 JOHD, n=6 AOHD), which is why this node is marked PROVISIONAL and is hypothesis-generating rather than a validated juvenile biomarker.

glucose transmembrane transport GO:1904659 ↓ DECREASED

frontal cortex UBERON:0001870

Downstream

Developmental Regression and Delay PROPOSED, NOT ESTABLISHED. The study's motivating rationale is that genetic GLUT-1 deficiency syndrome produces a symptom spectrum resembling highly expanded pediatric HD, which offers a candidate metabolic account of the neurodevelopmental delay seen at these repeat lengths. What is actually measured is the co-occurrence of the transporter deficit and the clinical picture in the same >80-CAG subgroup, not a demonstrated causal sequence; no rescue or intervention experiment has been done. Treat as a hypothesis to test, not a curated causal fact.

Seizures PROPOSED, NOT ESTABLISHED. Same standing as the developmental-delay edge: epilepsy is part of the atypical presentation reported for the highly expanded pediatric subgroup alongside abnormal brain glucose metabolism, and the GLUT-1 deficiency syndrome analogy supplies a candidate mechanism, but causation is not shown. Note the target phenotype is scoped to juvenile HD as a whole while this edge is restricted to the >80-CAG subgroup, so the edge explains only part of the juvenile seizure burden.

Show evidence (4 references)

PMID:37898095 SUPPORT Human Clinical

"Paediatric Huntington disease with highly expanded mutations (HE-PHD; >80 CAG repeats) presents atypically, compared to adult-onset Huntington disease (AOHD), with neurodevelopmental delay, epilepsy, abnormal brain glucose metabolism, early striatal damage, and reduced lifespan."

Defines the highly expanded pediatric subgroup to which this mechanism is scoped and its atypical clinical profile.

PMID:37898095 SUPPORT Human Clinical

"In the frontal cortex, this occurred without evidence of extensive neuronal degeneration."

Supports treating the transporter reduction as a primary metabolic change rather than a secondary consequence of neuronal loss.

PMID:37898095 SUPPORT Human Clinical

"Expression JOHD levels were consistently different to those of HE-PHD but similar to those of AOHD."

The scope caveat in its own words: juvenile-onset samples resembled adult-onset rather than highly expanded pediatric HD, so this mechanism must not be generalized to juvenile-onset HD as a whole. Recorded as PARTIAL because it constrains rather than supports the node's applicability.

+ 1 more reference

Mutant Huntingtin Protein Aggregation

The expanded polyglutamine tract causes mutant huntingtin to misfold and form intracellular aggregates (inclusion bodies) in neurons. These aggregates disrupt proteostasis, sequester essential cellular proteins including transcription factors (CBP, Sp1, TFIID, REST/NRSF), and interfere with transcriptional regulation, axonal transport, and synaptic function. Aberrant proteolytic cleavage by caspase-6 generates toxic N-terminal fragments that accumulate in the nucleus.

Protein aggregation GO:0070841

Downstream

Medium Spiny Neuron Degeneration Mutant huntingtin aggregates and toxic fragments cause selective death of striatal medium spiny neurons.

Transcriptional Dysregulation Nuclear mutant huntingtin and N-terminal fragments sequester transcription factors (Sp1, CBP, REST/NRSF), dysregulating neuronal gene expression.

Excitotoxicity Mutant huntingtin sensitizes striatal neurons to NMDA-receptor-mediated glutamatergic excitotoxicity.

Mitochondrial Dysfunction Mutant huntingtin impairs mitochondrial bioenergetics, contributing to oxidative stress and energy failure.

Show evidence (2 references)

PMID:18992820 SUPPORT In Vitro

"Cleavage of huntingtin by caspase-6 at amino acid 586 is a crucial event in the pathogenesis of HD. Nuclear localization of huntingtin is also an important marker of HD and preventing or delaying its nuclear accumulation is protective in disease models."

Demonstrates caspase-6 cleavage generates toxic N-terminal fragments and their nuclear accumulation drives pathogenesis.

PMID:41233526 SUPPORT Human Clinical

"Although Huntington disease has long been viewed as a consequence of age-dependent toxicity from mutant huntingtin, genome-wide association studies have identified genetic modifiers, mostly DNA repair genes, that significantly influence disease onset and progression."

Confirms the established view that mutant huntingtin protein toxicity is central to HD pathogenesis.

Medium Spiny Neuron Degeneration

GABAergic medium spiny neurons (MSNs) in the caudate nucleus and putamen are selectively vulnerable in HD. Indirect pathway MSNs expressing enkephalin and D2 dopamine receptors are affected earliest, followed by direct pathway MSNs. This selective vulnerability involves excitotoxicity from corticostriatal glutamatergic inputs, mitochondrial dysfunction, impaired BDNF signaling, and naturally low levels of protective S421 phosphorylation in striatal neurons.

Medium spiny neuron CL:1001474

Neuronal apoptosis GO:0006915 Glutamate excitotoxicity GO:0007215 Impaired BDNF trophic support GO:0031547 ↓ DECREASED

Animal models

Congenic HdhQ(150/150) knock-in mouse Mouse rescues The downstream survival arm of the same XJB-5-131 treatment experiment. Lowering the double-strand break burden rescued striatal neuron number and motor performance, which is the outcome that makes break burden a therapeutic target rather than merely a correlate.

Downstream

Chorea

Cognitive Decline

Memory Impairment

Bradyphrenia

Gait Disturbance

Gait Imbalance

Clumsiness

Poor Fine Motor Coordination

Abnormality of Eye Movement

Staring Gaze

Bradykinesia

Hypokinesia

Hyperreflexia

Involuntary Movements

Speech Articulation Difficulties

Oral-pharyngeal Dysphagia

Show evidence (3 references)

PMID:41233526 SUPPORT Human Clinical

"The disease leads to progressive motor, cognitive and psychiatric decline, primarily resulting from loss of medium spiny neurons in the striatum."

Directly confirms MSN loss in the striatum as the primary cause of HD clinical manifestations.

PMID:18992820 SUPPORT In Vitro

"Huntingtin is phosphorylated on serine-421 (S421) by the pro-survival signaling protein kinases Akt and SGK. Phosphorylation of huntingtin at S421 is variable in different regions of the brain with the lowest levels observed in the striatum, which is further reduced by the mutation for..."

Explains selective striatal vulnerability through naturally low levels of neuroprotective S421 phosphorylation in the striatum.

PMID:38427495 SUPPORT In Vitro

"HTT loss or mutation has impacts on neuro-epithelial and striatal neurons maturation, and on basal DNA damage and BDNF axonal transport in post-mitotic neurons"

iPSC-derived models show HTT mutation impairs striatal neuron maturation and BDNF transport, contributing to selective vulnerability.

Neuroinflammation

Reactive microglia and astrocytes contribute to HD pathogenesis through release of pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha) and impaired glutamate buffering. Microglial activation occurs early, even before symptom onset, and correlates with disease progression. Peripheral immune dysregulation is also observed.

Microglia CL:0000129 Astrocyte CL:0000127

Neuroinflammatory response GO:0150076

Downstream

Medium Spiny Neuron Degeneration Neuroinflammatory activation contributes to progressive striatal neuronal injury in HD.

Abnormality of the Sense of Smell

Show evidence (2 references)

PMID:39519337 SUPPORT Human Clinical

"Activation of the immune system and glial cell-mediated neuroinflammatory responses are early pathological features and have been found in all neurodegenerative diseases (NDDs), including HD."

Dedicated HD neuroinflammation review confirming glial-mediated neuroinflammatory responses as early pathological features of HD.

PMID:39519337 SUPPORT Human Clinical

"This review highlights the significantly elevated levels of inflammatory proteins and cellular markers observed in various HD animal models and HD patient tissues, emphasizing the critical roles of microglia, astrocytes, and oligodendrocytes in mediating neuroinflammation in HD."

Establishes microglia and astrocytes as key mediators of neuroinflammation in HD with elevated inflammatory markers in patient tissues.

Excitotoxicity

Overactivation of glutamate receptors leading to neuronal damage.

medium spiny neuron CL:1001474 astrocyte CL:0000127

chemical synaptic transmission GO:0007268 excitatory postsynaptic potential GO:0060079 response to oxidative stress GO:0006979

striatum UBERON:0002435

Downstream

Medium Spiny Neuron Degeneration Glutamate-receptor overactivation produces excitotoxic injury and death of striatal medium spiny neurons.

Seizures

Show evidence (4 references)

PMID:38776957 SUPPORT Model Organism

"We have identified transcriptional upregulation of genes encoding N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors in medium spiny neurons, the cell type preferentially lost early in HD."

The study identifies upregulation of glutamate receptors in medium spiny neurons, supporting the idea of excitotoxicity due to overactivation of these receptors leading to neuronal damage.

PMID:1464368 SUPPORT Other

"Excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors. A substantial body of evidence has implicated excitotoxicity as a mechanism of cell death in both acute and chronic neurologic diseases."

This reference explains the concept of excitotoxicity and supports the idea that overactivation of glutamate receptors can lead to neuronal damage.

PMID:7590394 SUPPORT Model Organism

"Our results indicated that elevated glutamate concentrations (15 mM, 1.5 mM, and 150 microM glutamate in perfusing solutions) would significantly increased both the concentrations of 2,3 and 2,5 DHBA."

The study provides direct evidence that elevated glutamate levels increase the formation of hydroxyl radicals, implying oxidative stress induced by excitotoxicity, which supports the statement.

+ 1 more reference

Mitochondrial Dysfunction

Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.

Double-Strand Break Accumulation as an Expansion-Independent Driver

medium spiny neuron CL:1001474 astrocyte CL:0000127

oxidative phosphorylation GO:0006119 mitochondrion organization GO:0007005 response to oxidative stress GO:0006979

striatum UBERON:0002435 cerebral cortex UBERON:0000956

Downstream

Medium Spiny Neuron Degeneration Bioenergetic failure and oxidative damage contribute to degeneration of energy-demanding striatal medium spiny neurons.

Oxidative Single-Strand to Double-Strand Break Conversion Mitochondrial reactive oxygen species raise the endogenous base-damage load, increasing base excision repair single-strand break intermediates and their conversion to double-strand breaks. This is the edge targeted by the mitochondria-directed antioxidant XJB-5-131.

Weight Loss

Generalized Muscle Weakness

Show evidence (2 references)

PMID:19622387 SUPPORT Other

"Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death."

Supports the pathophysiology entry by directly linking mitochondrial dysfunction in HD to compromised energy metabolism, oxidative damage, and neuronal death.

PMID:23602910 SUPPORT Other

"There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma..."

Supports the mitochondrial dysfunction mechanism by connecting impaired PGC-1alpha activity to defective mitochondrial biogenesis, metabolism, and antioxidant defense in HD.

D2 Receptor Medium Spiny Neuron Selective Vulnerability

D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.

medium spiny neuron CL:1001474

protein aggregation GO:0070841 synaptic transmission GO:0007268

striatum UBERON:0002435

Downstream

Medium Spiny Neuron Degeneration Indirect-pathway D2 medium spiny neurons show earliest aggregation and selective vulnerability, contributing to striatal neuron loss.

Dystonia

Myoclonus

Show evidence (2 references)

PMID:38291334 SUPPORT Human Clinical

"CAG expansions arise at mHTT in striatal medium spiny neurons (MSNs), cholinergic interneurons and cerebellar Purkinje neurons"

Establishes the selectivity paradox in human tissue: somatic expansion is not confined to the cell type that dies. Cholinergic interneurons and cerebellar Purkinje neurons expand too, yet striatal projection neurons are the population lost - so expansion alone does not determine which cells degenerate.

PMID:38291334 SUPPORT Human Clinical

"CAG expansions in MSNs are associated with higher levels of MSH2 and MSH3 (forming MutSβ), which can inhibit nucleolytic excision of CAG slip-outs by FAN1"

Provides the cell-type-specific molecular correlate of differential expansion - the MutS beta versus FAN1 balance - linking this node to the MSH3 and FAN1 modifier genes curated in the genetic section.

Transcriptional Dysregulation

Mutant huntingtin disrupts transcriptional regulation through sequestration of transcription factors including Sp1, CBP, and REST/NRSF, leading to widespread downregulation of neuronal genes including BDNF.

Mitochondrial Dysfunction and Bioenergetic Failure Transcriptional Dysregulation

medium spiny neuron CL:1001474

regulation of transcription by RNA polymerase II GO:0006357 chromatin remodeling GO:0006338

striatum UBERON:0002435 cerebral cortex UBERON:0000956

Downstream

Mitochondrial Dysfunction Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure.

Medium Spiny Neuron Degeneration Loss of neuronal maintenance and survival gene programs (including BDNF) contributes to medium spiny neuron degeneration.

Depression

Anxiety

Agitation

Aggressive Behavior

Compulsive Behaviors

Disinhibition

Irritability

Hallucinations

Apathy

Delusion

Hostility

Abnormal Libido

Sleep Disturbances

Show evidence (8 references)

PMID:11839795 SUPPORT Model Organism

"In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin."

In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.

PMID:11839795 SUPPORT In Vitro

"Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells."

Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.

PMID:11264541 SUPPORT In Vitro

"We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain."

HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.

+ 5 more references

mHTT Suppression of Non-Homologous End Joining

Mutant huntingtin physically associates with the core non-homologous end joining (NHEJ) machinery and suppresses double-strand break repair (DSBR) activity. In HdhQ(150/150) mice, immunoprecipitation-mass spectrometry recovered the Ku70-Ku80 heterodimer as the principal huntingtin capture products (with DNA-PKcs as a minor product, and minor associations with Rad50 and RPA), whereas base excision repair, nucleotide excision repair/transcription-coupled repair and mismatch repair components showed few interactions. Correspondingly, multiplexed host-cell reactivation assays found BER, NER/TCR and MMR activity unchanged by genotype, while clearance of radiation-induced gamma-H2AX foci was delayed in disease striatal cells and tissue - breaks form normally but are repaired inefficiently. The deficit is genotype-, cell-type- and region-specific (striatum over cerebellum, neurons over glia) and appears before the onset of somatic expansion.

Double-Strand Break Accumulation as an Expansion-Independent Driver

medium spiny neuron CL:1001474

non-homologous end joining repair of double-strand breaks GO:0006303 ↓ DECREASED

striatum UBERON:0002435

Animal models

Congenic HdhQ(150/150) knock-in mouse Mouse recapitulates Disease-genotype glia and striatal tissue induce double-strand breaks normally after ionising radiation but clear them inefficiently, while base excision, nucleotide excision and mismatch repair activities are unchanged by genotype - a repair deficit selective for the pathway whose components co-immunoprecipitate with huntingtin.

Downstream

Genome-Wide Double Strand Break Accumulation Inefficient end joining leaves double-strand breaks unrepaired, so break burden rises across the genome with age.

Show evidence (2 references)

PMID:42091595 SUPPORT Model Organism

"The site-specific increases in CAG tract length are driven by active mismatch repair (MMR), while DSBs occur genome-wide and are driven by mutant huntingtin-mediated suppression of nonhomologous joining of DNA broken ends."

States the central claim of this node - that mutant huntingtin suppresses non-homologous end joining - and separates it from the MMR-driven expansion mechanism.

PMID:42091595 SUPPORT Model Organism

"The disease-length CAG tract leads to early inhibition of DSBR and accumulating DSBs over time ultimately kill neurons."

Places inhibition of double-strand break repair upstream and early, establishing the direction of the causal chain from tract length to repair suppression to break accumulation.

Oxidative Single-Strand to Double-Strand Break Conversion

Post-mitotic neurons have no replication fork, so the dominant source of double-strand breaks is endogenous base damage. Base excision repair of oxidised, alkylated or deaminated bases generates transient single-strand break (SSB) intermediates, and closely spaced SSBs on opposite strands convert to a double-strand break. The normal brain runs high BER against low DSBR, an imbalance that makes this conversion sensitive to oxidative and metabolic load. This node is the point at which mitochondrial reactive oxygen species feed the double-strand break arm, and it is the node the mitochondria-targeted antioxidant XJB-5-131 acts on.

Double-Strand Break Accumulation as an Expansion-Independent Driver

medium spiny neuron CL:1001474

base-excision repair generating single-strand break intermediates GO:0006284 response to oxidative stress GO:0006979 ↑ INCREASED

Animal models

Congenic HdhQ(150/150) knock-in mouse Mouse rescues The XJB-5-131 treatment arm. Animals aged to 60 weeks to allow break accumulation, then dosed 2 mg/kg intraperitoneally three times weekly for 30 weeks to 90 weeks, against a saline vehicle control. Suppressing reactive oxygen species lowered break burden and rescued neuropathology without materially changing somatic tract length.

Downstream

Genome-Wide Double Strand Break Accumulation Oxidation-driven conversion of BER single-strand break intermediates supplies the double-strand breaks that inefficient end joining then fails to clear.

Show evidence (2 references)

PMID:39231940 SUPPORT Model Organism

"The brain has the same repair proteins as other tissues, but normal, canonical repair activity is unequal and is characterized by high base excision repair (BER) and low double strand break repair (DSBR)."

Establishes the BER-high/DSBR-low imbalance in normal brain that makes neurons vulnerable to SSB-to-DSB conversion.

PMID:39231940 SUPPORT Model Organism

"The natural imbalance creates conditions where single strand breaks (SSBs) can convert to double strand breaks (DSBs) and reversibly switch between states in response to oxidation both in vivo and in vitro."

Directly supports oxidation-dependent SSB-to-DSB conversion as the route by which oxidative load generates double-strand breaks in brain.

Genome-Wide Double Strand Break Accumulation

Unrepaired double-strand breaks accumulate genome-wide in striatal neurons, detected concordantly by gamma-H2AX, 53BP1 and pKAP-1 immunofluorescence and confirmed as physical DNA breakage by neutral comet assay. Breaks are detectable at 7-10 weeks in HdhQ(150/150) mice - before the onset of somatic expansion (~11-12 weeks), motor abnormalities (~20 weeks) and striatal neuron loss (~60 weeks) - and rise with age in the vulnerable striatum while remaining modest in the resistant cerebellum. Because the expanded CAG tract represents less than 1e-7 of the genome, the great majority of these breaks lie outside the repeat; and inside the repeat, Ku70/Ku80 constrains end-joining length changes to a few nucleotides. Break burden therefore does not translate into tract length, which is the structural basis for treating double-strand breaks and somatic expansion as separable drivers.

Double-Strand Break Accumulation as an Expansion-Independent Driver

medium spiny neuron CL:1001474

double-strand break repair GO:0006302 ↓ DECREASED

striatum UBERON:0002435

Animal models

Congenic HdhQ(150/150) knock-in mouse Mouse recapitulates Unrepaired double-strand breaks rise with age in striatal neurons and remain modest in cerebellum, reproducing the regional and cell-type selectivity of human striatal vulnerability. Concordant across four independent markers.

zQ175 knock-in mouse Mouse recapitulates 53BP1 and gamma-H2AX staining intensity is elevated in zQ175 striatal neurons relative to C57BL/6J background controls at 3 months and rises a further 30-50% by 6 months.

zQ175/MSH3(-/-) expansion-incompetent knock-in mouse Mouse recapitulates Double-strand breaks accumulate in these expansion-incompetent animals to the same degree as in expansion-competent zQ175 - elevated at 3 months and 30-50% higher by 6 months relative to Msh3(-/-) background controls. This is the strongest genetic evidence that break accumulation does not require somatic expansion.

Downstream

Medium Spiny Neuron Degeneration As break burden rises, the risk grows that an unrepaired double-strand break terminates transcription of a gene required for neuronal survival. Suppressing double-strand breaks pharmacologically reverses striatal neuron loss without altering tract length.

Transcriptional Dysregulation Error-prone end joining introduces somatic nucleotide variants at repair junctions, and unrepaired breaks interrupt transcription, both of which are proposed to contribute to the transcriptional pathology. Double-strand breaks and transcriptional dysfunction rise together in animals that cannot somatically expand their allele, but the causal direction between them was not tested.

Show evidence (2 references)

PMID:42091595 SUPPORT Model Organism

"we report that DSBs drive neuropathology in male HdhQ(150/150) mice, regardless of somatic expansion of the inherited disease allele"

Supports accumulated double-strand breaks as a driver of neuropathology in this model independently of somatic expansion.

PMID:42091595 SUPPORT Model Organism

"We propose that CAG expansion and DSBs promote downstream neuronal pathology as separable drivers."

States the separability claim that distinguishes this node from the Somatic CAG Repeat Expansion node.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

43

Digestive 1

Constipation HP:0002019

Show evidence (1 reference)

PMID:36253622 SUPPORT Human Clinical

"Individuals with JoHD had higher incidence rates of epilepsy, constipation and acute respiratory symptoms."

National registry cohort reporting a higher constipation incidence rate in juvenile-onset than adult-onset HD.

Eye 1

Abnormality of Eye Movement FREQUENT HP:0000496

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000496 | Abnormality of eye movement | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies abnormality of eye movement as a frequent Huntington disease phenotype.

Musculoskeletal 2

Generalized Muscle Weakness FREQUENT HP:0003324

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0003324 | Generalized muscle weakness | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies generalized muscle weakness as a frequent Huntington disease phenotype.

Spasticity HP:0001257

Show evidence (1 reference)

PMID:38669553 SUPPORT Human Clinical

"JHD specific features are epilepsy, ataxia, spasticity, pain, itching, and possibly liver steatosis."

Names spasticity as a juvenile-onset-specific feature.

Nervous System 27

Chorea VERY_FREQUENT HP:0002072

Show evidence (2 references)

PMID:38861215 SUPPORT Human Clinical

"HD is characterized by the presence of chorea, alongside other hyperkinesia, parkinsonism and a combination of cognitive and behavioural features."

Confirms chorea alongside other hyperkinesias as a characteristic feature of HD.

ORPHA:399 SUPPORT Other

"HP:0002072 | Chorea | Very frequent (99-80%)"

Orphanet's curated HPO annotation classifies chorea as a very frequent Huntington disease phenotype.

Cognitive Decline VERY_FREQUENT Mental deterioration HP:0001268

Show evidence (2 references)

PMID:40874597 SUPPORT Human Clinical

"Huntington's disease (HD) is an autosomal, progressive, dominant inherited neurological disorder characterized by motor dysfunction, cognitive decline, and psychiatric symptoms."

Confirms cognitive decline as one of the three cardinal features of HD.

ORPHA:399 SUPPORT Other

"HP:0001268 | Mental deterioration | Very frequent (99-80%)"

Orphanet's curated HPO annotation classifies mental deterioration as a very frequent Huntington disease phenotype.

Depression FREQUENT HP:0000716

Show evidence (2 references)

PMID:38861215 SUPPORT Human Clinical

"HD is characterized by the presence of chorea, alongside other hyperkinesia, parkinsonism and a combination of cognitive and behavioural features."

Confirms behavioral features as a core component of the HD clinical triad.

ORPHA:399 SUPPORT Other

"HP:0000716 | Depression | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies depression as a frequent Huntington disease phenotype.

Anxiety FREQUENT HP:0000739

Show evidence (2 references)

PMID:38861215 SUPPORT Human Clinical

"HD is characterized by the presence of chorea, alongside other hyperkinesia, parkinsonism and a combination of cognitive and behavioural features."

Confirms behavioral features as a core component of the HD clinical triad.

ORPHA:399 SUPPORT Other

"HP:0000739 | Anxiety | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies anxiety as a frequent Huntington disease phenotype.

Agitation FREQUENT HP:0000713

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000713 | Agitation | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies agitation as a frequent Huntington disease phenotype.

Aggressive Behavior FREQUENT HP:0000718

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000718 | Aggressive behavior | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies aggressive behavior as a frequent Huntington disease phenotype.

Compulsive Behaviors FREQUENT HP:0000722

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000722 | Compulsive behaviors | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies compulsive behaviors as a frequent Huntington disease phenotype.

Irritability FREQUENT HP:0000737

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000737 | Irritability | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies irritability as a frequent Huntington disease phenotype.

Hallucinations FREQUENT HP:0000738

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000738 | Hallucinations | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies hallucinations as a frequent Huntington disease phenotype.

Apathy FREQUENT HP:0000741

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000741 | Apathy | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies apathy as a frequent Huntington disease phenotype.

Delusion FREQUENT HP:0000746

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000746 | Delusion | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies delusion as a frequent Huntington disease phenotype.

Hostility FREQUENT Anger HP:0031473

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0031473 | Hostility | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies hostility as a frequent Huntington disease phenotype.

Memory Impairment FREQUENT HP:0002354

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0002354 | Memory impairment | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies memory impairment as a frequent Huntington disease phenotype.

Gait Disturbance FREQUENT HP:0001288

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0001288 | Gait disturbance | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies gait disturbance as a frequent Huntington disease phenotype.

Gait Imbalance FREQUENT HP:0002141

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0002141 | Gait imbalance | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies gait imbalance as a frequent Huntington disease phenotype.

Bradykinesia FREQUENT HP:0002067

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0002067 | Bradykinesia | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies bradykinesia as a frequent Huntington disease phenotype.

Hyperreflexia VERY_FREQUENT HP:0001347

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0001347 | Hyperreflexia | Very frequent (99-80%)"

Orphanet's curated HPO annotation classifies hyperreflexia as a very frequent Huntington disease phenotype.

Dystonia FREQUENT HP:0001332

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0001332 | Dystonia | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies dystonia as a frequent Huntington disease phenotype.

Myoclonus FREQUENT HP:0001336

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0001336 | Myoclonus | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies myoclonus as a frequent Huntington disease phenotype.

Involuntary Movements FREQUENT HP:0004305

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0004305 | Involuntary movements | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies involuntary movements as a frequent Huntington disease phenotype.

Seizures HP:0001250

Show evidence (4 references)

PMID:38669553 SUPPORT Human Clinical

"JHD specific features are epilepsy, ataxia, spasticity, pain, itching, and possibly liver steatosis."

Expert working group review names epilepsy as a juvenile-onset-specific feature, justifying the Juvenile HD subtype scoping of this phenotype.

PMID:30243861 SUPPORT Human Clinical

"Compared with the LE subgroup, development delay (0 [0%] in the LE subgroup vs nine [90%] in the HE subgroup; p<0·0001), severe gait impairment (nine [35%] in the LE subgroup vs nine [90%] in the HE subgroup; p=0·0072), and seizures (three [11%] in the LE subgroup vs eight [80%] in the HE..."

Quantifies the repeat-length gradient in seizure occurrence within juvenile-onset HD (80% in the highly expanded subgroup vs 11% in the low expansion subgroup).

PMID:16925544 SUPPORT Human Clinical

"Juvenile HD is far less common and presents with parkinsonism, dystonia and seizures."

Supports seizures as part of the characteristic juvenile-onset presentation, contrasted with the chorea of adult-onset HD.

+ 1 more reference

Developmental Regression and Delay HP:0002376

Show evidence (2 references)

PMID:30243861 SUPPORT Human Clinical

"Compared with the LE subgroup, development delay (0 [0%] in the LE subgroup vs nine [90%] in the HE subgroup; p<0·0001), severe gait impairment (nine [35%] in the LE subgroup vs nine [90%] in the HE subgroup; p=0·0072), and seizures (three [11%] in the LE subgroup vs eight [80%] in the HE..."

Quantifies developmental delay as a high-expansion juvenile feature (90% vs 0%), supporting both the phenotype and its repeat-length dependence.

PMID:38669553 SUPPORT Human Clinical

"Children with disease-onset between 0–10 years (n = 127) had significantly more gait disturbances/ataxia (p = 0.0001), dysarthria (p = 0.008), seizures (p = 0.0008) and developmental regression/delay (p = 0.0001) compared to those with an onset between 11–20 years (n = 101)"

Establishes that developmental regression/delay is significantly more frequent in childhood-onset than adolescent-onset juvenile HD.

Juvenile-Onset Parkinsonism HP:0001300

Show evidence (4 references)

PMID:31045518 SUPPORT Human Clinical

"Four groups of symptoms or signs were present in more than 15% of cases: behavioural disturbance, falls/gait disturbance, cognitive impairment and parkinsonian features."

Systematic review of 285 juvenile-onset individuals placing parkinsonian features among the four most common presenting sign groups.

PMID:30971481 SUPPORT Human Clinical

"Yet, the JOHD motor phenotype often manifests with parkinsonian features, such as bradykinesia, rigidity, and tremors."

Specifies the parkinsonian components (bradykinesia, rigidity, tremor) of the juvenile-onset motor phenotype.

PMID:36318082 SUPPORT Human Clinical

"Specifically, patients with JOHD have less chorea and present with prominent rigidity and bradykinesia."

Directly contrasts the juvenile hypokinetic-rigid phenotype with the chorea of adult-onset HD.

+ 1 more reference

Declining School Performance Cognitive impairment HP:0100543

Show evidence (2 references)

PMID:38669553 SUPPORT Human Clinical

"Cognitive decline is mostly detected by declining school performances."

Establishes the age-specific way cognitive decline presents in juvenile-onset HD.

PMID:31045518 SUPPORT Human Clinical

"Four groups of symptoms or signs were present in more than 15% of cases: behavioural disturbance, falls/gait disturbance, cognitive impairment and parkinsonian features."

Places cognitive impairment among the most common juvenile-onset presenting sign groups.

Behavioural Disturbance Mimicking Neurodevelopmental Disorder Atypical behavior HP:0000708

Show evidence (2 references)

PMID:38669553 SUPPORT Human Clinical

"Behavioral symptoms in general do not differ from AOHD but may be confused with autism spectrum disorder or attention deficit hyperactivity disorder and lead to misdiagnosis and/or diagnostic delay."

Directly supports both the behavioural phenotype and the age-specific misdiagnosis risk described here.

PMID:31045518 SUPPORT Human Clinical

"JHD can present with a wide variety of symptoms and signs, with non-motor characteristics being observed most frequently."

Supports the predominance of non-motor, including behavioural, presenting features in juvenile-onset HD.

Ataxia HP:0001251

Show evidence (2 references)

PMID:38669553 SUPPORT Human Clinical

"JHD specific features are epilepsy, ataxia, spasticity, pain, itching, and possibly liver steatosis."

Names ataxia as a juvenile-onset-specific feature.

PMID:38669553 SUPPORT Human Clinical

"Children with disease-onset between 0–10 years (n = 127) had significantly more gait disturbances/ataxia (p = 0.0001), dysarthria (p = 0.008), seizures (p = 0.0008) and developmental regression/delay (p = 0.0001) compared to those with an onset between 11–20 years (n = 101)"

Shows gait disturbance/ataxia is significantly more frequent in childhood-onset than adolescent-onset juvenile HD.

Sleep Disturbances HP:0002360

Show evidence (3 references)

PMID:41722529 SUPPORT Human Clinical

"Meta-analysed prevalence of objectively-measured sleep disturbances include: 35% for periodic limb movements (PLM index>15/hour), 3% for REM sleep behaviour disorder, 5% for REM sleep without atonia, and 9% for sleep-disordered breathing (AHI>5/hour); and of self-reported measures: 29% for use..."

Systematic review with meta-analysis quantifying the prevalence of multiple sleep disturbances in HD patients.

ORPHA:399 SUPPORT Other

"HP:0100785 | Insomnia | Occasional (29-5%)"

Orphanet's insomnia annotation supports one component of the broader sleep disturbance phenotype.

ORPHA:399 SUPPORT Other

"HP:0001262 | Excessive daytime somnolence | Occasional (29-5%)"

Orphanet's excessive daytime somnolence annotation supports another component of the broader sleep disturbance phenotype.

Respiratory 1

Acute Respiratory Symptoms Abnormal respiratory system physiology HP:0002795

Show evidence (1 reference)

PMID:36253622 SUPPORT Human Clinical

"Individuals with JoHD had higher incidence rates of epilepsy, constipation and acute respiratory symptoms."

National registry cohort reporting a higher incidence rate of acute respiratory symptoms in juvenile-onset than adult-onset HD.

Growth 1

Weight Loss FREQUENT HP:0001824

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0001824 | Weight loss | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies weight loss as a frequent Huntington disease phenotype.

Other 10

Disinhibition FREQUENT HP:0000734

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0000734 | Disinhibition | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies disinhibition as a frequent Huntington disease phenotype.

Abnormal Libido FREQUENT HP:0031845

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0031845 | Abnormal libido | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies abnormal libido as a frequent Huntington disease phenotype.

Bradyphrenia FREQUENT Abnormally slow thought process HP:0031843

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0031843 | Bradyphrenia | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies bradyphrenia as a frequent Huntington disease phenotype.

Clumsiness FREQUENT HP:0002312

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0002312 | Clumsiness | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies clumsiness as a frequent Huntington disease phenotype.

Poor Fine Motor Coordination FREQUENT HP:0007010

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0007010 | Poor fine motor coordination | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies poor fine motor coordination as a frequent Huntington disease phenotype.

Staring Gaze FREQUENT HP:0025401

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0025401 | Staring gaze | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies staring gaze as a frequent Huntington disease phenotype.

Hypokinesia FREQUENT HP:0002375

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0002375 | Hypokinesia | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies hypokinesia as a frequent Huntington disease phenotype.

Abnormality of the Sense of Smell FREQUENT HP:0004408

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0004408 | Abnormality of the sense of smell | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies abnormality of the sense of smell as a frequent Huntington disease phenotype.

Speech Articulation Difficulties FREQUENT HP:0009088

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0009088 | Speech articulation difficulties | Frequent (79-30%)"

Orphanet's curated HPO annotation classifies speech articulation difficulties as a frequent Huntington disease phenotype.

Oral-pharyngeal Dysphagia OCCASIONAL HP:0200136

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"HP:0200136 | Oral-pharyngeal dysphagia | Occasional (29-5%)"

Orphanet's curated HPO annotation classifies oral-pharyngeal dysphagia as an occasional Huntington disease phenotype.

🧬

Genetic Associations

15

HTT (Causative)

Gene: HTT hgnc:4851

Show evidence (2 references)

PMID:41130308 SUPPORT Human Clinical

"Huntington's Disease (HD) became the first disease mapped to a single chromosome and associated with mutations in the huntingtin (HTT) gene, specifically expansions in the trinucleotide cytosine-adenine-guanine (CAG) within exon 1."

Confirms the CAG repeat expansion in HTT exon 1 as the causative mutation.

CGGV:assertion_617c18ee-9476-4bc0-b403-20bc55150c7c-2021-11-08T193955.489Z SUPPORT Other

ClinGen classifies the HTT-Huntington disease gene-disease relationship as definitive with autosomal dominant inheritance.

MSH3 (Modifier)

Gene: MSH3 hgnc:7326

Show evidence (1 reference)

PMID:33579859 SUPPORT Human Clinical

"Validation of leads including the mismatch repair protein MSH3, and interstrand cross-link repair protein FAN1, suggest the mechanism is driven by somatic CAG instability, which is supported by the protective effect of CAA substitutions in the CAG tract."

Identifies MSH3 as a validated modifier driving somatic CAG instability.

FAN1 (Modifier)

Gene: FAN1 hgnc:29170

Show evidence (1 reference)

PMID:33579859 SUPPORT Human Clinical

"Validation of leads including the mismatch repair protein MSH3, and interstrand cross-link repair protein FAN1, suggest the mechanism is driven by somatic CAG instability, which is supported by the protective effect of CAA substitutions in the CAG tract."

Identifies FAN1 as a protective modifier against somatic CAG expansion.

SLC2A3 (Modifier)

Gene: SLC2A3 hgnc:11007

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"SLC2A3 | solute carrier family 2 member 3 | hgnc:11007 | Modifying germline mutation in"

Orphanet's gene table lists SLC2A3 as a modifying germline mutation association for Huntington disease.

MLH1 (Genetic Modifier)

Gene: MLH1 hgnc:7127

PMS1 (Genetic Modifier)

Gene: PMS1 hgnc:9121

PMS2 (Genetic Modifier)

Gene: PMS2 hgnc:9122

LIG1 (Genetic Modifier)

Gene: LIG1 hgnc:6598

PPARGC1A (Pathophysiological Role)

Gene: PPARGC1A hgnc:9237

SLC1A2 (Pathophysiological Role)

Gene: SLC1A2 hgnc:10940

BDNF (Pathophysiological Role)

Gene: BDNF hgnc:1033

NTRK2 (Pathophysiological Role)

Gene: NTRK2 hgnc:8032

DRD1 (Pathophysiological Role)

Gene: DRD1 hgnc:3020

DRD2 (Pathophysiological Role)

Gene: DRD2 hgnc:3023

SQSTM1 (Pathophysiological Role)

Gene: SQSTM1 hgnc:11280

🗃️

External Assertions

1

Orphanet Huntington disease structured record

Orphanet structured disease record ORPHA:399

Orphanet records Huntington disease as ORPHA:399 and provides curated inheritance, onset, epidemiology, gene, HPO phenotype, and external cross-reference rows used here as structured evidence.

Show evidence (5 references)

ORPHA:399 SUPPORT Other

"ORPHA:399 Huntington disease"

The Orphanet structured record heading identifies ORPHA:399 as the Huntington disease record.

ORPHA:399 SUPPORT Other

"MONDO:0007739 | Exact"

Orphanet maps ORPHA:399 exactly to the same MONDO disease identifier used by this entry.

ORPHA:399 SUPPORT Other

"OMIM:143100 | Exact"

Orphanet lists OMIM:143100 as an exact cross-reference for Huntington disease.

+ 2 more references

💊

Medical Actions

14

Tetrabenazine

Action: Tetrabenazine for chorea Ontology label: Pharmacotherapy NCIT:C15986

Agent: tetrabenazine CHEBI:9467

Vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment of chorea in HD. Reduces dopamine signaling in the basal ganglia. Most effective of the three VMAT2 inhibitors for chorea control but associated with higher rates of sedation and carries a boxed warning for depression.

Mechanism Target:

MODULATES D2 Receptor Medium Spiny Neuron Selective Vulnerability — Tetrabenazine inhibits VMAT2, depleting presynaptic dopamine and reducing striatal dopaminergic drive to compensate for the loss of D2-receptor-bearing indirect-pathway medium spiny neurons that underlies HD chorea.

Show evidence (1 reference)

PMID:41069601 SUPPORT Human Clinical

"This study suggests that three VMAT2 inhibitors are effective in ameliorating chorea symptoms in patients with Huntington's disease. Tetrabenazine is the most effective in controlling chorea, whereas valbenazine may be the optimal choice for patients with comorbid psychiatric symptoms."

Network meta-analysis confirms tetrabenazine as the most effective VMAT2 inhibitor for chorea symptom control.

Deutetrabenazine

Action: Deutetrabenazine for chorea Ontology label: Pharmacotherapy NCIT:C15986

Deuterated form of tetrabenazine with improved pharmacokinetics and tolerability profile, approved for HD chorea. Twice-daily dosing with less CYP2D6 interaction and lower sedation risk than tetrabenazine.

Mechanism Target:

MODULATES D2 Receptor Medium Spiny Neuron Selective Vulnerability — Deutetrabenazine inhibits VMAT2, depleting presynaptic dopamine and reducing striatal dopaminergic drive to compensate for the loss of D2-receptor-bearing indirect-pathway medium spiny neurons that underlies HD chorea.

Show evidence (1 reference)

PMID:41069601 SUPPORT Human Clinical

"This study suggests that three VMAT2 inhibitors are effective in ameliorating chorea symptoms in patients with Huntington's disease. Tetrabenazine is the most effective in controlling chorea, whereas valbenazine may be the optimal choice for patients with comorbid psychiatric symptoms."

Network meta-analysis confirms deutetrabenazine efficacy for HD chorea.

Valbenazine

Action: Valbenazine for chorea Ontology label: Pharmacotherapy NCIT:C15986

Selective VMAT2 inhibitor approved in 2023 for HD chorea. Once-daily dosing with minimal CYP2D6 interaction. May be optimal for patients with comorbid psychiatric symptoms. Available in sprinkle formulation for patients with dysphagia.

Mechanism Target:

MODULATES D2 Receptor Medium Spiny Neuron Selective Vulnerability — Valbenazine selectively inhibits VMAT2, depleting presynaptic dopamine and reducing striatal dopaminergic drive to compensate for the loss of D2-receptor-bearing indirect-pathway medium spiny neurons that underlies HD chorea.

Show evidence (2 references)

PMID:41069601 SUPPORT Human Clinical

"This study suggests that three VMAT2 inhibitors are effective in ameliorating chorea symptoms in patients with Huntington's disease. Tetrabenazine is the most effective in controlling chorea, whereas valbenazine may be the optimal choice for patients with comorbid psychiatric symptoms."

Network meta-analysis identifies valbenazine as optimal for patients with comorbid psychiatric symptoms.

PMID:41069601 SUPPORT Human Clinical

"valbenazine ranked first in withdrawals due to AEs (0.735), serious adverse events (0.807), as well as in reducing both suicide (0.683) and suicidal ideation (0.748)."

In the network meta-analysis ranking (SUCRA), valbenazine was the most favorable VMAT2 inhibitor for tolerability and psychiatric-safety endpoints, including reduced suicide and suicidal ideation - relevant given the high suicide risk in Huntington disease and supporting valbenazine as the preferred agent for patients with comorbid psychiatric symptoms.

HTT-Lowering Therapies

Action: HTT-lowering gene therapy Ontology label: Pharmacotherapy NCIT:C15986

Emerging disease-modifying approaches including antisense oligonucleotides (ASOs), splice modulators, and microRNA-based gene therapy targeting mutant huntingtin protein reduction. Allele-selective approaches that spare wild-type HTT are preferred after the tominersen trial showed non-selective lowering can cause harm.

Mechanism Target:

INHIBITS HTT CAG Repeat Expansion — HTT-lowering ASOs, splice modulators, and microRNA-based therapies reduce the expression of mutant huntingtin, directly suppressing the root CAG repeat-expansion-driven toxicity at the mRNA and protein level.

INHIBITS Mutant Huntingtin Protein Aggregation — By lowering mutant HTT protein levels, these therapies reduce the substrate available for mHTT misfolding and nuclear and cytoplasmic aggregate formation.

Show evidence (2 references)

PMID:38861215 SUPPORT Human Clinical

"HD is living in an era of target-specific drug development with emphasis on the mechanisms related to mutant Huntingtin (HTT) protein. Examples include antisense oligonucleotides (ASO), splicing modifiers and microRNA molecules that aim to reduce the levels of mutant HTT protein."

Reviews the current landscape of HTT-lowering therapeutic approaches.

PMID:41090742 SUPPORT Human Clinical

"Among emerging and novel treatments for central nervous system (CNS) disorders, gene therapy (GT), particularly using adeno-associated virus (AAV)-mediated gene delivery, holds great promise."

Reviews AAV-mediated gene therapy as a promising approach for HD treatment.

Somatic Expansion Inhibition

Action: Somatic expansion inhibitor therapy Ontology label: Pharmacotherapy NCIT:C15986

Novel therapeutic paradigm targeting DNA mismatch repair machinery (particularly MSH3) to slow or halt somatic CAG repeat expansion in striatal neurons. Considered the most promising emerging strategy as it addresses the upstream DNA-level mechanism rather than downstream protein toxicity.

Mechanism Target:

INHIBITS Somatic CAG Repeat Expansion — Inhibiting MSH3 and other mismatch repair factors slows or halts the somatic CAG repeat expansion that drives progressive striatal toxicity, targeting the upstream DNA-level mechanism rather than downstream protein aggregation.

Show evidence (1 reference)

PMID:41233526 SUPPORT Human Clinical

"interventions to limit somatic repeat expansion might be effective across multiple repeat expansion diseases and, when combined with disease-specific approaches, such as huntingtin lowering in Huntington disease, might offer more effective and longer-lasting clinical benefits than either..."

Supports somatic expansion inhibition as a promising combinatorial therapeutic strategy for HD and other repeat expansion disorders.

Human Neural Stem Cell Transplantation (hNSC-01)

Action: human neural stem cell transplantation Ontology label: Cellular Therapy NCIT:C70601

Investigational regenerative cell therapy in which good manufacturing practice (GMP)-grade human embryonic stem cell-derived neural stem cells (hNSC-01) are stereotactically implanted into the striatum. Rather than acting by neuronal replacement alone, the grafted cells are proposed to work through neuroprotection and trophic support (including BDNF), reconstruction of striatal synaptic circuitry, and reduction of mutant huntingtin accumulation. This is the cell-therapy approach being evaluated first-in-human in the UCI Health REGEN4HD trial (NCT07451613).

Mechanism Target:

MODULATES Medium Spiny Neuron Degeneration — Intrastriatal hNSC grafts provide trophic support (notably BDNF) and synaptic/circuit reconstruction intended to protect and functionally compensate for the vulnerable striatal medium spiny neurons whose degeneration drives HD motor and cognitive decline.

INHIBITS Mutant Huntingtin Protein Aggregation — In HD mouse models, hNSC transplantation reduced aberrant accumulation of mutant huntingtin, indicating a disease-modifying effect on mHTT proteostasis beyond simple cell replacement.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (2 references)

PMID:29233555 SUPPORT Model Organism

"Disease-modifying activity is suggested by the reduction of aberrant accumulation of mutant HTT protein and expression of brain-derived neurotrophic factor (BDNF) in both models."

Preclinical study of the GMP-grade hNSC line that forms the basis for hNSC-01, transplanted into the striatum of R6/2 and Q140 HD mice, showed improved motor function, reduced mutant HTT accumulation, and increased BDNF, supporting a disease-modifying neurotrophic mechanism.

clinicaltrials:NCT07451613 SUPPORT Human Clinical

"to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease"

The first-in-human REGEN4HD trial is evaluating intrastriatal hNSC-01 implantation for safety and tolerability in early-stage HD.

AMT-130 (AAV5-miHTT Gene Therapy)

Action: AAV5-miHTT gene therapy Ontology label: Gene Therapy NCIT:C15238

One-time HTT-lowering gene therapy delivering an engineered microRNA (miHTT) via an adeno-associated virus serotype 5 (rAAV5) vector by MRI-guided stereotactic infusion into the caudate and putamen. The vector-expressed miHTT drives non-allele-selective (total) lowering of huntingtin mRNA and protein in striatal neurons. In the Phase 1/2 program (NCT04120493 / NCT05243017) the high dose showed slowing of clinical progression and lowered CSF neurofilament light chain, and a BLA submission is planned.

Mechanism Target:

INHIBITS HTT CAG Repeat Expansion — The AAV5-delivered miHTT microRNA degrades huntingtin mRNA, lowering total (mutant and wild-type) huntingtin expression and thereby suppressing the downstream toxicity of the CAG-repeat-expanded transcript at its source.

INHIBITS Mutant Huntingtin Protein Aggregation — By reducing huntingtin mRNA, AMT-130 lowers mutant huntingtin protein levels, decreasing the substrate available for mHTT misfolding and aggregate formation in striatal neurons.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (2 references)

PMID:30984798 SUPPORT Model Organism

"AAV5-miHTT caused a dose-dependent and sustained HTT protein reduction with subsequent suppression of mutant HTT aggregate formation in the striatum and cortex."

Preclinical study of the AAV5-miHTT construct underlying AMT-130 showing dose-dependent, sustained huntingtin lowering and reduced mutant HTT aggregation after intrastriatal delivery in HD mouse models.

clinicaltrials:NCT04120493 SUPPORT Human Clinical

"This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC)."

ClinicalTrials.gov record for the first-in-human Phase 1/2 study of the rAAV5-miHTT gene therapy AMT-130 in early manifest Huntington's disease.

Allele-Selective CRISPR/Cas9 HTT Inactivation

Action: allele-selective genome editing Ontology label: Gene Therapy NCIT:C15238

Genome-editing strategy that permanently inactivates the expanded (mutant) HTT allele while sparing the wild-type allele. Allele selectivity is achieved by directing Cas9 to heterozygous, allele-specific single-nucleotide polymorphisms (SNPs) that create or destroy a CRISPR PAM motif on the mutant chromosome. Preclinical proof-of-concept in HD patient cells and a transgenic HD mouse model; not yet in clinical trials.

Mechanism Target:

INHIBITS HTT CAG Repeat Expansion — Allele-selective CRISPR/Cas9 editing introduces inactivating breaks in the mutant HTT allele, permanently abolishing expression of the CAG-expanded transcript while leaving the wild-type allele intact.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (2 references)

PMID:28129107 SUPPORT In Vitro

"HEK293 cells, which are homozygous for the targeting SNPs (Figure 2B), were transfected with SpCas9 and sgRNA expression plasmids and genomic deletion assessed."

In vitro demonstration of SNP-dependent, allele-selective CRISPR/Cas9 excision of HTT in human cells homozygous for the targeting SNPs.

PMID:28129107 SUPPORT Model Organism

"Interestingly, mouse Htt mRNA levels were also reduced on the injected hemisphere, although to a lesser degree than the human HTT allele."

In vivo confirmation in BacHD transgenic mice (carrying the human HD allele with the targeting SNPs) that intrastriatal CRISPR/Cas9 editing lowers HTT expression on the injected hemisphere.

Human Dental Pulp Stem Cell Therapy (NestaCell)

Action: human dental pulp stem cell therapy Ontology label: Cellular Therapy NCIT:C70601

Investigational allogeneic cell therapy using intravenously infused human dental pulp stem cells (hDPSCs; NestaCell, formerly Cellavita HD). The rationale is neurotrophic support and modulation of neuroinflammation rather than direct neuronal replacement. A randomized, double-blind, placebo-controlled Phase II trial (NCT03252535) reported a favorable safety profile and significant improvements in motor and functional scores, supporting advancement to Phase III.

Mechanism Target:

MODULATES Medium Spiny Neuron Degeneration — Infused dental pulp stem cells are proposed to act through neurotrophic support and modulation of neuroinflammation, aiming to protect vulnerable striatal medium spiny neurons rather than replace them.

MODULATES Neuroinflammation — hDPSCs have immunomodulatory and anti-inflammatory properties hypothesized to dampen the neuroinflammatory component of HD striatal degeneration.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (1 reference)

PMID:40770775 SUPPORT Human Clinical

"Both doses significantly improved UHDRS-TMS compared to placebo (p = 0.005), while the 2 million cells/kg group showed significant benefits in UHDRS-TFC (p = 0.011)."

Randomized, double-blind, placebo-controlled Phase II trial of allogeneic human dental pulp stem cells (NestaCell) showing significant motor (UHDRS-TMS) and functional (UHDRS-TFC) benefit over placebo in HD.

Genetic Counseling

Action: Genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Predictive genetic testing and counseling for at-risk family members. Pre-symptomatic testing follows international guidelines (HDSA/IHA/WFN) requiring pre- and post-test counseling. Only 5-20% of at-risk individuals choose predictive testing. Reproductive options include PGT-M, prenatal testing, and exclusion testing.

Supportive Care

Action: Supportive care Ontology label: Supportive Care NCIT:C15747

Multidisciplinary care including physical therapy (gait training, fall prevention), speech therapy (dysarthria and dysphagia management), occupational therapy, nutritional support (high-calorie diets, PEG tube in advanced stages), and psychiatric management (SSRIs, SNRIs for depression; antipsychotics for psychosis).

Antipsychotic Medications

Action: Pharmacotherapy NCIT:C15986

Used for psychiatric symptoms like irritability and agitation.

Show evidence (3 references)

PMID:27534434 SUPPORT Other

"In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms..."

The literature states that antipsychotics are used to manage psychiatric symptoms in Huntington's Disease.

PMID:16383221 SUPPORT Other

"According to clinical observation, HD patients with psychiatric symptoms respond to standard pharmacotherapy."

The literature supports the use of pharmacotherapy, which includes antipsychotic medications, for psychiatric symptoms in Huntington's Disease.

PMID:36496108 SUPPORT Other

"Several lines of evidence suggest a possible role of risperidone via the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington's disease..."

Risperidone, an antipsychotic, is mentioned as having a role in treating psychiatric symptoms in Huntington's Disease.

Selective Serotonin Reuptake Inhibitors (SSRIs)

Action: Pharmacotherapy NCIT:C15986

Used to manage depression.

Show evidence (2 references)

PMID:18394562 SUPPORT Other

"Several classes of medications have been used to ameliorate the various symptoms of HD, including typical and atypical neuroleptics, dopamine depleters, antidepressants..."

The abstract mentions that antidepressants, which include SSRIs, are used to manage symptoms in Huntington's Disease.

PMID:22119091 SUPPORT Human Clinical

"Cross-sectionally, suicidal mutation carriers were more likely to use antidepressants (odds ratio=5.3)..."

The use of antidepressants, which can include SSRIs, is associated with managing depressive symptoms in Huntington's Disease.

XJB-5-131 (Mitochondria-Targeted Antioxidant)

Action: Pharmacotherapy NCIT:C15986

Agent: XJB-5-131 CHEBI:173099

PRECLINICAL ONLY - no human trial has been conducted. XJB-5-131 is a synthetic antioxidant in which a tempol nitroxide radical-scavenging moiety is linked to a mitochondria-targeting carrier peptide derived from gramicidin S, concentrating the antioxidant at the mitochondrial membrane. By suppressing mitochondrial reactive oxygen species it prevents base oxidation and blocks the conversion of base excision repair single-strand break intermediates into double-strand breaks. In HdhQ(150/150) mice dosed at 2 mg/kg intraperitoneally three times weekly from 60 to 90 weeks - that is, started only after double-strand breaks had accumulated and disease was well established - it reduced striatal neuronal gamma-H2AX staining and neutral comet tail moments, restored NeuN staining, and improved motor performance, with no substantial change in somatic CAG tract length. That dissociation is the interventional basis for treating double-strand breaks as a therapeutic target separable from somatic expansion.

Mechanism Target:

INHIBITS Oxidative Single-Strand to Double-Strand Break Conversion — Mitochondrial localisation of the nitroxide lowers the reactive oxygen species load that drives endogenous base oxidation, reducing the supply of single-strand break intermediates that convert to double-strand breaks. The drug acts on break formation upstream; it does not restore non-homologous end joining.

Show evidence (1 reference)

PMID:23122961 SUPPORT Model Organism

"XJB-5-131 reduces oxidative damage to mitochondrial DNA, maintains mitochondrial DNA copy number, suppresses motor decline and weight loss, enhances neuronal survival, and improves mitochondrial function."

Establishes the drug's mechanism as suppression of mitochondrial oxidative DNA damage, the input to the SSB-to-DSB conversion node.

INHIBITS Genome-Wide Double Strand Break Accumulation — Thirty weeks of treatment begun at 60 weeks lowered striatal neuronal double-strand break burden by both gamma-H2AX immunofluorescence and neutral comet assay, and rescued striatal neuron number and motor performance, while somatic tract length was substantially unchanged.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"Conversely, suppression of DSBs is sufficient to reverse neuropathology even when somatic expansion is active."

The interventional result linking pharmacological double-strand break suppression to reversal of neuropathology with expansion ongoing.

Show evidence (3 references)

PMID:26908614 SUPPORT Model Organism

"We have developed a novel synthetic antioxidant, XJB-5-131, which directly targets MT, the primary site and primary target of oxidative damage."

Describes the agent and its mitochondrial targeting.

PMID:26908614 SUPPORT Model Organism

"In animals with well-developed pathology, XJB-5-131 promotes weight gain, prevents neuronal death, reduces oxidative damage in neurons, suppresses the decline of motor performance or improves it"

Establishes efficacy when dosing begins after disease onset in the same HdhQ150 model, which is the regimen used in the 2026 double-strand break study.

PMID:23122961 SUPPORT Model Organism

"To increase specificity and efficacy, we have designed a synthetic antioxidant, XJB-5-131, to target mitochondria."

Original description of the compound's design rationale.

🔬

Biochemical Markers

3

Neurofilament Light Chain (NfL)

Show evidence (2 references)

PMID:41081429 SUPPORT Human Clinical

"Evidence for neurofilament light (NfL) is sufficient to meet evidentiary guidelines as a prognostic biomarker in preHD (ie, before clinical motor diagnosis)."

Systematic review with meta-analysis establishes NfL as a validated prognostic biomarker in pre-manifest HD.

PMID:39891767 SUPPORT Human Clinical

"sNfL levels differed significantly between preHD and early HD, and HC (all p values < 0.05)"

Confirms serum NfL can distinguish pre-manifest and early HD from healthy controls.

Mutant Huntingtin Protein (mHTT)

Show evidence (1 reference)

PMID:38861215 SUPPORT Human Clinical

"The possibility of quantifying mHTT in CSF, along with the development of an integrated biological staging system in HD are important innovations applicable to clinical trial design that enhance the drug development process."

Highlights CSF mHTT quantification as a key innovation for HD clinical trial design.

Elevated Neuronal Inclusions (Positive)

Show evidence (4 references)

PMID:22200539 SUPPORT Other

"Here we will review the state of knowledge of HD, focusing especially on a hallmark pathological feature-intracellular aggregates of mutant Htt called inclusion bodies (IBs)."

The article discusses the presence of intracellular aggregates of mutant huntingtin, which are referred to as inclusion bodies, supporting the statement.

PMID:38810948 SUPPORT Human Clinical

"We confirmed the presence of mHtt aggregates within grafts of all three cases as well as tau neuropil threads in the grafts of two of the three transplanted HD patients."

The study confirms the presence of mutant huntingtin (mHtt) aggregates within neurons, supporting the statement.

PMID:19172113 SUPPORT Other

"It is likely that the aggregates containing expanded huntingtin are toxic to neurons, but it remains to be determined whether the oligomer or the inclusion is the toxic species."

The article mentions that aggregates containing expanded huntingtin are found in neurons, supporting the statement.

+ 1 more reference

🔬

Diagnosis

3

Genetic Testing for HTT CAG Expansion (Positive)

Confirmation of diagnosis through DNA analysis.

Show evidence (4 references)

PMID:26439718 SUPPORT Other

"Huntington disease (HD) is caused by expansion of a CAG trinucleotide repeat in the first exon of the Huntingtin (HTT) gene. Molecular testing of Huntington disease for diagnostic confirmation and disease prediction requires detection of the CAG repeat expansion."

The literature confirms that genetic testing for HTT CAG expansion is used for the diagnostic confirmation of Huntington's Disease.

PMID:23390178 SUPPORT Human Clinical

"We analyzed the clinical and genetic characteristics of 76 juvenile-onset patients referred consecutively for HD genetic testing over a 16-year period. ... All expanded cases had a family history of genetically confirmed HD compared to only 13.5% of unexpanded cases (p = 0.000)."

This study supports the use of genetic testing for confirming the diagnosis of Huntington's Disease by identifying the CAG expansion.

PMID:31820322 SUPPORT Human Clinical

"Huntington's disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by a CAG expansion greater than 35 in the IT-15 gene."

This reference supports the statement that Huntington's Disease is confirmed through genetic testing for HTT CAG expansion.

+ 1 more reference

Neuropsychological Evaluation

Formal neuropsychological assessment to detect and monitor the cognitive and neuropsychiatric changes of Huntington disease, whose functional impact frequently equals or exceeds that of motor symptoms.

neuropsychological assessment NCIT:C165543

Show evidence (2 references)

PMID:37849335 SUPPORT Other

"Neuropsychological evaluation is critical to detection and management of cognitive and neuropsychiatric changes associated with Huntington disease (HD)."

The Huntington Study Group neuropsychology working group establishes neuropsychological evaluation as critical for detecting and managing the cognitive and neuropsychiatric features of HD.

PMID:37849335 SUPPORT Other

"Accurate assessment of non-motor complications of HD is critical given the prominent impact on functional disability, frequently commensurate with or exceeding that of motor symptoms."

Motivates neuropsychological assessment by the large functional impact of HD's non-motor complications.

Neurological Examination

Assessment of motor disturbances, cognitive function, and psychiatric symptoms.

Show evidence (5 references)

PMID:29856017 SUPPORT Model Organism

"Motor deficits are a characteristic consequence of striatal damage, whether induced by experimental lesions, or in genetic models of Huntington's disease involving polyglutamine expansion in the huntingtin protein."

This reference supports the assessment of motor disturbances in Huntington's Disease.

PMID:29278291 SUPPORT Other

"Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum."

This reference supports the assessment of cognitive function in Huntington's Disease.

PMID:30012004 SUPPORT Other

"This clinical update review focuses on the common neuropsychiatric manifestations in HD, and outlines and evaluates the various neuropsychiatric facets of HD, including the aetiology, symptoms and diagnosis."

This reference supports the assessment of psychiatric symptoms in Huntington's Disease.

+ 2 more references

📈

Progression

4

Age of onset (juvenile-onset HD)

Juvenile HD Age: 20 years or younger, median 9 years at onset

Juvenile-onset HD is defined by motor onset at or before age 20. Pooled case reports and case series give a median age at onset of 9 years, and onset is conventionally split into childhood (0-10 years) and adolescent (11-20 years) onset, which differ in presenting features.

Show evidence (1 reference)

PMID:31045518 SUPPORT Human Clinical

"Where data were available, the median age of onset was 9 years, 52% were female, the mutant HTT allele was transmitted paternally in 80% of cases, and the median CAG repeat length was 64."

Systematic review of 285 juvenile-onset individuals reporting the median age at onset used here.

Disease duration and survival (juvenile-onset HD)

Juvenile HD Duration: Median about 9 years from motor onset in childhood-onset JHD, versus about 18 years in adolescent- and adult-onset HD.

Juvenile-onset HD progresses faster and is fatal sooner than adult-onset disease, and the effect is graded by repeat length - the most highly expanded cases have the shortest survival.

Show evidence (3 references)

PMID:34636452 SUPPORT Human Clinical

"The median disease duration after motor onset in childhood JHD is 9 years, compared to 18 years in adolescent and adult HD."

Provides the childhood-onset versus adolescent/adult disease-duration figures recorded in this record.

PMID:30243861 SUPPORT Human Clinical

"Of 121 deceased patients, median survival was shorter in the juvenile Huntington's disease (n=17) cohort than in adult-onset Huntington's disease (n=104) cohort"

REGISTRY/Enroll-HD retrospective analysis showing shorter median survival in juvenile-onset than adult-onset HD.

PMID:38669553 SUPPORT Human Clinical

"Disease progression of JHD is faster compared to AOHD and the disease duration is shorter, particularly in case of higher CAG repeat lengths."

Expert working group review confirming faster progression and shorter duration graded by repeat length.

Motor progression rate (juvenile-onset HD)

Juvenile HD

Juvenile-onset HD progresses faster than adult-onset HD on the UHDRS Total Motor Score, but the chorea subscales do not track that progression - they do not change reliably over time in juvenile-onset patients. This is a measurement consequence of the hypokinetic-rigid phenotype and is why chorea-based endpoints are poor outcome measures in this group.

Show evidence (2 references)

PMID:38142629 SUPPORT Human Clinical

"The JOHD cohort had faster TMS progression compared to AOHD (p = 0.006) but no group difference in the rate of change of chorea."

Enroll-HD analysis directly comparing juvenile- and adult-onset motor progression rates.

PMID:38142629 SUPPORT Human Clinical

"Patients with JOHD did not show significant change in any of the chorea subscales."

Supports the statement that chorea subscales fail to track juvenile-onset disease progression.

Age of onset

Age: Childhood, adolescent, adult, or elderly

Orphanet lists Huntington disease onset categories spanning childhood through elderly onset.

Show evidence (4 references)

ORPHA:399 SUPPORT Other

"Age of onset: Childhood"

Orphanet includes childhood among Huntington disease onset categories.

ORPHA:399 SUPPORT Other

"Age of onset: Adolescent"

Orphanet includes adolescent among Huntington disease onset categories.

ORPHA:399 SUPPORT Other

"Age of onset: Adult"

Orphanet includes adult among Huntington disease onset categories.

+ 1 more reference

📊

Prevalence

3

Western populations (USA, Canada, Europe)

Point Prevalence 8.2–9.0 per 100,000 1–9 per 100,000

Show evidence (1 reference)

PMID:34350853 SUPPORT Human Clinical

"Diagnosed prevalence is estimated to be 8.2-9.0 per 100,000 in the USA, Canada, and the 5 included European countries and 3.5 per 100,000 in Brazil."

Epidemiological model using diagnosed incidence and survival data from eight countries estimates HD prevalence in Western populations.

Worldwide (Orphanet point prevalence)

Point Prevalence 1.0–9.0 per 100,000 1–9 per 100,000

Orphanet classifies worldwide Huntington disease point prevalence as 1-9 per 100,000.

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"1-9 / 100 000 | Worldwide | Point prevalence | PMID:22692795"

Orphanet's epidemiology table provides the worldwide point-prevalence class for Huntington disease.

United States (Orphanet point prevalence)

Point Prevalence 1.0–9.0 per 100,000 1–9 per 100,000

Orphanet classifies United States Huntington disease point prevalence as 1-9 per 100,000.

Show evidence (1 reference)

ORPHA:399 SUPPORT Other

"1-9 / 100 000 | United States | Point prevalence | PMID:8018043"

Orphanet's epidemiology table provides a United States point-prevalence class for Huntington disease.

📊

Related Datasets

6

Multiple Tissue Monitoring in Huntington disease - RNAseq fibroblasts ega:EGAS00001006472

We examined whether peripheral tissues can serve as a source of readily accessible biological signatures at the RNA and protein level in Huntington disease (HD) patients. Under the MTM-HD study we generated large, high-quality human datasets from skeletal muscle, skin and adipose tissue, as well as primary human fibroblast lines to probe molecular changes in human pre-manifest and early manifest HD patients. We document the involvement of inflammation, energy metabolism and extracellular vesicle homeostasis. This demonstrates the potential to identify biological signatures from peripheral tissues in HD suitable as biomarkers in clinical trials.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Huntington Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Multiple Tissue Monitoring in Huntington disease - RNAseq adipose tissue ega:EGAS00001006473

We examined whether peripheral tissues can serve as a source of readily accessible biological signatures at the RNA and protein level in Huntington disease (HD) patients. Under the MTM-HD study we generated large, high-quality human datasets from skeletal muscle, skin and adipose tissue, as well as primary human fibroblast lines to probe molecular changes in human pre-manifest and early manifest HD patients. We document the involvement of inflammation, energy metabolism and extracellular vesicle homeostasis. This demonstrates the potential to identify biological signatures from peripheral tissues in HD suitable as biomarkers in clinical trials.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Huntington Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Multiple Tissue Monitoring in Huntington disease - RNAseq skeletal muscle ega:EGAS00001006474

We examined whether peripheral tissues can serve as a source of readily accessible biological signatures at the RNA and protein level in Huntington disease (HD) patients. Under the MTM-HD study we generated large, high-quality human datasets from skeletal muscle, skin and adipose tissue, as well as primary human fibroblast lines to probe molecular changes in human pre-manifest and early manifest HD patients. We document the involvement of inflammation, energy metabolism and extracellular vesicle homeostasis. This demonstrates the potential to identify biological signatures from peripheral tissues in HD suitable as biomarkers in clinical trials.

human

European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Huntington Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.

Alterations in CSF Urea Occur in Late Manifest Stage Huntington Disease metabolomics_workbench:ST002442

Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Huntington Disease"). Retrieved 2026-08-02.

Integration-independent Transgenic Huntington Disease Fragment Mouse Models massive:MSV000079178

Data from Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo CoIP of HTT full length and fragment proteins from mouse cortical lysates. Controlled with preimmune mouse IgG IP.

mouse PROTEOMICS

Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Huntington Disease"). Retrieved 2026-08-02.

PREDICT-HD Huntington Disease Study dbgap:phs000222

The purpose of this project is to make clinical measurements from the PREDICT-HD consortium available through the dbGaP mechanism. The phenotype data will first be converted into a community open standard and subsequently exported to dbGaP for archival and open access distribution of the results of the studies. This will permit members of the scientific community to utilize a permanent resource for investigating the interactions of phenotypes upon an international cohort of early Huntington Disease. In version 2 cut of the data we provided HD CAG repeat lengths for both allele

Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Huntington Disease"). Retrieved 2026-08-02.

🔬

Clinical Trials

3

NCT07451613 PHASE_I RECRUITING

REGEN4HD — the first-in-human Phase 1b/2a study (UCI Health) evaluating the safety and tolerability of hNSC-01, GMP-grade human embryonic stem cell-derived neural stem cells, stereotactically implanted into the striatum of adults with genetically confirmed early-stage Huntington's disease. The Phase 1b arm is a dose-escalation cohort followed by a Phase 2a expansion group, with treatment-related adverse events as the primary outcome.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (1 reference)

clinicaltrials:NCT07451613 SUPPORT Human Clinical

"to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease"

ClinicalTrials.gov record for REGEN4HD describes the first-in-human evaluation of intrastriatal hNSC-01 neural stem cell therapy for safety and tolerability in Huntington's disease.

NCT04120493 PHASE_I ACTIVE_NOT_RECRUITING

First-in-human Phase 1/2, randomized, double-blind, sham-controlled and open-label study of striatally-administered rAAV5-miHTT total HTT-lowering gene therapy (AMT-130) in early manifest Huntington's disease. The high-dose cohort showed slowing of clinical progression and lowered CSF neurofilament light chain at 36 months.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (1 reference)

clinicaltrials:NCT04120493 SUPPORT Human Clinical

"This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC)."

ClinicalTrials.gov record for the first-in-human gene therapy trial of AAV5-miHTT (AMT-130) in early manifest Huntington's disease.

NCT03252535 PHASE_II COMPLETED

Phase II, single-center, randomized (2:2:1), triple-blind, placebo-controlled dose-response study of intravenous allogeneic human dental pulp stem cells (Cellavita HD / NestaCell) in Huntington's disease. Reported a favorable safety profile with significant motor and functional improvement over placebo, supporting advancement to Phase III.

Target Phenotypes: Chorea HP:0002072 Progressive cognitive decline HP:0001268

Show evidence (1 reference)

clinicaltrials:NCT03252535 SUPPORT Human Clinical

"Cellavita HD is a stem-cell therapy for Huntington's Disease."

ClinicalTrials.gov record describing the Phase II dental pulp stem cell (Cellavita HD) study in Huntington's disease.

🐁

Animal Models

4

R6/2 transgenic mouse

Mice expressing human mutant huntingtin with expanded CAG repeats used to model motor and cognitive deficits.

Species

Mouse

Genotype

R6/2 Transgenic

Show evidence (5 references)

PMID:18638556 SUPPORT Other

"Huntington disease (HD) is a dominantly inherited human neurodegenerative disorder characterized by motor deficits, cognitive impairment, and psychiatric symptoms leading to inexorable decline and death. Since the identification of the huntingtin gene and the characteristic expanded CAG..."

This reference supports the statement as it describes Huntington's disease as involving motor deficits and cognitive impairment, and mentions the use of murine genetic models, including transgenic ones with expanded CAG repeats like the R6/2 model.

PMID:35007790 SUPPORT Model Organism

"We used the R6/2 and BACHD mouse models that express different lengths of mutant HTT to develop lean- and obese phenotypes, respectively. We utilized adeno-associated viral vectors to overexpress either mutant or wild-type HTT in the hypothalamus of R6/2, BACHD, and their wild-type littermates...."

This reference supports the statement by describing the use of R6/2 mice, which express mutant HTT, to study metabolic phenotypes including weight changes, indicating weight loss as part of the disease phenotype.

PMID:29856017 SUPPORT Model Organism

"Motor deficits are a characteristic consequence of striatal damage, whether induced by experimental lesions, or in genetic models of Huntington's disease involving polyglutamine expansion in the huntingtin protein."

This reference supports the statement by confirming that motor deficits are a characteristic consequence of genetic models of Huntington's disease, including those with polyglutamine expansion such as the R6/2 model.

+ 2 more references

Congenic HdhQ(150/150) knock-in mouse

Knock-in of an approximately 150-unit CAG tract into the endogenous mouse Hdh locus, the closest available genetic replica of the human mutation. The congenic derivation is deliberate: because every animal is essentially a genetic clone expressing the same proteins at the same level, variance between animals in DNA repair protein expression is suppressed, which is what makes small repair-activity differences between genotypes detectable. Disease course: double-strand breaks from 7-10 weeks, somatic expansion onset ~11-12 weeks, motor abnormalities ~20 weeks, striatal neuron loss ~60 weeks, with the cerebellum spared.

Species

Mouse

Genotype

Hdh CAG(150) homozygous knock-in (HdhQ150), congenic on C57BL/6J

Background

C57BL/6J, backcrossed more than 15 generations to a congenic (clonal) line

Publication

PMID:42091595

Pathograph links

mHTT Suppression of Non-Homologous End Joining recapitulates fidelity: moderate Disease-genotype glia and striatal tissue induce double-strand breaks normally after ionising radiation but clear them inefficiently, while base excision, nucleotide excision and mismatch repair activities are unchanged by genotype - a repair deficit selective for the pathway whose components co-immunoprecipitate with huntingtin.

Limitations: The repair deficit is inferred from clearance of exogenously induced (2 Gy in vitro, 5 Gy in vivo) breaks rather than from endogenous repair kinetics, so the measured quantity is the response to an acute supraphysiological insult. All experiments used male mice only. The model carries a mouse Hdh knock-in of ~150 CAG, a repeat length that in humans would cause childhood-onset disease, so it does not model the adult-onset expansion trajectory. No corresponding NHEJ deficit has been demonstrated in human HD tissue.

Readouts

Clearance of radiation-induced gamma-H2AX foci in striatal cells

Direction: DECREASED

Interpretation: Foci induction was equivalent between genotypes, but loss of foci over 1-24 h in vitro and 2-4 h in vivo was slower in disease striatum, indicating suppressed double-strand break repair rather than increased break formation.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"The site-specific increases in CAG tract length are driven by active mismatch repair (MMR), while DSBs occur genome-wide and are driven by mutant huntingtin-mediated suppression of nonhomologous joining of DNA broken ends."

Reports suppression of non-homologous end joining as the measured defect underlying this readout.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"The disease-length CAG tract leads to early inhibition of DSBR and accumulating DSBs over time ultimately kill neurons."

Supports treating this model as informative for early inhibition of double-strand break repair.

Genome-Wide Double Strand Break Accumulation recapitulates fidelity: moderate Unrepaired double-strand breaks rise with age in striatal neurons and remain modest in cerebellum, reproducing the regional and cell-type selectivity of human striatal vulnerability. Concordant across four independent markers.

Limitations: Male mice only. Break burden in human HD striatum has not been quantified with comparable methods, so the correspondence to human disease is inferred from the matching anatomical pattern rather than measured.

Readouts

Striatal neuronal gamma-H2AX immunofluorescence intensity

Direction: INCREASED

Interpretation: Elevated in NeuN-positive striatal neurons of disease animals versus wild type at both young and old ages; modest in cerebellum in both genotypes.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"we report that DSBs drive neuropathology in male HdhQ(150/150) mice, regardless of somatic expansion of the inherited disease allele"

Reports elevated double-strand breaks in this model as the basis for the neuropathology claim.

Neutral comet assay tail moment in dispersed striatal cells

Direction: INCREASED

Interpretation: Direct physical measurement of DNA breakage, confirming that the antibody-based markers reflect real double-strand breaks rather than signalling changes.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"We propose that CAG expansion and DSBs promote downstream neuronal pathology as separable drivers."

Frames the measured break burden as an independent pathological driver in this model.

Show evidence (1 reference)

PMID:11152661 SUPPORT Model Organism

"Mice with alleles of approximately 150 units in length exhibit late-onset behavioral and neuroanatomic abnormalities consistent with HD."

Establishes the HdhQ150 knock-in line as a phenotypically valid HD model for the mechanism claims built on it.

Oxidative Single-Strand to Double-Strand Break Conversion rescues fidelity: moderate The XJB-5-131 treatment arm. Animals aged to 60 weeks to allow break accumulation, then dosed 2 mg/kg intraperitoneally three times weekly for 30 weeks to 90 weeks, against a saline vehicle control. Suppressing reactive oxygen species lowered break burden and rescued neuropathology without materially changing somatic tract length.

Limitations: The rescue demonstrates that lowering break burden is sufficient to improve outcome; it does not show that non-homologous end joining was restored, since the drug acts upstream on break formation. Male mice only, n = 3 per group. The reported absence of an effect on somatic expansion conflicts with an earlier report from the same group in differently treated HdhQ(150) animals - see the discussion controversy_hd_xjb_effect_on_somatic_expansion.

Readouts

Striatal neuronal gamma-H2AX intensity after 30 weeks of XJB-5-131

Direction: DECREASED

Interpretation: Vehicle-treated disease animals showed roughly doubled neuronal gamma-H2AX versus wild type; treatment inhibited the increase.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"Conversely, suppression of DSBs is sufficient to reverse neuropathology even when somatic expansion is active."

Reports the treatment-driven reduction in double-strand breaks and the resulting reversal of neuropathology.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"Conversely, suppression of DSBs is sufficient to reverse neuropathology even when somatic expansion is active."

Supports this model plus treatment arm as informative for the oxidation-driven break-formation node.

Medium Spiny Neuron Degeneration rescues fidelity: moderate The downstream survival arm of the same XJB-5-131 treatment experiment. Lowering the double-strand break burden rescued striatal neuron number and motor performance, which is the outcome that makes break burden a therapeutic target rather than merely a correlate.

Limitations: Neuronal rescue is measured by NeuN immunofluorescence rather than by stereological cell counts. Male mice only, n = 3 per group, and treatment began at 60 weeks so the result speaks to halting further loss in established disease rather than to preventing onset. The drug acts upstream on break formation, so this rescue does not show that non-homologous end joining was restored.

Readouts

Striatal NeuN immunofluorescence after 30 weeks of XJB-5-131

Direction: RESTORED

Interpretation: Neuronal marker staining recovered in treated disease animals, indicating rescue of striatal neuron loss alongside the fall in break burden.

Show evidence (1 reference)

PMID:26908614 SUPPORT Model Organism

"In animals with well-developed pathology, XJB-5-131 promotes weight gain, prevents neuronal death, reduces oxidative damage in neurons, suppresses the decline of motor performance or improves it"

Reports prevention of neuronal death under the same late-start dosing regimen in the same model.

Show evidence (1 reference)

PMID:26908614 SUPPORT Model Organism

"In animals with well-developed pathology, XJB-5-131 promotes weight gain, prevents neuronal death, reduces oxidative damage in neurons, suppresses the decline of motor performance or improves it"

Supports this model plus treatment arm as informative for rescue of striatal neuron degeneration.

Parental HdhQ(-/150) line a gift from P. Detloff; congenic line generated by backcrossing to C57BL/6J for more than 15 generations. All experiments in PMID:42091595 used male mice.

zQ175 knock-in mouse

Knock-in model carrying a CAG tract of approximately 175-190 that develops transcriptional dysregulation and protein aggregation by 6 months and undergoes somatic expansion. Used here as the expansion-competent comparator against zQ175/MSH3(-/-).

Species

Mouse

Genotype

Htt CAG(175-190) knock-in (zQ175)

Publication

PMID:27378694

Pathograph links

Genome-Wide Double Strand Break Accumulation recapitulates fidelity: moderate 53BP1 and gamma-H2AX staining intensity is elevated in zQ175 striatal neurons relative to C57BL/6J background controls at 3 months and rises a further 30-50% by 6 months.

Limitations: Break levels were quantified by antibody staining intensity only in this strain, without the neutral comet confirmation applied in HdhQ(150/150). The strain carries a much longer repeat than adult-onset human disease.

Readouts

Striatal neuronal 53BP1 immunofluorescence intensity

Direction: INCREASED

Interpretation: Elevated versus genetic background control and increasing between 3 and 6 months, in a strain that expresses mutant huntingtin.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"DSBs and transcriptional dysfunction occur in animals that cannot somatically expand their inherited allele."

Reports the double-strand break measurements made across the zQ175 and zQ175/MSH3(-/-) comparison.

Show evidence (1 reference)

PMID:27378694 SUPPORT Model Organism

"The zQ175 model was the first KI mouse to exhibit significant HD-like phenotypes when heterozygous."

Establishes zQ175 as a phenotypically validated knock-in HD model.

zQ175/MSH3(-/-) expansion-incompetent knock-in mouse

Separation-of-function cross. Because somatic CAG expansion requires MutS beta (MSH2-MSH3), ablating Msh3 abolishes expansion while leaving mutant huntingtin expression intact. This dissociates the two candidate drivers: any pathology that persists in these animals cannot be attributed to ongoing somatic expansion. Double-strand breaks are elevated and rise with age here just as in expansion-competent zQ175, and transcriptional dysfunction and aggregation still develop.

Species

Mouse

Genotype

Htt CAG(175-190) knock-in on an Msh3 null background

Publication

PMID:38387080

Pathograph links

Somatic CAG Repeat Expansion fails to recapitulate fidelity: high By design this model does not reproduce somatic CAG expansion - Msh3 ablation prevents it throughout brain and periphery. The negative result is the point of the model, not a shortcoming of it: it is what licenses attributing the residual pathology to an expansion-independent driver.

Limitations: Msh3 is ablated constitutively and germline-wide rather than conditionally in striatal neurons, so loss of any expansion-independent MSH3 function is not controlled for. The starting repeat of ~185 CAG already exceeds the proposed pathogenic threshold, so absence of further expansion may matter less in this strain than it would at shorter adult-onset repeat lengths - the authors of the source study make exactly this argument.

Readouts

Somatic CAG repeat expansion in striatum

Direction: ABOLISHED

Interpretation: Msh3 ablation prevents somatic expansion in brain and periphery, while 50% reduction slows it - a dose-dependent confirmation that the expansion arm is switched off in this cross.

Show evidence (1 reference)

PMID:38387080 SUPPORT Model Organism

"Ablation of Msh3 prevented somatic expansion throughout the brain and periphery, and reduction of Msh3 by 50% decreased the rate of expansion."

Directly reports that this cross does not undergo somatic expansion.

Show evidence (1 reference)

PMID:38387080 SUPPORT Model Organism

"This had no effect on the deposition of huntingtin aggregation in the nuclei of striatal neurons, nor on the dysregulated striatal transcriptional profile."

Abolishing somatic expansion leaves striatal aggregation and transcriptional dysregulation intact, which is the substantive negative result this model contributes.

Genome-Wide Double Strand Break Accumulation recapitulates fidelity: moderate Double-strand breaks accumulate in these expansion-incompetent animals to the same degree as in expansion-competent zQ175 - elevated at 3 months and 30-50% higher by 6 months relative to Msh3(-/-) background controls. This is the strongest genetic evidence that break accumulation does not require somatic expansion.

Limitations: The study established that breaks and transcriptional dysfunction co-occur in these animals but did not test whether the breaks cause the transcriptional dysfunction. Neuronal death is not observed at these ages in either strain, so the model demonstrates expansion-independent break accumulation rather than expansion-independent neurodegeneration.

Readouts

Striatal neuronal 53BP1 immunofluorescence intensity at 3 and 6 months

Direction: INCREASED

Interpretation: Elevated relative to Msh3(-/-) background controls despite the complete absence of somatic expansion, separating break burden from tract length.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"DSBs and transcriptional dysfunction occur in animals that cannot somatically expand their inherited allele."

States precisely the result this readout captures.

Show evidence (1 reference)

PMID:42091595 SUPPORT Model Organism

"We propose that CAG expansion and DSBs promote downstream neuronal pathology as separable drivers."

Supports treating this cross as informative for expansion-independent double-strand break accumulation.

{ }

Source YAML

click to show

name: Huntington Disease
creation_date: "2026-04-07T12:00:00Z"
category: Mendelian
description: >-
  Huntington disease (HD) is an autosomal dominant neurodegenerative disorder caused by
  an expanded CAG trinucleotide repeat in the huntingtin (HTT) gene on chromosome 4p16.3.
  The expansion produces a mutant huntingtin protein with an abnormally long polyglutamine
  tract, leading to progressive neuronal dysfunction and death, particularly in the
  striatum and cortex. HD is characterized by a triad of motor dysfunction (chorea),
  cognitive decline, and psychiatric disturbances, typically manifesting in midlife
  with relentless progression over 15-20 years.
disease_term:
  preferred_term: Huntington disease
  term:
    id: MONDO:0007739
    label: Huntington disease
gene_sets:
- gene_set: MYGENESET:KEGG_HUNTINGTONS_DISEASE
  relationship: CANONICAL_PATHWAY
  note: >-
    KEGG Huntington disease pathway.
parents:
- Neurodegenerative Disorders
- Trinucleotide Repeat Disorders
synonyms:
- Huntington's Chorea
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0007739
      label: Huntington disease
    mapping_predicate: skos:exactMatch
    mapping_source: ORPHA:399
    mapping_justification: >-
      Orphanet lists MONDO:0007739 as an exact cross-reference for the
      ORPHA:399 Huntington disease record.
external_assertions:
- name: Orphanet Huntington disease structured record
  source: Orphanet
  assertion_type: structured_disease_record
  external_id: ORPHA:399
  url: http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=399
  description: >-
    Orphanet records Huntington disease as ORPHA:399 and provides curated
    inheritance, onset, epidemiology, gene, HPO phenotype, and external
    cross-reference rows used here as structured evidence.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ORPHA:399  Huntington disease"
    explanation: >-
      The Orphanet structured record heading identifies ORPHA:399 as the
      Huntington disease record.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "MONDO:0007739 | Exact"
    explanation: >-
      Orphanet maps ORPHA:399 exactly to the same MONDO disease identifier used
      by this entry.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "OMIM:143100 | Exact"
    explanation: >-
      Orphanet lists OMIM:143100 as an exact cross-reference for Huntington
      disease.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-10:G10 | Exact"
    explanation: >-
      Orphanet lists ICD-10 G10 as an exact cross-reference for Huntington
      disease.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "ICD-11:8A01.10 | Exact"
    explanation: >-
      Orphanet lists ICD-11 8A01.10 as an exact cross-reference for Huntington
      disease.
definitions:
- name: Orphanet Huntington disease definition
  definition_type: CASE_DEFINITION
  description: >-
    Orphanet defines Huntington disease as a rare central nervous system
    neurodegenerative disorder characterized by choreatic movements, psychiatric
    and behavioral disturbances, and dementia.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia.
    explanation: >-
      Orphanet's definition supports the entry's high-level disease framing and
      cardinal clinical domains.
has_subtypes:
- name: Adult-onset HD
  display_name: Adult-onset Huntington Disease
  description: >-
    Classical form with onset typically between ages 30-50, CAG repeat length
    36-55, characterized by chorea, cognitive decline, and psychiatric symptoms.
- name: Juvenile HD
  display_name: Juvenile-Onset Huntington Disease
  subtype_term:
    preferred_term: juvenile Huntington disease
    term:
      id: MONDO:0016621
      label: juvenile Huntington disease
  subtype_frequency: approximately 1-5% of clinically manifest Huntington disease cases
  genes:
  - preferred_term: HTT
    term:
      id: hgnc:4851
      label: HTT
  description: >-
    Juvenile-onset Huntington disease (JHD/JOHD) is defined by motor symptom onset at
    or before age 20 and accounts for roughly 1-5% of manifest HD. It is driven by the
    longest CAG expansions - repeat length is usually above 55, around half of cases
    carry 60 or more repeats, and childhood-onset cases can exceed 80 - which arise by
    anticipation, most often through paternal transmission (about 80% of cases). The
    motor phenotype inverts that of adult-onset disease: chorea is uncommon early,
    while rigidity, axial bradykinesia, dystonia, dysarthria and gait disturbance
    dominate, and epilepsy, ataxia, spasticity and developmental regression are
    JHD-specific features. Presentation is frequently non-motor first (behavioural
    disturbance, declining school performance), which drives misdiagnosis and
    diagnostic delay. Progression is faster and disease duration shorter than in
    adult-onset HD.
    Terminology note: this subtype is historically called the "Westphal variant",
    but the European Huntington Disease Network JHD working group advises against
    that usage because the hypokinetic-rigid Westphal phenotype also occurs in
    adult-onset HD and so is not specific to juvenile onset. The term is retained
    here only as a synonym, and the preferred label is juvenile-onset HD.
  mappings:
    mondo_mappings:
    - term:
        id: MONDO:0016621
        label: juvenile Huntington disease
      mapping_predicate: skos:exactMatch
      mapping_source: MONDO
      mapping_justification: >-
        MONDO:0016621 (juvenile Huntington disease) is asserted in MONDO as a
        direct subclass of MONDO:0007739 (Huntington disease) and is defined by
        onset of signs and symptoms before 20 years of age, which is exactly the
        boundary used for this subtype.
  evidence:
  - reference: PMID:31045518
    reference_title: "Clinical Presentation and Features of Juvenile-Onset Huntington's Disease: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Juvenile-onset Huntington's disease (JHD) is defined by onset at the age of
      20 or younger and represents approximately 5% of all HD cases.
    explanation: >-
      Establishes the age-at-onset boundary and the approximate share of HD cases
      that define this subtype.
  - reference: PMID:39121132
    reference_title: "Prevalence of Juvenile-Onset and Pediatric Huntington's Disease and Their Availability and Ability to Participate in Trials: A Dutch Population and Enroll-HD Observational Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Juvenile-onset Huntington's disease (JHD) represents 1-5% of Huntington's
      disease (HD) patients, with onset before the age of 21.
    explanation: >-
      Supports the 1-5% subtype frequency band recorded in subtype_frequency.
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Repeat length in JHD is usually > 55 and caused by anticipation, usually via
      paternal transmission.
    explanation: >-
      European Huntington Disease Network JHD working group review supporting the
      repeat-length range, anticipation, and paternal transmission bias.
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      JHD specific features are epilepsy, ataxia, spasticity, pain, itching, and
      possibly liver steatosis.
    explanation: >-
      Names the features the working group regards as distinctive of juvenile
      onset relative to adult-onset HD.
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    directness: DIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thus, the Westphal variant is not specific for JHD exclusively and should
      therefore be avoided to address childhood-onset HD.
    explanation: >-
      Supports naming this subtype by age at onset rather than by phenotype: the
      EHDN JHD working group states that the hypokinetic-rigid Westphal phenotype
      is not exclusive to juvenile onset, so "Westphal variant" does not pick out
      the same set of patients as juvenile-onset HD.
  - reference: PMID:34636452
    reference_title: "Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Juvenile-onset patients have distinct symptoms and signs with more severe
      pathology of involved brain structures in comparison with disease onset in
      adulthood.
    explanation: >-
      Supports treating juvenile onset as a clinically and pathologically distinct
      subtype rather than merely an early adult-onset presentation.
- name: Late-onset HD
  display_name: Late-Onset Huntington Disease
  description: >
    Onset over 60 years of age, accounting for roughly 4.4-11.5% of individuals
    with HD, and often with a slower, milder course than the typical fourth-decade
    onset.
  evidence:
  - reference: PMID:28671137
    reference_title: "What do we know about Late Onset Huntington's Disease?"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: 'BACKGROUND: Although the typical age of onset for Huntington''s disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age).'
    explanation: Defines late-onset HD as onset over 60 years of age, occurring in 4.4-11.5% of individuals with HD, supporting the corrected subtype description.
  - reference: PMID:17390259
    reference_title: "Huntington's Disease."
    supports: REFUTE
    evidence_source: OTHER
    snippet: Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment.
    explanation: Refutes any characterization of late onset as beginning after age 50; HD most typically manifests between ages 35 and 45, so the late-onset subtype is best defined by onset over 60 rather than over 50.
inheritance:
- name: Autosomal Dominant
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: COMPLETE
  parent_of_origin_effect: >-
    Strong paternal transmission bias for large intergenerational expansions. Male
    meiotic instability of the CAG tract drives anticipation, and the effect is most
    extreme in juvenile-onset HD, where the mutant HTT allele is paternally inherited
    in roughly 80% of cases.
  description: >-
    HD follows autosomal dominant inheritance with complete penetrance at 40+ CAG
    repeats. Reduced penetrance occurs with 36-39 repeats. Anticipation is observed,
    particularly with paternal transmission due to meiotic instability of the CAG repeat.
  evidence:
  - reference: PMID:31045518
    reference_title: "Clinical Presentation and Features of Juvenile-Onset Huntington's Disease: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Where data were available, the median age of onset was 9 years, 52% were
      female, the mutant HTT allele was transmitted paternally in 80% of cases, and
      the median CAG repeat length was 64.
    explanation: >-
      Quantifies the paternal transmission bias and median repeat length recorded in
      parent_of_origin_effect, pooled across 285 juvenile-onset cases.
  - reference: PMID:20301482
    reference_title: "Huntington Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Expansion and contraction of CAG repeat length can occur with maternal or
      paternal transmission; however, expansion occurs far more commonly in paternal
      transmission and contraction occurs more commonly in maternal transmission.
    explanation: >-
      GeneReviews, the authoritative expert clinical reference for HD, corroborates the
      directional parent-of-origin asymmetry recorded here: expansion is
      paternally biased while contraction is maternally biased. This is the general-HD
      statement underlying the more extreme ~80% paternal transmission seen
      specifically in juvenile-onset cases.
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Huntington disease is a fatal, inherited, neurodegenerative disease caused
      by a CAG repeat expansion in the huntingtin gene (HTT), resulting in a toxic
      polyglutamine tract in the huntingtin protein.
    explanation: >-
      Confirms HD is an inherited disorder caused by CAG repeat expansion in HTT.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Autosomal dominant"
    explanation: >-
      Orphanet's inheritance section directly states autosomal dominant
      inheritance for Huntington disease.
prevalence:
- population: Western populations (USA, Canada, Europe)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 8.2
  rate_high: 9.0
  percentage: 8.2-9.0 per 100,000
  evidence:
  - reference: PMID:34350853
    reference_title: "Modeling Manifest Huntington's Disease Prevalence Using Diagnosed Incidence and Survival Time."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diagnosed prevalence is estimated to be 8.2-9.0 per 100,000 in the USA,
      Canada, and the 5 included European countries and 3.5 per 100,000 in Brazil.
    explanation: >-
      Epidemiological model using diagnosed incidence and survival data from
      eight countries estimates HD prevalence in Western populations.
- population: Worldwide (Orphanet point prevalence)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.0
  rate_high: 9.0
  percentage: 1-9 / 100 000
  notes: >-
    Orphanet classifies worldwide Huntington disease point prevalence as 1-9
    per 100,000.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | Worldwide | Point prevalence | PMID:22692795"
    explanation: >-
      Orphanet's epidemiology table provides the worldwide point-prevalence
      class for Huntington disease.
- population: United States (Orphanet point prevalence)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_low: 1.0
  rate_high: 9.0
  percentage: 1-9 / 100 000
  notes: >-
    Orphanet classifies United States Huntington disease point prevalence as
    1-9 per 100,000.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "1-9 / 100 000 | United States | Point prevalence | PMID:8018043"
    explanation: >-
      Orphanet's epidemiology table provides a United States point-prevalence
      class for Huntington disease.
progression:
- phase: Age of onset (juvenile-onset HD)
  subtype: Juvenile HD
  age_range: 20 years or younger, median 9 years at onset
  notes: >-
    Juvenile-onset HD is defined by motor onset at or before age 20. Pooled case
    reports and case series give a median age at onset of 9 years, and onset is
    conventionally split into childhood (0-10 years) and adolescent (11-20 years)
    onset, which differ in presenting features.
  evidence:
  - reference: PMID:31045518
    reference_title: "Clinical Presentation and Features of Juvenile-Onset Huntington's Disease: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Where data were available, the median age of onset was 9 years, 52% were
      female, the mutant HTT allele was transmitted paternally in 80% of cases, and
      the median CAG repeat length was 64.
    explanation: >-
      Systematic review of 285 juvenile-onset individuals reporting the median age
      at onset used here.
- phase: Disease duration and survival (juvenile-onset HD)
  subtype: Juvenile HD
  duration: >-
    Median about 9 years from motor onset in childhood-onset JHD, versus about 18
    years in adolescent- and adult-onset HD.
  notes: >-
    Juvenile-onset HD progresses faster and is fatal sooner than adult-onset
    disease, and the effect is graded by repeat length - the most highly expanded
    cases have the shortest survival.
  evidence:
  - reference: PMID:34636452
    reference_title: "Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The median disease duration after motor onset in childhood JHD is 9 years,
      compared to 18 years in adolescent and adult HD.
    explanation: >-
      Provides the childhood-onset versus adolescent/adult disease-duration figures
      recorded in this record.
  - reference: PMID:30243861
    reference_title: "Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of 121 deceased patients, median survival was shorter in the juvenile
      Huntington's disease (n=17) cohort than in adult-onset Huntington's disease
      (n=104) cohort
    explanation: >-
      REGISTRY/Enroll-HD retrospective analysis showing shorter median survival in
      juvenile-onset than adult-onset HD.
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Disease progression of JHD is faster compared to AOHD and the disease duration
      is shorter, particularly in case of higher CAG repeat lengths.
    explanation: >-
      Expert working group review confirming faster progression and shorter duration
      graded by repeat length.
- phase: Motor progression rate (juvenile-onset HD)
  subtype: Juvenile HD
  notes: >-
    Juvenile-onset HD progresses faster than adult-onset HD on the UHDRS Total Motor
    Score, but the chorea subscales do not track that progression - they do not change
    reliably over time in juvenile-onset patients. This is a measurement consequence of
    the hypokinetic-rigid phenotype and is why chorea-based endpoints are poor outcome
    measures in this group.
  evidence:
  - reference: PMID:38142629
    reference_title: "Evaluating motor progression of juvenile-onset Huntington's Disease: An Enroll-HD analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The JOHD cohort had faster TMS progression compared to AOHD (p = 0.006) but no
      group difference in the rate of change of chorea.
    explanation: >-
      Enroll-HD analysis directly comparing juvenile- and adult-onset motor
      progression rates.
  - reference: PMID:38142629
    reference_title: "Evaluating motor progression of juvenile-onset Huntington's Disease: An Enroll-HD analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with JOHD did not show significant change in any of the chorea
      subscales.
    explanation: >-
      Supports the statement that chorea subscales fail to track juvenile-onset
      disease progression.
- phase: Age of onset
  age_range: Childhood, adolescent, adult, or elderly
  notes: >-
    Orphanet lists Huntington disease onset categories spanning childhood
    through elderly onset.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Childhood"
    explanation: >-
      Orphanet includes childhood among Huntington disease onset categories.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adolescent"
    explanation: >-
      Orphanet includes adolescent among Huntington disease onset categories.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Adult"
    explanation: >-
      Orphanet includes adult among Huntington disease onset categories.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Age of onset: Elderly"
    explanation: >-
      Orphanet includes elderly among Huntington disease onset categories.
pathophysiology:
- name: HTT CAG Repeat Expansion
  conforms_to: "polyglutamine_expansion_proteotoxicity#Translated CAG / Polyglutamine Repeat Expansion"
  description: >-
    Huntington disease is caused by expansion of a CAG trinucleotide repeat in exon 1
    of the HTT gene beyond 36 repeats. The expanded repeat produces a mutant huntingtin
    protein with an elongated polyglutamine tract that confers a toxic gain of function.
    Repeat length inversely correlates with age of onset. Normal alleles have 6-26
    repeats; intermediate alleles (27-35) can expand in offspring; 36-39 repeats show
    reduced penetrance; 40+ repeats are fully penetrant.
  evidence:
  - reference: PMID:41130308
    reference_title: "Inhibiting Cytosine-Adenine-Guanine (CAG) repeat expansions as a therapeutic strategy for Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Huntington's Disease (HD) became the first disease mapped to a single
      chromosome and associated with mutations in the huntingtin (HTT) gene,
      specifically expansions in the trinucleotide cytosine-adenine-guanine (CAG)
      within exon 1.
    explanation: >-
      Confirms the causative CAG repeat expansion in HTT exon 1.
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Huntington disease is a fatal, inherited, neurodegenerative disease caused
      by a CAG repeat expansion in the huntingtin gene (HTT), resulting in a toxic
      polyglutamine tract in the huntingtin protein.
    explanation: >-
      Confirms the toxic polyglutamine tract from CAG expansion as the primary
      molecular cause.
  downstream:
  - target: Mutant Huntingtin Protein Aggregation
    description: >-
      Expanded CAG repeat produces mutant huntingtin with toxic polyglutamine tract
      that misfolds and aggregates.
  - target: Somatic CAG Repeat Expansion
    description: >-
      Germline CAG repeat undergoes further somatic expansion in post-mitotic
      striatal neurons, accelerating disease onset.
  - target: mHTT Suppression of Non-Homologous End Joining
    description: >-
      The inherited disease-length tract produces mutant huntingtin that
      associates with the Ku70-Ku80 end-joining machinery and inhibits
      double-strand break repair early, before somatic expansion begins.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - mutant huntingtin protein interaction with the Ku70-Ku80 heterodimer
    hypothesis_groups:
    - dsb_expansion_independent_driver
    evidence:
    - reference: PMID:42091595
      reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The disease-length CAG tract leads to early inhibition of DSBR and
        accumulating DSBs over time ultimately kill neurons.
      explanation: >-
        Directly links the disease-length tract to early inhibition of
        double-strand break repair.
  - target: Uninterrupted CAG Tract Length and Loss of CAA Interruption
    description: >-
      The inherited expanded allele carries a specific repeat structure, and
      expanding the tract lengthens the run of uninterrupted CAG in alleles
      that lack the penultimate CAA interruption. Note the direction of this
      edge carefully: expansion sets the length of the uninterrupted run, but
      it does NOT create the loss-of-interruption variant, which is an
      independently inherited sequence change. This edge connects the allele to
      its repeat structure; it is not a claim that expansion removes the
      interruption.
    causal_link_type: DIRECT
- name: Uninterrupted CAG Tract Length and Loss of CAA Interruption
  biological_scale: MOLECULAR
  description: >-
    The glutamine-encoding repeat in HTT is normally (CAG)n-CAA-CAG: a
    penultimate CAA codon interrupts the pure CAG tract while encoding the same
    glutamine. Because CAA and CAG are synonymous, two alleles can encode an
    identical polyglutamine length while differing in the length of
    *uninterrupted* CAG at the DNA level. A loss-of-interruption (LOI) variant
    that removes the interrupting adenines yields a pure CAG tract and is
    associated with onset roughly 25 years earlier at matched polyglutamine
    length, and with increased somatic repeat instability. Conversely, patients
    retaining or duplicating the CAA interruption have later onset than their
    polyglutamine length predicts. The determinant of onset is therefore a
    property of the DNA sequence - its propensity for length instability, and
    hence its somatic expansion rate - rather than the length of the
    polyglutamine tract in the protein product. This node is why the KB models
    CAG tract structure separately from polyglutamine proteotoxicity, and it
    sits upstream of somatic expansion rather than of protein aggregation.
  biological_processes:
  - preferred_term: DNA repeat instability of the uninterrupted CAG tract
    modifier: DECREASED
    term:
      id: GO:0035753
      label: maintenance of DNA trinucleotide repeats
  evidence:
  - reference: PMID:31398342
    reference_title: "CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Variable, glutamine-encoding, CAA interruptions indicate that a property
      of the uninterrupted HTT CAG repeat sequence, distinct from the length of
      huntingtin's polyglutamine segment, dictates the rate at which
      Huntington's disease (HD) develops.
    explanation: >-
      The defining statement that onset is set by the uninterrupted CAG repeat
      at the DNA level rather than by polyglutamine length in the protein.
  - reference: PMID:31398342
    reference_title: "CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      suggesting that the special onset-determining property of the
      uninterrupted CAG repeat is a propensity for length instability that
      leads to its somatic expansion
    explanation: >-
      Identifies the mechanism connecting this node to the next: the
      onset-determining property of the uninterrupted tract is its instability,
      acting through somatic expansion.
  - reference: PMID:31104771
    reference_title: "Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      this LOI variant is associated with dramatically earlier AOO (average of
      25 years) despite the same polyglutamine length as in individuals with
      the interrupting penultimate CAA codon
    explanation: >-
      Quantifies the effect and provides the controlled comparison - matched
      polyglutamine length, differing uninterrupted CAG length, 25-year
      difference in age of onset.
  - reference: PMID:31104771
    reference_title: "Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      we show that the LOI variant is associated with increased somatic repeat
      instability, highlighting this as a significant driver of this effect
    explanation: >-
      Establishes increased somatic instability as the mediator of the
      loss-of-interruption effect, supporting the downstream edge.
  notes: >-
    Clinically consequential beyond onset timing: the LOI allele is enriched
    among carriers of reduced-penetrance (36-39 CAG) alleles who do manifest
    disease, so repeat-structure sequencing rather than repeat-length sizing
    alone can matter for interpreting alleles near the penetrance boundary.
  downstream:
  - target: Somatic CAG Repeat Expansion
    description: >-
      A longer uninterrupted CAG tract is more prone to length instability, so
      it raises the somatic expansion rate - the step through which repeat
      structure translates into earlier onset.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:31104771
      reference_title: "Length of Uninterrupted CAG, Independent of Polyglutamine Size, Results in Increased Somatic Instability, Hastening Onset of Huntington Disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        the number of uninterrupted CAG repeats, which is lengthened by the
        LOI, is the most significant contributor to AOO of HD and is more
        significant than polyglutamine length
      explanation: >-
        Directly supports uninterrupted tract length, acting via instability,
        as the dominant determinant of onset.
- name: Somatic CAG Repeat Expansion
  conforms_to: "mismatch_repair_driven_repeat_instability#Somatic Repeat Expansion in Post-Mitotic Cells"
  description: >-
    Somatic expansion of the CAG repeat in post-mitotic striatal neurons, driven by
    DNA mismatch repair machinery (particularly MSH3 and FAN1), accelerates disease
    progression beyond what is predicted by the inherited germline repeat length.
    This mechanism is now recognized as a key determinant of onset timing and a
    major therapeutic target. GWAS have identified DNA repair gene variants as the
    principal genetic modifiers of HD age of onset.
  cell_types:
  - preferred_term: striatal medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  biological_processes:
  - preferred_term: DNA mismatch repair driving somatic expansion
    term:
      id: GO:0006298
      label: mismatch repair
  evidence:
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      genome-wide association studies have identified genetic modifiers, mostly
      DNA repair genes, that significantly influence disease onset and progression.
      These findings point to somatic CAG repeat expansions in affected tissues as
      a key pathological mechanism.
    explanation: >-
      GWAS studies identify DNA repair gene modifiers influencing onset via
      somatic CAG expansion.
  - reference: PMID:33579859
    reference_title: "DNA Repair in Huntington's Disease and Spinocerebellar Ataxias: Somatic Instability and Alternative Hypotheses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Validation of leads including the mismatch repair protein MSH3, and
      interstrand cross-link repair protein FAN1, suggest the mechanism is driven
      by somatic CAG instability, which is supported by the protective effect of
      CAA substitutions in the CAG tract.
    explanation: >-
      Validates MSH3 and FAN1 as key mediators of somatic CAG instability.
  - reference: PMID:41130308
    reference_title: "Inhibiting Cytosine-Adenine-Guanine (CAG) repeat expansions as a therapeutic strategy for Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Somatic expansion of the CAG repeat length, beyond the inherited length, has
      been associated with hastening the onset of symptoms compared to that predicted
      from the germline length.
    explanation: >-
      Confirms somatic expansion accelerates onset beyond germline prediction.
  - reference: PMID:42400823
    reference_title: "Update on Genetic Chorea."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Striatal pallidal neurons (SPNs) with 150-500 + CAG repeats seem to lose
      positive and then negative features of neuronal identity, de-repress
      senescence/apoptosis genes, ultimately leading to cell death.
    explanation: >-
      Recent review (2026) provides mechanistic detail on how somatic CAG expansion
      leads to loss of neuronal identity features and de-repression of senescence/apoptosis
      pathways, culminating in neuronal death. Represents paradigm shift in understanding
      of somatic instability pathophysiology.
  - reference: PMID:42400823
    reference_title: "Update on Genetic Chorea."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The findings on somatic instability in HD suggest that neurodegeneration in
      HD is an asynchronous DNA process for >95% of a neuron's life, with majority
      of neurons in all disease stages having a HTT gene which is not biologically
      harmful.
    explanation: >-
      Characterizes somatic instability-driven neurodegeneration as asynchronous,
      with most neurons remaining non-harmful throughout disease, having significant
      implications for therapeutic targeting of expansion-bearing neurons.
  - reference: PMID:39824182
    reference_title: "Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We found that the HTT CAG repeat expands somatically from 40-45 to
      100-500+ CAGs in SPNs.
    explanation: >-
      Direct single-cell measurement in human striatal projection neurons of the
      magnitude of somatic expansion, establishing the scale of this node in
      human tissue rather than by inference from mouse.
  - reference: PMID:31607598
    reference_title: "A genetic association study of glutamine-encoding DNA sequence structures, somatic CAG expansion, and DNA repair gene variants, with Huntington disease clinical outcomes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      individuals with higher blood DNA somatic CAG repeat expansion scores have
      worse HD outcomes
    explanation: >-
      Quantitative human cohort evidence (TRACK-HD and Enroll-HD) linking
      measured somatic expansion to clinical outcome, independent of the
      mouse-model literature.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Somatic expansion in striatal neurons exacerbates local protein toxicity
      and accelerates neuronal death. Human single-cell data indicate this is
      threshold-like rather than graded: expansion from 40 to about 150 CAGs has
      no apparent cell-autonomous effect, while neurons crossing roughly 150
      repeats lose neuronal identity and die quickly and asynchronously.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - crossing a somatic repeat-length threshold of approximately 150 CAG
    - loss of neuronal identity gene expression and de-repression of senescence/apoptosis genes
    evidence:
    - reference: PMID:39824182
      reference_title: "Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        SPNs with 150-500+ CAGs lost positive and then negative features of
        neuronal identity, de-repressed senescence/apoptosis genes, and were
        lost
      explanation: >-
        Establishes the threshold character of this edge in human tissue and
        names the intermediate transcriptional steps between long somatic
        expansion and neuronal loss.
- name: Paternal Germline CAG Repeat Instability and Anticipation
  subtypes:
  - Juvenile HD
  biological_scale: MOLECULAR
  description: >-
    The HTT CAG tract is meiotically unstable, and the largest intergenerational
    expansions occur during male gametogenesis. Juvenile-onset HD is therefore
    overwhelmingly a paternally transmitted phenomenon: pooled across juvenile-onset
    series the mutant allele is inherited from the father in about 80% of cases, and
    the resulting anticipation is what carries an allele from the adult-onset range
    in the transmitting parent into the very long juvenile range in the child. This
    node is the germline counterpart of the somatic instability that operates within
    an affected individual's own striatal neurons: the same repeat-length-dependent
    instability acts once in the paternal germline to set the inherited allele, and
    again post-zygotically in post-mitotic neurons.
  biological_processes:
  - preferred_term: loss of fidelity in maintaining the HTT CAG trinucleotide repeat
    term:
      id: GO:0035753
      label: maintenance of DNA trinucleotide repeats
    modifier: DECREASED
  - preferred_term: male meiosis, the cell-division context in which the expansion occurs
    term:
      id: GO:0007140
      label: male meiotic nuclear division
  notes: >-
    Ontology note on the two biological_processes terms. GO:0035753 (maintenance of DNA
    trinucleotide repeats) is the node's actual subject: its definition is "sustaining
    the fidelity and copy number of DNA trinucleotide repeats", so repeat instability is
    that process running at DECREASED fidelity. GO:0007140 is retained alongside it only
    as the cell-division context that makes the instability paternal rather than
    maternal; it names the division, not the instability, and should not be read as
    annotating the repeat-expansion claim on its own. GO was searched for a term naming
    repeat instability or expansion directly ("trinucleotide repeat", "repeat
    instability", "DNA repeat") and no such term exists - GO models the maintenance
    process, not its failure - so the DECREASED modifier carries that direction.
  evidence:
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Repeat length in JHD is usually > 55 and caused by anticipation, usually via
      paternal transmission.
    explanation: >-
      Directly attributes the juvenile-range repeat length to anticipation occurring
      predominantly through paternal transmission.
  - reference: PMID:31045518
    reference_title: "Clinical Presentation and Features of Juvenile-Onset Huntington's Disease: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Where data were available, the median age of onset was 9 years, 52% were
      female, the mutant HTT allele was transmitted paternally in 80% of cases, and
      the median CAG repeat length was 64.
    explanation: >-
      Quantifies the paternal transmission bias across 285 pooled juvenile-onset
      cases.
  - reference: PMID:34636452
    reference_title: "Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      About 80% of JHD patients inherit the repeat expansion via paternal
      transmission.
    explanation: >-
      Independent review confirming the ~80% paternal transmission figure.
  downstream:
  - target: Juvenile-Range CAG Expansion
    description: >-
      Male meiotic expansion of the inherited tract is the mechanism by which a
      juvenile-range allele is generated in the offspring.
    causal_link_type: DIRECT
- name: Juvenile-Range CAG Expansion
  subtypes:
  - Juvenile HD
  biological_scale: MOLECULAR
  description: >-
    Age at motor onset in HD is inversely related to CAG repeat length, and juvenile
    onset sits at the extreme end of that relationship. Repeat length in juvenile-onset
    HD is usually above 55, roughly half of juvenile cases carry 60 or more repeats,
    and childhood-onset cases can exceed 80. The dose-response is steeper here than in
    adult-onset disease: repeat length explains around 60% of onset-age variability in
    adult-onset HD but up to 84% in juvenile-onset HD, so in this subtype the inherited
    allele - rather than modifier genes or somatic expansion - is the dominant
    determinant of when disease begins. The same repeat-length gradient operates within
    the juvenile group, separating a low-expansion from a high-expansion clinical
    phenotype.
  genetic_context:
    gene:
      preferred_term: HTT
      term:
        id: hgnc:4851
        label: HTT
    allele_type: Expanded CAG trinucleotide repeat, usually >55 and commonly >=60 repeats
    variant_origin: GERMLINE
    zygosity: HETEROZYGOUS
    functional_impact_category: GAIN_OF_FUNCTION
    description: >-
      Heterozygous germline HTT CAG expansion in the juvenile range, produced by
      intergenerational expansion and conferring a toxic polyglutamine gain of
      function of greater magnitude than the adult-onset range.
  evidence:
  - reference: PMID:34636452
    reference_title: "Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Age at onset is inversely correlated with CAG repeat length.
    explanation: >-
      States the inverse repeat-length/onset-age relationship on which the juvenile
      threshold rests.
  - reference: PMID:34636452
    reference_title: "Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In approximately 50% of JHD cases the CAG expansion is ≥60, exceeding 80
      repeats in childhood onset.
    explanation: >-
      Provides the juvenile repeat-length distribution and the childhood-onset
      extreme quoted in this node.
  - reference: PMID:32825467
    reference_title: "The Association between CAG Repeat Length and Age of Onset of Juvenile-Onset Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, CAG repeat length predicted 84% of the variance in AMO amongst
      participants from the Kids-JOHD study (p < 0.0001).
    explanation: >-
      Primary Kids-JOHD analysis establishing that repeat length explains 84% of
      age-at-motor-onset variance in juvenile-onset HD.
  - reference: PMID:32825467
    reference_title: "The Association between CAG Repeat Length and Age of Onset of Juvenile-Onset Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In line with previous reports, the variance in AMO that was predicted by CAG
      repeat length was 59% (p < 0.0001) in the Predict-HD study and 57% from the
      Enroll-HD platform (p < 0.0001).
    explanation: >-
      Provides the adult-onset comparator (57-59% of onset-age variance) against
      which the juvenile-onset 84% figure is a genuine increase.
  - reference: PMID:39121132
    reference_title: "Prevalence of Juvenile-Onset and Pediatric Huntington's Disease and Their Availability and Ability to Participate in Trials: A Dutch Population and Enroll-HD Observational Study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      explaining approximately 60% of variability in adult-onset HD (AHD) and up to
      84% in JHD
    explanation: >-
      Independent restatement of the stronger dependence of onset age on repeat
      length in juvenile-onset than adult-onset HD.
  - reference: PMID:38108356
    reference_title: "Dysregulation of Human Juvenile Huntington's Disease Brain Proteomes in Cortex and Putamen Involves Mitochondrial and Neuropeptide Systems."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      JHD brain tissues were heterozygous for one mutant HTT allele containing 60 to
      120 CAG repeats, and one normal HTT allele with 10 to 19 CAG repeats.
    explanation: >-
      Post-mortem confirmation of the heterozygous juvenile-range genotype recorded
      in genetic_context, measured directly in JHD brain tissue.
  downstream:
  - target: Mutant Huntingtin Protein Aggregation
    description: >-
      A longer polyglutamine tract raises the aggregation propensity of mutant
      huntingtin, so the juvenile-range allele drives the same aggregation mechanism
      as adult-onset HD but earlier and more severely.
    causal_link_type: DIRECT
  - target: Juvenile-Onset Brain Morphometric Divergence
    description: >-
      The juvenile-range allele acts on a brain that is still developing, producing a
      structural phenotype that differs from the adult-onset pattern rather than
      simply preceding it.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - mutant huntingtin interference with early neurodevelopment and postnatal brain maturation
  - target: Somatic CAG Repeat Expansion
    description: >-
      Longer inherited tracts are more somatically unstable, so the juvenile-range
      allele also enters the somatic expansion cycle from a higher starting length.
    causal_link_type: DIRECT
  - target: Highly Expanded Pediatric HD Cerebral Hypometabolic State
    description: >-
      SCOPE-RESTRICTED EDGE. This edge does NOT apply across the juvenile range. It is
      asserted only at the highly expanded pediatric extreme (above 80 CAG repeats),
      where reduced GLUT-1/GLUT-3, mitochondrial complex II-III and hexokinase-II
      expression were measured in frontal cortex. In the same study, juvenile-onset
      samples below that threshold had expression levels resembling adult-onset HD, so
      the edge must not be read as "juvenile-range expansion causes cerebral
      hypometabolism". The intervening steps are not established, and the target node
      is marked PROVISIONAL on an n=2 brain sample.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - repeat-length-dependent transcriptional dysregulation of glucose transporter expression
    - mutant huntingtin interference with mitochondrial respiratory chain assembly
    evidence:
    - reference: PMID:37898095
      reference_title: "GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Expression JOHD levels were consistently different to those of HE-PHD but similar
        to those of AOHD.
      explanation: >-
        Recorded as PARTIAL because it is the constraint on this edge rather than
        support for it: the hypometabolic state tracks the >80-CAG pediatric subgroup,
        not juvenile-range expansion generally, which is why the edge carries an
        explicit scope restriction.
- name: Juvenile-Onset Brain Morphometric Divergence
  subtypes:
  - Juvenile HD
  biological_scale: TISSUE
  description: >-
    Because the juvenile-range allele is expressed throughout brain development, the
    structural phenotype of juvenile-onset HD is not simply an accelerated version of
    the adult-onset pattern. Juvenile-onset patients have substantially reduced
    intracranial volume - a developmental rather than degenerative signature, since
    intracranial volume is set by brain growth. After correcting for that smaller
    cranial vault, the caudate, putamen, globus pallidus, thalamus and cortical white
    matter are all significantly reduced, while the cerebral cortex is largely spared
    and the cerebellum is proportionately enlarged. The same striatal-down,
    cerebellum-up pattern is reproduced in R6/2, zQ175 and HdhQ250 mouse models, whose
    very long repeats make them better models of juvenile than adult-onset disease.
    This combination - extrastriatal involvement plus relative cerebellar preservation
    or enlargement - is the leading structural explanation for why juvenile-onset
    patients present hypokinetic and rigid rather than choreic. Progression is measurable:
    striatal volume falls about 4% per year in juvenile-onset patients versus essentially
    no change in gene-non-expanded controls.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  evidence:
  - reference: PMID:30971481
    reference_title: "Brain structure in juvenile-onset Huntington disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Participants with JHD had substantially reduced intracranial volumes.
    explanation: >-
      Establishes the reduced intracranial volume that distinguishes the
      juvenile-onset structural phenotype.
  - reference: PMID:30971481
    reference_title: "Brain structure in juvenile-onset Huntington disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      After controlling for the small intracranial volume size, the volumes of
      subcortical regions (caudate, putamen, globus pallidus, and thalamus) and of
      cortical white matter were significantly decreased in patients with JHD.
    explanation: >-
      Specifies which structures are reduced once intracranial volume is accounted
      for.
  - reference: PMID:30971481
    reference_title: "Brain structure in juvenile-onset Huntington disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, the cerebellum was proportionately enlarged in the JHD sample.
    explanation: >-
      Supports the relative cerebellar enlargement that is specific to the
      juvenile-onset pattern.
  - reference: PMID:30971481
    reference_title: "Brain structure in juvenile-onset Huntington disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Likewise, HD mice had a lower volume of striatum and a higher volume of
      cerebellum, mirroring the human MRI results.
    explanation: >-
      Mouse models carrying very long repeats reproduce the human juvenile-onset
      morphometric pattern, supporting it as a repeat-length-driven phenotype rather
      than a cohort artefact.
  - reference: PMID:36318082
    reference_title: "Longitudinal Clinical and Biological Characteristics in Juvenile-Onset Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The mean annualized decrease in striatal volume in the JOHD group was -3.99%
      compared to -0.06% in the GNE
    explanation: >-
      Quantifies the annual rate of striatal volume loss in juvenile-onset HD against
      gene-non-expanded controls.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Striatal, pallidal and thalamic volume loss in juvenile-onset HD reflects the
      same medium spiny neuron degeneration seen in adult-onset disease, reached
      earlier and extending further beyond the striatum.
    causal_link_type: DIRECT
- name: Highly Expanded Pediatric HD Cerebral Hypometabolic State
  subtypes:
  - Juvenile HD
  biological_scale: TISSUE
  mechanism_confidence: PROVISIONAL
  description: >-
    A candidate mechanism specific to the most extreme end of the juvenile spectrum.
    In post-mortem frontal cortex from pediatric HD with highly expanded mutations
    (HE-PHD, above 80 CAG repeats), the glucose transporters GLUT-1 and GLUT-3 are
    reduced, as are mitochondrial complexes II-III and hexokinase-II, and the same
    transporter reduction is seen in patient fibroblasts. Critically, the reduction
    occurs in cortex WITHOUT evidence of extensive neuronal degeneration, so it is not
    simply a readout of tissue loss, and the resemblance to GLUT-1 deficiency syndrome
    offers a mechanistic account of the neurodevelopmental delay and epilepsy seen at
    these repeat lengths.
    SCOPE CAVEAT, which curators must preserve: this is NOT a general juvenile-onset
    HD finding. Juvenile-onset (JOHD) samples in the same study had expression levels
    consistently different from HE-PHD and similar to adult-onset HD, so the
    hypometabolic signature segregates with the >80-CAG pediatric subgroup rather than
    with juvenile onset as such. The study is also very small (brain n=2 HE-PHD, n=3
    JOHD, n=6 AOHD), which is why this node is marked PROVISIONAL and is
    hypothesis-generating rather than a validated juvenile biomarker.
  locations:
  - preferred_term: frontal cortex
    term:
      id: UBERON:0001870
      label: frontal cortex
  biological_processes:
  - preferred_term: glucose transmembrane transport
    term:
      id: GO:1904659
      label: D-glucose transmembrane transport
    modifier: DECREASED
  evidence:
  - reference: PMID:37898095
    reference_title: "GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Paediatric Huntington disease with highly expanded mutations (HE-PHD; >80 CAG
      repeats) presents atypically, compared to adult-onset Huntington disease (AOHD),
      with neurodevelopmental delay, epilepsy, abnormal brain glucose metabolism,
      early striatal damage, and reduced lifespan.
    explanation: >-
      Defines the highly expanded pediatric subgroup to which this mechanism is scoped
      and its atypical clinical profile.
  - reference: PMID:37898095
    reference_title: "GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the frontal cortex, this occurred without evidence of extensive neuronal
      degeneration.
    explanation: >-
      Supports treating the transporter reduction as a primary metabolic change rather
      than a secondary consequence of neuronal loss.
  - reference: PMID:37898095
    reference_title: "GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Expression JOHD levels were consistently different to those of HE-PHD but similar
      to those of AOHD.
    explanation: >-
      The scope caveat in its own words: juvenile-onset samples resembled adult-onset
      rather than highly expanded pediatric HD, so this mechanism must not be
      generalized to juvenile-onset HD as a whole. Recorded as PARTIAL because it
      constrains rather than supports the node's applicability.
  - reference: PMID:37898095
    reference_title: "GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our data suggest a dysfunctional hypometabolic state occurring specifically in
      paediatric Huntington disease brains.
    explanation: >-
      The authors' own hedged interpretation, matching the PROVISIONAL mechanism
      confidence recorded here.
  downstream:
  - target: Developmental Regression and Delay
    description: >-
      PROPOSED, NOT ESTABLISHED. The study's motivating rationale is that genetic
      GLUT-1 deficiency syndrome produces a symptom spectrum resembling highly expanded
      pediatric HD, which offers a candidate metabolic account of the neurodevelopmental
      delay seen at these repeat lengths. What is actually measured is the co-occurrence
      of the transporter deficit and the clinical picture in the same >80-CAG subgroup,
      not a demonstrated causal sequence; no rescue or intervention experiment has been
      done. Treat as a hypothesis to test, not a curated causal fact.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37898095
      reference_title: "GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Since genetic GLUT-1 deficiency syndrome shows a symptom spectrum similar to
        HE-PHD, we investigated the potential role of the two main glucose transporters,
        GLUT-1 and GLUT-3, in HE-PHD.
      explanation: >-
        PARTIAL because this states the authors' analogy-based rationale for
        investigating the transporters, not a demonstration that the transporter deficit
        causes the neurodevelopmental phenotype.
  - target: Seizures
    description: >-
      PROPOSED, NOT ESTABLISHED. Same standing as the developmental-delay edge: epilepsy
      is part of the atypical presentation reported for the highly expanded pediatric
      subgroup alongside abnormal brain glucose metabolism, and the GLUT-1 deficiency
      syndrome analogy supplies a candidate mechanism, but causation is not shown. Note
      the target phenotype is scoped to juvenile HD as a whole while this edge is
      restricted to the >80-CAG subgroup, so the edge explains only part of the juvenile
      seizure burden.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:37898095
      reference_title: "GLUT-1 changes in paediatric Huntington disease brain cortex and fibroblasts: an observational case-control study."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Paediatric Huntington disease with highly expanded mutations (HE-PHD; >80 CAG
        repeats) presents atypically, compared to adult-onset Huntington disease (AOHD),
        with neurodevelopmental delay, epilepsy, abnormal brain glucose metabolism,
        early striatal damage, and reduced lifespan.
      explanation: >-
        Establishes that epilepsy and abnormal brain glucose metabolism co-occur in this
        subgroup. INDIRECT because co-occurrence in the same subgroup is not evidence of
        the causal direction this edge proposes.
- name: Mutant Huntingtin Protein Aggregation
  conforms_to: "polyglutamine_expansion_proteotoxicity#Misfolded Polyglutamine Protein Aggregation"
  description: >-
    The expanded polyglutamine tract causes mutant huntingtin to misfold and form
    intracellular aggregates (inclusion bodies) in neurons. These aggregates disrupt
    proteostasis, sequester essential cellular proteins including transcription factors
    (CBP, Sp1, TFIID, REST/NRSF), and interfere with transcriptional regulation,
    axonal transport, and synaptic function. Aberrant proteolytic cleavage by caspase-6
    generates toxic N-terminal fragments that accumulate in the nucleus.
  biological_processes:
  - preferred_term: Protein aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  evidence:
  - reference: PMID:18992820
    reference_title: "Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Cleavage of huntingtin by caspase-6 at amino acid 586 is a crucial event
      in the pathogenesis of HD. Nuclear localization of huntingtin is also an
      important marker of HD and preventing or delaying its nuclear accumulation
      is protective in disease models.
    explanation: >-
      Demonstrates caspase-6 cleavage generates toxic N-terminal fragments and
      their nuclear accumulation drives pathogenesis.
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although Huntington disease has long been viewed as a consequence of
      age-dependent toxicity from mutant huntingtin, genome-wide association
      studies have identified genetic modifiers, mostly DNA repair genes, that
      significantly influence disease onset and progression.
    explanation: >-
      Confirms the established view that mutant huntingtin protein toxicity
      is central to HD pathogenesis.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Mutant huntingtin aggregates and toxic fragments cause selective death of
      striatal medium spiny neurons.
  - target: Transcriptional Dysregulation
    description: >-
      Nuclear mutant huntingtin and N-terminal fragments sequester transcription
      factors (Sp1, CBP, REST/NRSF), dysregulating neuronal gene expression.
  - target: Excitotoxicity
    description: >-
      Mutant huntingtin sensitizes striatal neurons to NMDA-receptor-mediated
      glutamatergic excitotoxicity.
  - target: Mitochondrial Dysfunction
    description: >-
      Mutant huntingtin impairs mitochondrial bioenergetics, contributing to
      oxidative stress and energy failure.
- name: Medium Spiny Neuron Degeneration
  conforms_to: "polyglutamine_expansion_proteotoxicity#Selective Neuronal Dysfunction and Loss"
  description: >-
    GABAergic medium spiny neurons (MSNs) in the caudate nucleus and putamen are
    selectively vulnerable in HD. Indirect pathway MSNs expressing enkephalin and
    D2 dopamine receptors are affected earliest, followed by direct pathway MSNs.
    This selective vulnerability involves excitotoxicity from corticostriatal
    glutamatergic inputs, mitochondrial dysfunction, impaired BDNF signaling, and
    naturally low levels of protective S421 phosphorylation in striatal neurons.
  cell_types:
  - preferred_term: Medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: Neuronal apoptosis
    term:
      id: GO:0006915
      label: apoptotic process
  - preferred_term: Glutamate excitotoxicity
    term:
      id: GO:0007215
      label: glutamate receptor signaling pathway
  - preferred_term: Impaired BDNF trophic support
    term:
      id: GO:0031547
      label: brain-derived neurotrophic factor receptor signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The disease leads to progressive motor, cognitive and psychiatric decline,
      primarily resulting from loss of medium spiny neurons in the striatum.
    explanation: >-
      Directly confirms MSN loss in the striatum as the primary cause of HD
      clinical manifestations.
  - reference: PMID:18992820
    reference_title: "Phosphorylation of huntingtin reduces the accumulation of its nuclear fragments."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Huntingtin is phosphorylated on serine-421 (S421) by the pro-survival
      signaling protein kinases Akt and SGK. Phosphorylation of huntingtin at S421
      is variable in different regions of the brain with the lowest levels observed
      in the striatum, which is further reduced by the mutation for Huntington
      disease (HD).
    explanation: >-
      Explains selective striatal vulnerability through naturally low levels of
      neuroprotective S421 phosphorylation in the striatum.
  - reference: PMID:38427495
    reference_title: "Mono- and Biallelic Inactivation of Huntingtin Gene in Patient-Specific Induced Pluripotent Stem Cells Reveal HTT Roles in Striatal Development and Neuronal Functions."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      HTT loss or mutation has impacts on neuro-epithelial and striatal neurons
      maturation, and on basal DNA damage and BDNF axonal transport in post-mitotic
      neurons
    explanation: >-
      iPSC-derived models show HTT mutation impairs striatal neuron maturation
      and BDNF transport, contributing to selective vulnerability.
  downstream:
  - target: Chorea
  - target: Cognitive Decline
  - target: Memory Impairment
  - target: Bradyphrenia
  - target: Gait Disturbance
  - target: Gait Imbalance
  - target: Clumsiness
  - target: Poor Fine Motor Coordination
  - target: Abnormality of Eye Movement
  - target: Staring Gaze
  - target: Bradykinesia
  - target: Hypokinesia
  - target: Hyperreflexia
  - target: Involuntary Movements
  - target: Speech Articulation Difficulties
  - target: Oral-pharyngeal Dysphagia
- name: Neuroinflammation
  description: >-
    Reactive microglia and astrocytes contribute to HD pathogenesis through release
    of pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha) and impaired glutamate
    buffering. Microglial activation occurs early, even before symptom onset, and
    correlates with disease progression. Peripheral immune dysregulation is also
    observed.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  - preferred_term: Astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: Neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
  evidence:
  - reference: PMID:39519337
    reference_title: "Neuroinflammatory Proteins in Huntington's Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Activation of the immune system and glial cell-mediated neuroinflammatory
      responses are early pathological features and have been found in all
      neurodegenerative diseases (NDDs), including HD.
    explanation: >-
      Dedicated HD neuroinflammation review confirming glial-mediated
      neuroinflammatory responses as early pathological features of HD.
  - reference: PMID:39519337
    reference_title: "Neuroinflammatory Proteins in Huntington's Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This review highlights the significantly elevated levels of inflammatory
      proteins and cellular markers observed in various HD animal models and HD
      patient tissues, emphasizing the critical roles of microglia, astrocytes,
      and oligodendrocytes in mediating neuroinflammation in HD.
    explanation: >-
      Establishes microglia and astrocytes as key mediators of neuroinflammation
      in HD with elevated inflammatory markers in patient tissues.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Neuroinflammatory activation contributes to progressive striatal neuronal
      injury in HD.
  - target: Abnormality of the Sense of Smell
- name: Excitotoxicity
  description: Overactivation of glutamate receptors leading to neuronal damage.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: chemical synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  - preferred_term: excitatory postsynaptic potential
    term:
      id: GO:0060079
      label: excitatory postsynaptic potential
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:38776957
    reference_title: "Single nuclei RNA-seq reveals a medium spiny neuron glutamate excitotoxicity signature prior to the onset of neuronal death in an ovine Huntington's disease model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We have identified transcriptional upregulation of genes encoding N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate receptors in medium spiny neurons, the cell type preferentially lost early in HD.
    explanation: The study identifies upregulation of glutamate receptors in medium spiny neurons, supporting the idea of excitotoxicity due to overactivation of these receptors leading to neuronal damage.
  - reference: PMID:1464368
    reference_title: "Mechanisms of excitotoxicity in neurologic diseases."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Excitotoxicity refers to neuronal cell death caused by activation of excitatory amino acid receptors. A substantial body of evidence has implicated excitotoxicity as a mechanism of cell death in both acute and chronic neurologic diseases.
    explanation: This reference explains the concept of excitotoxicity and supports the idea that overactivation of glutamate receptors can lead to neuronal damage.
  - reference: PMID:7590394
    reference_title: "Elevated extracellular glutamate levels increased the formation of hydroxyl radical in the striatum of anesthetized rat."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Our results indicated that elevated glutamate concentrations (15 mM, 1.5 mM, and 150 microM glutamate in perfusing solutions) would significantly increased both the concentrations of 2,3 and 2,5 DHBA.
    explanation: The study provides direct evidence that elevated glutamate levels increase the formation of hydroxyl radicals, implying oxidative stress induced by excitotoxicity, which supports the statement.
  - reference: PMID:19805493
    reference_title: "Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Induction of striatal excitotoxicity in CB(2) receptor-deficient mice by quinolinic acid administration exacerbated brain oedema, microglial activation, proinflammatory-mediator state and medium-sized spiny neuron degeneration.
    explanation: This study shows that excitotoxicity induced in the striatum leads to medium spiny neuron degeneration, supporting the idea of excitotoxicity causing neuronal damage in Huntington's Disease.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Glutamate-receptor overactivation produces excitotoxic injury and death of
      striatal medium spiny neurons.
  - target: Seizures
- name: Mitochondrial Dysfunction
  conforms_to: "polyglutamine_expansion_proteotoxicity#Mitochondrial and Bioenergetic Dysfunction"
  description: Reduced efficiency of oxidative phosphorylation complexes, loss of mitochondrial membrane potential, and impaired mitochondrial DNA stability leading to bioenergetic failure.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  - preferred_term: mitochondrion organization
    term:
      id: GO:0007005
      label: mitochondrion organization
  - preferred_term: response to oxidative stress
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:19622387
    reference_title: "Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death.
    explanation: Supports the pathophysiology entry by directly linking mitochondrial dysfunction in HD to compromised energy metabolism, oxidative damage, and neuronal death.
  - reference: PMID:23602910
    reference_title: "PGC-1alpha, mitochondrial dysfunction, and Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1alpha), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD.
    explanation: Supports the mitochondrial dysfunction mechanism by connecting impaired PGC-1alpha activity to defective mitochondrial biogenesis, metabolism, and antioxidant defense in HD.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Bioenergetic failure and oxidative damage contribute to degeneration of
      energy-demanding striatal medium spiny neurons.
  - target: Oxidative Single-Strand to Double-Strand Break Conversion
    description: >-
      Mitochondrial reactive oxygen species raise the endogenous base-damage
      load, increasing base excision repair single-strand break intermediates
      and their conversion to double-strand breaks. This is the edge targeted
      by the mitochondria-directed antioxidant XJB-5-131.
    causal_link_type: DIRECT
    hypothesis_groups:
    - dsb_expansion_independent_driver
  - target: Weight Loss
  - target: Generalized Muscle Weakness
- name: D2 Receptor Medium Spiny Neuron Selective Vulnerability
  conforms_to: "polyglutamine_expansion_proteotoxicity#Selective Neuronal Dysfunction and Loss"
  description: D2 receptor-expressing medium spiny neurons show earlier huntingtin aggregation and greater sensitivity to CAG somatic instability compared to D1 receptor-expressing neurons.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: protein aggregation
    term:
      id: GO:0070841
      label: inclusion body assembly
  - preferred_term: synaptic transmission
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  evidence:
  - reference: PMID:38291334
    reference_title: "Cell-type-specific CAG repeat expansions and toxicity of mutant Huntingtin in human striatum and cerebellum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CAG expansions arise at mHTT in striatal medium spiny neurons (MSNs),
      cholinergic interneurons and cerebellar Purkinje neurons
    explanation: >-
      Establishes the selectivity paradox in human tissue: somatic expansion is
      not confined to the cell type that dies. Cholinergic interneurons and
      cerebellar Purkinje neurons expand too, yet striatal projection neurons
      are the population lost - so expansion alone does not determine which
      cells degenerate.
  - reference: PMID:38291334
    reference_title: "Cell-type-specific CAG repeat expansions and toxicity of mutant Huntingtin in human striatum and cerebellum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      CAG expansions in MSNs are associated with higher levels of MSH2 and MSH3
      (forming MutSβ), which can inhibit nucleolytic excision of CAG slip-outs
      by FAN1
    explanation: >-
      Provides the cell-type-specific molecular correlate of differential
      expansion - the MutS beta versus FAN1 balance - linking this node to the
      MSH3 and FAN1 modifier genes curated in the genetic section.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Indirect-pathway D2 medium spiny neurons show earliest aggregation and
      selective vulnerability, contributing to striatal neuron loss.
  - target: Dystonia
  - target: Myoclonus
- name: Transcriptional Dysregulation
  conforms_to: "polyglutamine_expansion_proteotoxicity#Transcriptional Dysregulation"
  description: Mutant huntingtin disrupts transcriptional regulation through sequestration of transcription factors including Sp1, CBP, and REST/NRSF, leading to widespread downregulation of neuronal genes including BDNF.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: regulation of transcription by RNA polymerase II
    term:
      id: GO:0006357
      label: regulation of transcription by RNA polymerase II
  - preferred_term: chromatin remodeling
    term:
      id: GO:0006338
      label: chromatin remodeling
  evidence:
  - reference: PMID:11839795
    reference_title: "Interaction of Huntington disease protein with transcriptional activator Sp1."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin.
    explanation: In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.
  - reference: PMID:11839795
    reference_title: "Interaction of Huntington disease protein with transcriptional activator Sp1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells.
    explanation: Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD transgenic mice confirming CBP sequestration into polyglutamine aggregates in vivo.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: Human HD postmortem brain tissue showing CBP depletion and sequestration into polyglutamine aggregates.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aberrant accumulation of REST/NRSF in the nucleus is present in Huntington disease. We show that wild-type huntingtin coimmunoprecipitates with REST/NRSF and that less immunoprecipitated material is found in brain tissue with Huntington disease.
    explanation: Human postmortem brain data showing aberrant nuclear REST/NRSF accumulation and reduced huntingtin-REST/NRSF interaction in HD.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: loss of expression of NRSE-controlled neuronal genes is shown in cells, mice and human brain with Huntington disease.
    explanation: Mouse model data confirming loss of NRSE-controlled gene expression in HD, corroborating the REST/NRSF dysregulation mechanism.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Wild-type huntingtin inhibits the silencing activity of NRSE, increasing transcription of BDNF. We show that this effect occurs through cytoplasmic sequestering of repressor element-1 transcription factor/neuron restrictive silencer factor (REST/NRSF), the transcription factor that binds to NRSE.
    explanation: Cell-based experiments showing wild-type huntingtin sequesters REST/NRSF in the cytoplasm to permit BDNF transcription, a function lost with the mutant protein.
  downstream:
  - target: Mitochondrial Dysfunction
    description: Reduced transcription of PGC-1alpha-dependent mitochondrial and antioxidant programs drives downstream bioenergetic failure.
    hypothesis_groups:
    - canonical_transcriptional_dysregulation
    - canonical_mitochondrial_bioenergetic_failure
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - reduced PGC-1alpha activity
    - impaired mitochondrial biogenesis and antioxidant defense
    evidence:
    - reference: PMID:23602910
      reference_title: "PGC-1alpha, mitochondrial dysfunction, and Huntington's disease."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1alpha), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD.
      explanation: Provides the missing causal bridge from transcriptional dysregulation to mitochondrial failure via impaired PGC-1alpha programs.
  - target: Medium Spiny Neuron Degeneration
    description: >-
      Loss of neuronal maintenance and survival gene programs (including BDNF)
      contributes to medium spiny neuron degeneration.
  - target: Depression
  - target: Anxiety
  - target: Agitation
  - target: Aggressive Behavior
  - target: Compulsive Behaviors
  - target: Disinhibition
  - target: Irritability
  - target: Hallucinations
  - target: Apathy
  - target: Delusion
  - target: Hostility
  - target: Abnormal Libido
  - target: Sleep Disturbances
- name: mHTT Suppression of Non-Homologous End Joining
  biological_scale: MOLECULAR
  description: >-
    Mutant huntingtin physically associates with the core non-homologous end
    joining (NHEJ) machinery and suppresses double-strand break repair (DSBR)
    activity. In HdhQ(150/150) mice, immunoprecipitation-mass spectrometry
    recovered the Ku70-Ku80 heterodimer as the principal huntingtin capture
    products (with DNA-PKcs as a minor product, and minor associations with
    Rad50 and RPA), whereas base excision repair, nucleotide excision
    repair/transcription-coupled repair and mismatch repair components showed
    few interactions. Correspondingly, multiplexed host-cell reactivation
    assays found BER, NER/TCR and MMR activity unchanged by genotype, while
    clearance of radiation-induced gamma-H2AX foci was delayed in disease
    striatal cells and tissue - breaks form normally but are repaired
    inefficiently. The deficit is genotype-, cell-type- and region-specific
    (striatum over cerebellum, neurons over glia) and appears before the onset
    of somatic expansion.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: non-homologous end joining repair of double-strand breaks
    modifier: DECREASED
    term:
      id: GO:0006303
      label: double-strand break repair via nonhomologous end joining
  evidence:
  - reference: PMID:42091595
    reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The site-specific increases in CAG tract length are driven by active
      mismatch repair (MMR), while DSBs occur genome-wide and are driven by
      mutant huntingtin-mediated suppression of nonhomologous joining of DNA
      broken ends.
    explanation: >-
      States the central claim of this node - that mutant huntingtin suppresses
      non-homologous end joining - and separates it from the MMR-driven
      expansion mechanism.
  - reference: PMID:42091595
    reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The disease-length CAG tract leads to early inhibition of DSBR and
      accumulating DSBs over time ultimately kill neurons.
    explanation: >-
      Places inhibition of double-strand break repair upstream and early,
      establishing the direction of the causal chain from tract length to
      repair suppression to break accumulation.
  notes: >-
    The Ku70/Ku80/DNA-PKcs interaction detail is recorded in prose rather than
    as bound gene-product or protein-complex descriptors because it is reported
    in the paper's results rather than its abstract, and no committed cellular
    component term for the NHEJ complex is available offline. Evidence snippets
    are deliberately restricted to abstract text.
  downstream:
  - target: Genome-Wide Double Strand Break Accumulation
    description: >-
      Inefficient end joining leaves double-strand breaks unrepaired, so break
      burden rises across the genome with age.
    causal_link_type: DIRECT
    hypothesis_groups:
    - dsb_expansion_independent_driver
- name: Oxidative Single-Strand to Double-Strand Break Conversion
  biological_scale: MOLECULAR
  description: >-
    Post-mitotic neurons have no replication fork, so the dominant source of
    double-strand breaks is endogenous base damage. Base excision repair of
    oxidised, alkylated or deaminated bases generates transient single-strand
    break (SSB) intermediates, and closely spaced SSBs on opposite strands
    convert to a double-strand break. The normal brain runs high BER against
    low DSBR, an imbalance that makes this conversion sensitive to oxidative
    and metabolic load. This node is the point at which mitochondrial reactive
    oxygen species feed the double-strand break arm, and it is the node the
    mitochondria-targeted antioxidant XJB-5-131 acts on.
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: base-excision repair generating single-strand break intermediates
    term:
      id: GO:0006284
      label: base-excision repair
  - preferred_term: response to oxidative stress
    modifier: INCREASED
    term:
      id: GO:0006979
      label: response to oxidative stress
  evidence:
  - reference: PMID:39231940
    reference_title: "Base excision repair and double strand break repair cooperate to modulate the formation of unrepaired double strand breaks in mouse brain."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The brain has the same repair proteins as other tissues, but normal,
      canonical repair activity is unequal and is characterized by high base
      excision repair (BER) and low double strand break repair (DSBR).
    explanation: >-
      Establishes the BER-high/DSBR-low imbalance in normal brain that makes
      neurons vulnerable to SSB-to-DSB conversion.
  - reference: PMID:39231940
    reference_title: "Base excision repair and double strand break repair cooperate to modulate the formation of unrepaired double strand breaks in mouse brain."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The natural imbalance creates conditions where single strand breaks
      (SSBs) can convert to double strand breaks (DSBs) and reversibly switch
      between states in response to oxidation both in vivo and in vitro.
    explanation: >-
      Directly supports oxidation-dependent SSB-to-DSB conversion as the route
      by which oxidative load generates double-strand breaks in brain.
  downstream:
  - target: Genome-Wide Double Strand Break Accumulation
    description: >-
      Oxidation-driven conversion of BER single-strand break intermediates
      supplies the double-strand breaks that inefficient end joining then fails
      to clear.
    causal_link_type: DIRECT
    hypothesis_groups:
    - dsb_expansion_independent_driver
- name: Genome-Wide Double Strand Break Accumulation
  biological_scale: CELLULAR
  description: >-
    Unrepaired double-strand breaks accumulate genome-wide in striatal neurons,
    detected concordantly by gamma-H2AX, 53BP1 and pKAP-1 immunofluorescence
    and confirmed as physical DNA breakage by neutral comet assay. Breaks are
    detectable at 7-10 weeks in HdhQ(150/150) mice - before the onset of
    somatic expansion (~11-12 weeks), motor abnormalities (~20 weeks) and
    striatal neuron loss (~60 weeks) - and rise with age in the vulnerable
    striatum while remaining modest in the resistant cerebellum. Because the
    expanded CAG tract represents less than 1e-7 of the genome, the great
    majority of these breaks lie outside the repeat; and inside the repeat,
    Ku70/Ku80 constrains end-joining length changes to a few nucleotides. Break
    burden therefore does not translate into tract length, which is the
    structural basis for treating double-strand breaks and somatic expansion as
    separable drivers.
  locations:
  - preferred_term: striatum
    term:
      id: UBERON:0002435
      label: striatum
  cell_types:
  - preferred_term: medium spiny neuron
    term:
      id: CL:1001474
      label: medium spiny neuron
  biological_processes:
  - preferred_term: double-strand break repair
    modifier: DECREASED
    term:
      id: GO:0006302
      label: double-strand break repair
  evidence:
  - reference: PMID:42091595
    reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      we report that DSBs drive neuropathology in male HdhQ(150/150) mice,
      regardless of somatic expansion of the inherited disease allele
    explanation: >-
      Supports accumulated double-strand breaks as a driver of neuropathology
      in this model independently of somatic expansion.
  - reference: PMID:42091595
    reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We propose that CAG expansion and DSBs promote downstream neuronal
      pathology as separable drivers.
    explanation: >-
      States the separability claim that distinguishes this node from the
      Somatic CAG Repeat Expansion node.
  notes: >-
    Ontology grounding gap - neither GO nor MPATH provides a continuant for
    "accumulated unrepaired DNA double-strand break burden". GO:0006302 is
    carried with modifier DECREASED to express the repair deficit that produces
    the accumulation, which is the closest available grounding; the accumulated
    lesion itself remains ungrounded. This is the same class of open-ontology
    gap recorded by the Xogenesis modules for amyloid deposit and thrombus,
    except that a double-strand break is a molecular lesion rather than a body
    structure and so is not a candidate for the OGMS/MPATH anchor convention.
  downstream:
  - target: Medium Spiny Neuron Degeneration
    description: >-
      As break burden rises, the risk grows that an unrepaired double-strand
      break terminates transcription of a gene required for neuronal survival.
      Suppressing double-strand breaks pharmacologically reverses striatal
      neuron loss without altering tract length.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - unrepaired breaks in essential genes terminating transcription
    hypothesis_groups:
    - dsb_expansion_independent_driver
    evidence:
    - reference: PMID:42091595
      reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Conversely, suppression of DSBs is sufficient to reverse neuropathology
        even when somatic expansion is active.
      explanation: >-
        Pharmacological suppression of double-strand breaks reversing
        neuropathology is the interventional evidence for this causal edge.
  - target: Transcriptional Dysregulation
    description: >-
      Error-prone end joining introduces somatic nucleotide variants at repair
      junctions, and unrepaired breaks interrupt transcription, both of which
      are proposed to contribute to the transcriptional pathology. Double-strand
      breaks and transcriptional dysfunction rise together in animals that
      cannot somatically expand their allele, but the causal direction between
      them was not tested.
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - error-prone non-homologous end joining generating somatic nucleotide variants
    - transcription blockade at unrepaired breaks
    hypothesis_groups:
    - dsb_expansion_independent_driver
    evidence:
    - reference: PMID:42091595
      reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        DSBs and transcriptional dysfunction occur in animals that cannot
        somatically expand their inherited allele.
      explanation: >-
        Establishes co-occurrence of double-strand breaks and transcriptional
        dysfunction independently of somatic expansion. Marked PARTIAL because
        the study reports co-occurrence, not that breaks cause the
        transcriptional dysfunction - see the KNOWLEDGE_GAP discussion
        gap_hd_dsb_transcriptional_causality.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_toxic_gain_of_function
  hypothesis_label: Toxic Gain-of-Function (Polyglutamine Aggregation)
  status: CANONICAL
  description: >
    The expanded polyglutamine tract in mutant huntingtin confers a toxic
    gain-of-function through protein misfolding, oligomerization, and aggregation
    into inclusion bodies. This is the widely accepted primary disease mechanism,
    with polyQ expansion beyond the pathogenic threshold (~36 repeats) driving
    neurodegeneration predominantly in the striatum.
  notes: >-
    Retained as CANONICAL. The 2026 openscientist hypothesis-search report
    (kb/hypotheses/Huntingtons_Disease/canonical_toxic_gain_of_function)
    reviewed 81 papers and found the gain-of-function model robustly
    validated, but identified three critical refinements: (1) **somatic
    CAG repeat instability** driven by MMR genes (MSH3, MSH2, PMS1, MLH1,
    FAN1) is an upstream amplifier that expands repeats far beyond the
    inherited length in vulnerable striatal MSNs — inherited repeat length
    is necessary but not sufficient for toxicity; (2) gain-of-function
    operates alongside **loss of normal HTT function** (aggregates
    sequester wild-type HTT) rather than independently; (3) RNA-level
    toxicity from expanded CAG repeats is an additional pathogenic layer
    independent of protein aggregation. The first-generation HTT-lowering
    trials' disappointing results also signal that simple mHTT removal is
    insufficient and reinforce the multi-layered model.
  evidence:
  - reference: PMID:22180703
    reference_title: "The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It is caused by expansion of a polyglutamine tract within the N-terminal domain of the Huntingtin protein. The mutation confers a toxic gain-of-function phenotype, resulting in neurodegeneration that is most severe in the striatum.
    explanation: Explicitly names the toxic gain-of-function phenotype as the consequence of polyQ expansion and links it to striatal neurodegeneration.
  - reference: PMID:25336039
    reference_title: "Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The mutational expansion of polyglutamine beyond a critical length produces a toxic gain of function in huntingtin and results in neuronal death. In the course of the disease, expanded huntingtin is proteolyzed, becomes abnormally folded, and accumulates in oligomers, fibrils, and microscopic inclusions.
    explanation: Directly states the toxic gain-of-function framing and details the aggregation cascade from proteolysis through misfolding to inclusion body formation.
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "These findings point to somatic CAG repeat expansions"
    explanation: >
      Major review reframes HD pathogenesis: somatic CAG repeat expansion
      driven by DNA repair (MMR) gene activity is now recognized as a
      rate-limiting upstream process that determines disease onset and
      progression — qualifying the simple gain-of-function model with a
      necessary upstream-amplifier step.
  - reference: PMID:22970194
    reference_title: "Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "MSN-specific deletion of Msh2"
    explanation: >
      MSN-specific Msh2 deletion eliminates striatal HTT CAG expansions
      and dramatically inhibits intranuclear huntingtin inclusions —
      providing direct genetic evidence that somatic expansion in MSNs
      is a critical step in the toxic gain-of-function pathway.
  - reference: PMID:39938516
    reference_title: "Distinct mismatch-repair complex genes set neuronal CAG-repeat expansion rate to drive selective pathogenesis in HD mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Msh3 and Pms1 drive fast somatic mHtt CAG-expansion"
    explanation: >
      Msh3 deficiency in HD knockin mice eliminates striatal CAG
      expansions, keeps somatic MSN repeat length below the ~150-repeat
      aggregation threshold, and corrects synaptic/astrocytic/locomotor
      defects — establishing somatic expansion as a causal upstream step
      in striatal pathogenesis.
  - reference: PMID:37177784
    reference_title: "Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "siRNA-mediated silencing of Msh3 effectively blocked CAG-repeat expansion in the"
    explanation: >
      Therapeutic proof-of-concept: di-valent siRNA targeting MSH3 blocks
      somatic CAG expansion in the striatum of HD mouse models without
      affecting other MMR functions, validating somatic expansion as a
      tractable therapeutic target downstream of the canonical
      gain-of-function mutation.
- hypothesis_group_id: canonical_transcriptional_dysregulation
  hypothesis_label: Transcriptional Dysregulation
  status: CANONICAL
  description: >
    Mutant huntingtin disrupts transcriptional regulation by sequestering key
    transcription factors and co-activators (Sp1, CBP, REST/NRSF), leading to
    widespread downregulation of neuronal survival genes including BDNF. This
    is a canonical downstream mechanistic layer in HD, linking mutant huntingtin
    protein interactions to loss of neuronal maintenance programs.
  evidence:
  - reference: PMID:11839795
    reference_title: "Interaction of Huntington disease protein with transcriptional activator Sp1."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: In HD transgenic mice (R6/2) that express N-terminal-mutant huntingtin, Sp1 binds to the soluble form of mutant huntingtin but not to aggregated huntingtin.
    explanation: In vivo evidence from HD transgenic mice showing that Sp1 binds soluble mutant huntingtin, supporting the sequestration mechanism.
  - reference: PMID:11839795
    reference_title: "Interaction of Huntington disease protein with transcriptional activator Sp1."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Mutant huntingtin inhibits the binding of nuclear Sp1 to the promoter of nerve growth factor receptor and suppresses its transcriptional activity in cultured cells.
    explanation: Cell culture experiments demonstrating that mutant huntingtin suppresses Sp1-regulated transcription.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD cell culture models showing CBP depletion from its normal nuclear location and sequestration into polyglutamine aggregates.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: HD transgenic mice confirming CBP sequestration into polyglutamine aggregates in vivo.
  - reference: PMID:11264541
    reference_title: "Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We found that CBP was depleted from its normal nuclear location and was present in polyglutamine aggregates in HD cell culture models, HD transgenic mice, and human HD postmortem brain.
    explanation: Human HD postmortem brain tissue showing CBP depletion and sequestration into polyglutamine aggregates.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: aberrant accumulation of REST/NRSF in the nucleus is present in Huntington disease. We show that wild-type huntingtin coimmunoprecipitates with REST/NRSF and that less immunoprecipitated material is found in brain tissue with Huntington disease.
    explanation: Human postmortem brain data showing aberrant nuclear REST/NRSF accumulation and reduced huntingtin-REST/NRSF interaction in HD.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: loss of expression of NRSE-controlled neuronal genes is shown in cells, mice and human brain with Huntington disease.
    explanation: Mouse model data confirming loss of NRSE-controlled gene expression in HD, corroborating the REST/NRSF dysregulation mechanism.
  - reference: PMID:12881722
    reference_title: "Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Wild-type huntingtin inhibits the silencing activity of NRSE, increasing transcription of BDNF. We show that this effect occurs through cytoplasmic sequestering of repressor element-1 transcription factor/neuron restrictive silencer factor (REST/NRSF), the transcription factor that binds to NRSE.
    explanation: Cell-based experiments showing wild-type huntingtin sequesters REST/NRSF in the cytoplasm to permit BDNF transcription, a function lost with the mutant protein.
- hypothesis_group_id: canonical_mitochondrial_bioenergetic_failure
  hypothesis_label: Mitochondrial Dysfunction and Bioenergetic Failure
  status: CANONICAL
  description: >
    Mutant huntingtin impairs mitochondrial function through reduced oxidative
    phosphorylation complex activity, disrupted calcium homeostasis, and
    transcriptional repression of PGC-1alpha. This is a canonical convergent
    mechanism in HD that links transcriptional dysregulation and mutant huntingtin
    stress to bioenergetic failure, oxidative damage, and neuronal death,
    particularly in energy-demanding striatal medium spiny neurons.
  notes: >-
    Retained as CANONICAL but reframed as a **downstream convergent
    mediator** rather than an independent initiating event. The 2026
    openscientist hypothesis-search report
    (kb/hypotheses/Huntingtons_Disease/canonical_mitochondrial_bioenergetic_failure)
    reviewed 76 papers and identified three refinements: (1) the
    transcriptional-repression-of-PGC-1α pathway (PMID:17018277) is the
    strongest mechanistic link, validated by genetic and rescue
    experiments; (2) the "direct mHTT-mitochondria interaction" model is
    challenged by isolated-mitochondria studies, shifting emphasis toward
    indirect transcription-mediated mechanisms; (3) GWAS overwhelmingly
    implicate DNA-repair/somatic-expansion genes — not mitochondrial
    genes — as rate-limiting modifiers, positioning mitochondrial
    dysfunction as a downstream amplifier rather than an upstream driver.
    Failed clinical trials of mitochondrial-targeting agents (CoQ10,
    creatine) are consistent with this reframing. Bioenergetic failure
    critically synergizes with NMDAR-mediated excitotoxicity through ATP
    loss and Mg²⁺-block removal, creating a feedforward loop in
    energy-demanding striatal MSNs.
  evidence:
  - reference: PMID:17018277
    reference_title: "Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "mutant huntingtin causes disruption of mitochondrial function by inhibiting expression of PGC-1alpha"
    explanation: >
      Identifies PGC-1α transcriptional repression as the strongest
      mechanistic link from mHTT to mitochondrial dysfunction. PGC-1α KO
      crossbred with HD KI exacerbates striatal neurodegeneration; PGC-1α
      restoration via lentivirus is neuroprotective in HD mice — direct
      causal validation of the canonical pathway.
  - reference: PMID:19622387
    reference_title: "Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Nonetheless, it is becoming increasingly clear that alterations in mitochondrial function play key roles in the pathogenic processes in HD. The net result of these events is compromised energy metabolism and increased oxidative damage, which eventually contribute to neuronal dysfunction and death.
    explanation: Frames mitochondrial dysfunction as a key pathogenic mechanism linking compromised energy metabolism and oxidative damage to neuronal death.
  - reference: PMID:23602910
    reference_title: "PGC-1alpha, mitochondrial dysfunction, and Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: There is strong evidence that mitochondrial dysfunction results in neurodegeneration and may contribute to the pathogenesis of Huntington's disease (HD). Studies over the past few years have implicated an impaired function of peroxisome proliferator-activated receptor (PPAR)-gamma coactivator-1alpha (PGC-1alpha), a transcriptional master coregulator of mitochondrial biogenesis, metabolism, and antioxidant defenses, in causing mitochondrial dysfunction in HD.
    explanation: Links PGC-1alpha impairment to mitochondrial dysfunction in HD, connecting transcriptional dysregulation of mitochondrial biogenesis genes to bioenergetic failure.
- hypothesis_group_id: alternative_excitotoxicity
  hypothesis_label: NMDA Receptor-Mediated Excitotoxicity
  status: ALTERNATIVE
  description: >
    Historical but still supported superimposed model proposing that mutant
    huntingtin and corticostriatal circuit dysfunction enhance NMDA receptor-mediated
    excitotoxicity in striatal medium spiny neurons. This hypothesis is best viewed
    as a selective-vulnerability amplifier rather than the sole initiating lesion.
  evidence:
  - reference: PMID:17188796
    reference_title: "N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Many lines of evidence support a role for neuronal damage arising as a result of excessive activation of glutamate receptors by excitatory amino acids in the pathogenesis of Huntington disease. The N-methyl-d-aspartate subclass of ionotropic glutamate receptors (NMDARs) is more selective and effective than the other subclasses in mediating this damage.
    explanation: Comprehensive review establishing NMDAR-mediated excitotoxicity as a key pathogenic mechanism in HD with evidence from human tissue, animal models, and cell-based systems.
  - reference: PMID:19279257
    reference_title: "In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: This is the first direct in vivo evidence of NR2B-NMDAR-mediated excitotoxicity in the context of HD. Our results are consistent with previous suggestions that direct and/or indirect interactions of mutant huntingtin with NMDARs are a proximate cause of neurodegeneration in HD.
    explanation: Provides the first direct in vivo genetic evidence for the excitotoxicity hypothesis by showing exacerbated striatal neurodegeneration when NR2B-NMDAR subunits are overexpressed in an HD mouse model.
- hypothesis_group_id: dsb_expansion_independent_driver
  hypothesis_label: Double-Strand Break Accumulation as an Expansion-Independent Driver
  status: EMERGING
  description: >
    Genome-wide DNA double-strand breaks (DSBs) are a driver of HD
    neuropathology that is mechanistically separable from somatic CAG
    expansion. On this model the two forms of DNA damage coexist but act
    through distinct routes: site-specific CAG tract lengthening is driven by
    active mismatch repair, whereas DSBs arise genome-wide from mutant
    huntingtin-mediated suppression of non-homologous end joining acting on a
    background where oxidation converts base excision repair single-strand
    break intermediates into double-strand breaks. Three observations support
    separability. (1) DSBs accumulate in zQ175/MSH3(-/-) mice, which cannot
    somatically expand their allele, alongside the same transcriptional
    dysfunction seen in expansion-competent zQ175. (2) Pharmacological
    suppression of DSBs with the mitochondria-targeted antioxidant XJB-5-131
    rescues striatal neuron loss and motor performance in HdhQ(150/150) mice
    while leaving somatic tract length substantially unchanged. (3) Geometry -
    the CAG tract is under 1e-7 of the genome, so most breaks fall outside it,
    and Ku70/Ku80 limits end-joining length changes inside it to a few
    nucleotides, so break burden and tract length are largely decoupled. The
    therapeutic implication is that expansion suppression and DSB suppression
    are independent targets that may need to be combined.
  notes: >-
    Recorded as EMERGING rather than CANONICAL or ALTERNATIVE. It does not
    displace the canonical toxic gain-of-function or somatic-expansion models;
    it adds a parallel arm. Four caveats a curator should preserve. (a) All
    primary evidence is mouse and, in HdhQ(150/150), male only. (b) The DSBR
    deficit is measured as delayed clearance of radiation-induced breaks rather
    than as endogenous repair kinetics. (c) XJB-5-131 suppresses DSB formation
    upstream via mitochondrial reactive oxygen species; it does not restore
    end joining, so the rescue shows that break burden matters, not that NHEJ
    was repaired. (d) No DSBR or NHEJ gene has emerged from human HD GWAS,
    which the authors attribute to breaks being randomly distributed and NHEJ
    being reduced rather than absent - this remains an unresolved
    human/model discrepancy, recorded as the HUMAN_MODEL_MISMATCH discussion
    mismatch_hd_dsbr_absent_from_human_gwas.
  evidence:
  - reference: PMID:42091595
    reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We propose that CAG expansion and DSBs promote downstream neuronal
      pathology as separable drivers.
    explanation: >-
      States the hypothesis in the authors' own terms.
  - reference: PMID:42091595
    reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      DSBs and transcriptional dysfunction occur in animals that cannot
      somatically expand their inherited allele.
    explanation: >-
      The zQ175/MSH3(-/-) separation-of-function result - double-strand breaks
      and transcriptional pathology without any somatic expansion.
  - reference: PMID:42091595
    reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Conversely, suppression of DSBs is sufficient to reverse neuropathology
      even when somatic expansion is active.
    explanation: >-
      The interventional arm - rescue of neuropathology by suppressing breaks
      while expansion continues.
  - reference: PMID:38387080
    reference_title: "A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      This had no effect on the deposition of huntingtin aggregation in the
      nuclei of striatal neurons, nor on the dysregulated striatal
      transcriptional profile.
    explanation: >-
      Independent support for the premise that abolishing somatic expansion
      does not by itself correct striatal molecular pathology in zQ175, which
      is what motivates looking for a second, expansion-independent driver.
  - reference: PMID:39231940
    reference_title: "Base excision repair and double strand break repair cooperate to modulate the formation of unrepaired double strand breaks in mouse brain."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The natural imbalance creates conditions where single strand breaks
      (SSBs) can convert to double strand breaks (DSBs) and reversibly switch
      between states in response to oxidation both in vivo and in vitro.
    explanation: >-
      Supplies the mechanistic basis in normal brain for the oxidation-driven
      route by which double-strand breaks are generated in this model.
  - reference: PMID:38291334
    reference_title: "Cell-type-specific CAG repeat expansions and toxicity of mutant Huntingtin in human striatum and cerebellum."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our data support a model in which CAG expansions are necessary but may not
      be sufficient for cell death
    explanation: >-
      The one piece of HUMAN evidence bearing on this hypothesis. Deep molecular
      profiling of human striatum and cerebellum reaches the same premise the
      mouse work starts from - somatic expansion is necessary but not sufficient
      for neuronal death - independently of any mouse model. Marked PARTIAL
      because it establishes only the insufficiency premise; it says nothing
      about double-strand breaks or end joining, which remain mouse-only claims
      (see mismatch_hd_dsbr_absent_from_human_gwas).
phenotypes:
- name: Chorea
  category: Clinical
  frequency: VERY_FREQUENT
  description: >-
    Involuntary, irregular, dance-like movements that are the hallmark motor feature
    of adult-onset HD. Chorea typically begins subtly and worsens over time before
    giving way to rigidity and bradykinesia in advanced stages.
  phenotype_term:
    preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  evidence:
  - reference: PMID:38861215
    reference_title: "Huntington's Disease: Latest Frontiers in Therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HD is characterized by the presence of chorea, alongside other hyperkinesia,
      parkinsonism and a combination of cognitive and behavioural features.
    explanation: >-
      Confirms chorea alongside other hyperkinesias as a characteristic feature of HD.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002072 | Chorea | Very frequent (99-80%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies chorea as a very frequent
      Huntington disease phenotype.
- name: Cognitive Decline
  category: Clinical
  frequency: VERY_FREQUENT
  description: >-
    Progressive cognitive impairment affecting executive function, attention,
    psychomotor speed, and visuospatial skills, eventually progressing to subcortical
    dementia. Cognitive changes may precede motor onset by 10-15 years.
  phenotype_term:
    preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:40874597
    reference_title: "Therapeutic strategies for Huntington's disease: current approaches and future direction."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Huntington's disease (HD) is an autosomal, progressive, dominant inherited
      neurological disorder characterized by motor dysfunction, cognitive decline,
      and psychiatric symptoms.
    explanation: >-
      Confirms cognitive decline as one of the three cardinal features of HD.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001268 | Mental deterioration | Very frequent (99-80%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies mental deterioration as a
      very frequent Huntington disease phenotype.
- name: Depression
  category: Clinical
  frequency: FREQUENT
  description: >-
    Depressive symptoms are a common psychiatric manifestation of Huntington
    disease and may precede motor onset.
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:38861215
    reference_title: "Huntington's Disease: Latest Frontiers in Therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HD is characterized by the presence of chorea, alongside other hyperkinesia,
      parkinsonism and a combination of cognitive and behavioural features.
    explanation: >-
      Confirms behavioral features as a core component of the HD clinical triad.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000716 | Depression | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies depression as a frequent
      Huntington disease phenotype.
- name: Anxiety
  category: Clinical
  frequency: FREQUENT
  description: >-
    Anxiety is a frequent psychiatric manifestation of Huntington disease.
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
  evidence:
  - reference: PMID:38861215
    reference_title: "Huntington's Disease: Latest Frontiers in Therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HD is characterized by the presence of chorea, alongside other hyperkinesia,
      parkinsonism and a combination of cognitive and behavioural features.
    explanation: >-
      Confirms behavioral features as a core component of the HD clinical triad.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000739 | Anxiety | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies anxiety as a frequent
      Huntington disease phenotype.
- name: Agitation
  category: Clinical
  frequency: FREQUENT
  description: >-
    Agitation is a frequent behavioral manifestation in the Orphanet Huntington
    disease phenotype profile.
  phenotype_term:
    preferred_term: Agitation
    term:
      id: HP:0000713
      label: Agitation
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000713 | Agitation | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies agitation as a frequent
      Huntington disease phenotype.
- name: Aggressive Behavior
  category: Clinical
  frequency: FREQUENT
  description: >-
    Aggressive behavior is a frequent behavioral manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Aggressive behavior
    term:
      id: HP:0000718
      label: Aggressive behavior
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000718 | Aggressive behavior | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies aggressive behavior as a
      frequent Huntington disease phenotype.
- name: Compulsive Behaviors
  category: Clinical
  frequency: FREQUENT
  description: >-
    Compulsive behaviors are frequent behavioral manifestations in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Compulsive behaviors
    term:
      id: HP:0000722
      label: Compulsive behaviors
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000722 | Compulsive behaviors | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies compulsive behaviors as a
      frequent Huntington disease phenotype.
- name: Disinhibition
  category: Clinical
  frequency: FREQUENT
  description: >-
    Disinhibition is a frequent behavioral manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Disinhibition
    term:
      id: HP:0000734
      label: Disinhibition
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000734 | Disinhibition | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies disinhibition as a frequent
      Huntington disease phenotype.
- name: Irritability
  category: Clinical
  frequency: FREQUENT
  description: >-
    Irritability is a frequent psychiatric manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Irritability
    term:
      id: HP:0000737
      label: Irritability
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000737 | Irritability | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies irritability as a frequent
      Huntington disease phenotype.
- name: Hallucinations
  category: Clinical
  frequency: FREQUENT
  description: >-
    Hallucinations are a frequent psychiatric manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Hallucinations
    term:
      id: HP:0000738
      label: Hallucinations
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000738 | Hallucinations | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies hallucinations as a frequent
      Huntington disease phenotype.
- name: Apathy
  category: Clinical
  frequency: FREQUENT
  description: >-
    Apathy is a frequent neuropsychiatric manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Apathy
    term:
      id: HP:0000741
      label: Apathy
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000741 | Apathy | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies apathy as a frequent
      Huntington disease phenotype.
- name: Delusion
  category: Clinical
  frequency: FREQUENT
  description: >-
    Delusion is a frequent psychiatric manifestation in the Orphanet Huntington
    disease phenotype profile.
  phenotype_term:
    preferred_term: Delusion
    term:
      id: HP:0000746
      label: Delusion
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000746 | Delusion | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies delusion as a frequent
      Huntington disease phenotype.
- name: Hostility
  category: Clinical
  frequency: FREQUENT
  description: >-
    Hostility is a frequent behavioral manifestation in the Orphanet Huntington
    disease phenotype profile.
  phenotype_term:
    preferred_term: Hostility
    term:
      id: HP:0031473
      label: Anger
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0031473 | Hostility | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies hostility as a frequent
      Huntington disease phenotype.
- name: Abnormal Libido
  category: Clinical
  frequency: FREQUENT
  description: >-
    Abnormal libido is a frequent behavioral manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Abnormal libido
    term:
      id: HP:0031845
      label: Abnormal libido
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0031845 | Abnormal libido | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies abnormal libido as a frequent
      Huntington disease phenotype.
- name: Memory Impairment
  category: Clinical
  frequency: FREQUENT
  description: >-
    Memory impairment is a frequent cognitive manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Memory impairment
    term:
      id: HP:0002354
      label: Memory impairment
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002354 | Memory impairment | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies memory impairment as a
      frequent Huntington disease phenotype.
- name: Bradyphrenia
  category: Clinical
  frequency: FREQUENT
  description: >-
    Bradyphrenia is a frequent cognitive manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Bradyphrenia
    term:
      id: HP:0031843
      label: Abnormally slow thought process
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0031843 | Bradyphrenia | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies bradyphrenia as a frequent
      Huntington disease phenotype.
- name: Gait Disturbance
  category: Clinical
  frequency: FREQUENT
  description: >-
    Abnormal gait is a common motor manifestation of Huntington disease,
    reflecting progressive basal ganglia and motor circuit dysfunction.
  phenotype_term:
    preferred_term: Gait disturbance
    term:
      id: HP:0001288
      label: Gait disturbance
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001288 | Gait disturbance | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies gait disturbance as a
      frequent Huntington disease phenotype.
- name: Gait Imbalance
  category: Clinical
  frequency: FREQUENT
  description: >-
    Gait imbalance is a frequent motor manifestation in the Orphanet Huntington
    disease phenotype profile.
  phenotype_term:
    preferred_term: Gait imbalance
    term:
      id: HP:0002141
      label: Gait imbalance
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002141 | Gait imbalance | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies gait imbalance as a frequent
      Huntington disease phenotype.
- name: Clumsiness
  category: Clinical
  frequency: FREQUENT
  description: >-
    Clumsiness is a frequent motor coordination manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Clumsiness
    term:
      id: HP:0002312
      label: Clumsiness
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002312 | Clumsiness | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies clumsiness as a frequent
      Huntington disease phenotype.
- name: Poor Fine Motor Coordination
  category: Clinical
  frequency: FREQUENT
  description: >-
    Poor fine motor coordination is a frequent motor manifestation in the
    Orphanet Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Poor fine motor coordination
    term:
      id: HP:0007010
      label: Poor fine motor coordination
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0007010 | Poor fine motor coordination | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies poor fine motor coordination
      as a frequent Huntington disease phenotype.
- name: Abnormality of Eye Movement
  category: Clinical
  frequency: FREQUENT
  description: >-
    Abnormal eye movements are frequent neurologic manifestations in the
    Orphanet Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Abnormality of eye movement
    term:
      id: HP:0000496
      label: Abnormality of eye movement
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0000496 | Abnormality of eye movement | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies abnormality of eye movement
      as a frequent Huntington disease phenotype.
- name: Staring Gaze
  category: Clinical
  frequency: FREQUENT
  description: >-
    Staring gaze is a frequent ocular-motor manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Staring gaze
    term:
      id: HP:0025401
      label: Staring gaze
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0025401 | Staring gaze | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies staring gaze as a frequent
      Huntington disease phenotype.
- name: Bradykinesia
  category: Clinical
  frequency: FREQUENT
  description: >-
    Slowness of movement can accompany or follow hyperkinetic features,
    especially in juvenile-onset or later-stage Huntington disease.
  phenotype_term:
    preferred_term: Bradykinesia
    term:
      id: HP:0002067
      label: Bradykinesia
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002067 | Bradykinesia | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies bradykinesia as a frequent
      Huntington disease phenotype.
- name: Hypokinesia
  category: Clinical
  frequency: FREQUENT
  description: >-
    Hypokinesia is a frequent hypokinetic motor manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Hypokinesia
    term:
      id: HP:0002375
      label: Hypokinesia
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0002375 | Hypokinesia | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies hypokinesia as a frequent
      Huntington disease phenotype.
- name: Hyperreflexia
  category: Clinical
  frequency: VERY_FREQUENT
  description: >-
    Increased deep tendon reflexes are included in Orphanet's very frequent HPO
    phenotype annotations for Huntington disease.
  phenotype_term:
    preferred_term: Hyperreflexia
    term:
      id: HP:0001347
      label: Hyperreflexia
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001347 | Hyperreflexia | Very frequent (99-80%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies hyperreflexia as a very
      frequent Huntington disease phenotype.
- name: Dystonia
  category: Clinical
  frequency: FREQUENT
  description: >-
    Sustained muscle contractions causing abnormal postures, particularly prominent
    in juvenile-onset HD and in later stages of adult-onset disease.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001332 | Dystonia | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies dystonia as a frequent
      Huntington disease phenotype.
- name: Myoclonus
  category: Clinical
  frequency: FREQUENT
  description: >-
    Myoclonus is a frequent motor manifestation in the Orphanet Huntington
    disease phenotype profile.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001336 | Myoclonus | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies myoclonus as a frequent
      Huntington disease phenotype.
- name: Involuntary Movements
  category: Clinical
  frequency: FREQUENT
  description: >-
    Involuntary movements are a frequent motor manifestation in the Orphanet
    Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Involuntary movements
    term:
      id: HP:0004305
      label: Involuntary movements
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004305 | Involuntary movements | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies involuntary movements as a
      frequent Huntington disease phenotype.
- name: Weight Loss
  category: Clinical
  frequency: FREQUENT
  description: >-
    Progressive involuntary weight loss despite adequate caloric intake, related to
    hypermetabolic state from chorea, dysphagia, and central hypothalamic dysfunction.
  phenotype_term:
    preferred_term: Weight loss
    term:
      id: HP:0001824
      label: Weight loss
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001824 | Weight loss | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies weight loss as a frequent
      Huntington disease phenotype.
- name: Generalized Muscle Weakness
  category: Clinical
  frequency: FREQUENT
  description: >-
    Generalized muscle weakness is a frequent motor manifestation in the
    Orphanet Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Generalized muscle weakness
    term:
      id: HP:0003324
      label: Generalized muscle weakness
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0003324 | Generalized muscle weakness | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies generalized muscle weakness
      as a frequent Huntington disease phenotype.
- name: Abnormality of the Sense of Smell
  category: Clinical
  frequency: FREQUENT
  description: >-
    Abnormality of the sense of smell is a frequent sensory manifestation in the
    Orphanet Huntington disease phenotype profile.
  phenotype_term:
    preferred_term: Abnormality of the sense of smell
    term:
      id: HP:0004408
      label: Abnormality of the sense of smell
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0004408 | Abnormality of the sense of smell | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies abnormality of the sense of
      smell as a frequent Huntington disease phenotype.
- name: Speech Articulation Difficulties
  category: Clinical
  frequency: FREQUENT
  description: >-
    Progressive speech difficulty due to impaired motor control of muscles
    involved in speech production.
  phenotype_term:
    preferred_term: Speech articulation difficulties
    term:
      id: HP:0009088
      label: Speech articulation difficulties
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0009088 | Speech articulation difficulties | Frequent (79-30%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies speech articulation
      difficulties as a frequent Huntington disease phenotype.
- name: Oral-pharyngeal Dysphagia
  category: Clinical
  frequency: OCCASIONAL
  description: >-
    Difficulty swallowing that increases aspiration risk. Aspiration pneumonia is a
    leading cause of death in HD.
  phenotype_term:
    preferred_term: Oral-pharyngeal dysphagia
    term:
      id: HP:0200136
      label: Oral-pharyngeal dysphagia
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0200136 | Oral-pharyngeal dysphagia | Occasional (29-5%)"
    explanation: >-
      Orphanet's curated HPO annotation classifies oral-pharyngeal dysphagia as
      an occasional Huntington disease phenotype.
- name: Seizures
  category: Clinical
  subtype: Juvenile HD
  description: >-
    Epilepsy is one of the features the European Huntington Disease Network working
    group regards as specific to juvenile-onset HD, and it is uncommon in adult-onset
    disease. Within juvenile-onset HD, seizure occurrence is graded by repeat length:
    in a REGISTRY/Enroll-HD retrospective series seizures prevailed over time in 8 of
    10 (80%) highly expanded juvenile patients compared with 3 of 26 (11%) with lower
    expansions. Seizures are also significantly more frequent in childhood-onset
    (0-10 years) than adolescent-onset (11-20 years) juvenile disease.
  phenotype_term:
    preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      JHD specific features are epilepsy, ataxia, spasticity, pain, itching, and
      possibly liver steatosis.
    explanation: >-
      Expert working group review names epilepsy as a juvenile-onset-specific
      feature, justifying the Juvenile HD subtype scoping of this phenotype.
  - reference: PMID:30243861
    reference_title: "Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Compared with the LE subgroup, development delay (0 [0%] in the LE subgroup vs
      nine [90%] in the HE subgroup; p<0·0001), severe gait impairment (nine [35%] in
      the LE subgroup vs nine [90%] in the HE subgroup; p=0·0072), and seizures (three
      [11%] in the LE subgroup vs eight [80%] in the HE subgroup; p<0·0001) prevailed
      over time in the HE subgroup.
    explanation: >-
      Quantifies the repeat-length gradient in seizure occurrence within
      juvenile-onset HD (80% in the highly expanded subgroup vs 11% in the low
      expansion subgroup).
  - reference: PMID:16925544
    reference_title: "Juvenile Huntington disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Juvenile HD is far less common and presents with parkinsonism, dystonia and
      seizures.
    explanation: >-
      Supports seizures as part of the characteristic juvenile-onset presentation,
      contrasted with the chorea of adult-onset HD.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001250 | Seizure | Frequent (79-30%)"
    explanation: >-
      Orphanet records seizures as a frequent disease-level HPO annotation. This
      partially supports the seizure phenotype here, while this entry retains the
      juvenile-HD subtype context for clinical specificity.
- name: Developmental Regression and Delay
  category: Clinical
  subtype: Juvenile HD
  description: >-
    Loss of previously acquired skills, or failure to acquire them on schedule, is a
    presenting feature of childhood-onset HD that has no counterpart in adult-onset
    disease. It is strongly graded by repeat length - developmental delay was recorded
    in 9 of 10 (90%) highly expanded juvenile patients and in none of 26 with lower
    expansions - and it is significantly more frequent in onset before age 10 than in
    adolescent onset. Speech and language delay may precede other motor signs when
    onset is in the first decade.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:30243861
    reference_title: "Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Compared with the LE subgroup, development delay (0 [0%] in the LE subgroup vs
      nine [90%] in the HE subgroup; p<0·0001), severe gait impairment (nine [35%] in
      the LE subgroup vs nine [90%] in the HE subgroup; p=0·0072), and seizures (three
      [11%] in the LE subgroup vs eight [80%] in the HE subgroup; p<0·0001) prevailed
      over time in the HE subgroup.
    explanation: >-
      Quantifies developmental delay as a high-expansion juvenile feature (90% vs 0%),
      supporting both the phenotype and its repeat-length dependence.
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with disease-onset between 0–10 years (n = 127) had significantly more
      gait disturbances/ataxia (p = 0.0001), dysarthria (p = 0.008), seizures (p =
      0.0008) and developmental regression/delay (p = 0.0001) compared to those with
      an onset between 11–20 years (n = 101)
    explanation: >-
      Establishes that developmental regression/delay is significantly more frequent
      in childhood-onset than adolescent-onset juvenile HD.
- name: Juvenile-Onset Parkinsonism
  category: Clinical
  subtype: Juvenile HD
  description: >-
    The juvenile-onset motor phenotype is hypokinetic and rigid rather than choreic -
    the inverse of adult-onset HD. Rigidity, axial bradykinesia, dystonia and tremor
    dominate, chorea is uncommon in the first decade of life, and parkinsonian features
    were one of only four sign groups present in more than 15% of pooled juvenile-onset
    presentations. This is the presentation historically named the Westphal variant,
    though that term is no longer recommended as a label for juvenile onset because the
    same hypokinetic-rigid picture also occurs in adult-onset disease.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  evidence:
  - reference: PMID:31045518
    reference_title: "Clinical Presentation and Features of Juvenile-Onset Huntington's Disease: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Four groups of symptoms or signs were present in more than 15% of cases:
      behavioural disturbance, falls/gait disturbance, cognitive impairment and
      parkinsonian features.
    explanation: >-
      Systematic review of 285 juvenile-onset individuals placing parkinsonian
      features among the four most common presenting sign groups.
  - reference: PMID:30971481
    reference_title: "Brain structure in juvenile-onset Huntington disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Yet, the JOHD motor phenotype often manifests with parkinsonian features, such
      as bradykinesia, rigidity, and tremors.
    explanation: >-
      Specifies the parkinsonian components (bradykinesia, rigidity, tremor) of the
      juvenile-onset motor phenotype.
  - reference: PMID:36318082
    reference_title: "Longitudinal Clinical and Biological Characteristics in Juvenile-Onset Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Specifically, patients with JOHD have less chorea and present with prominent
      rigidity and bradykinesia.
    explanation: >-
      Directly contrasts the juvenile hypokinetic-rigid phenotype with the chorea of
      adult-onset HD.
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In the first decade of life speech difficulties, rigidity, and dystonia are
      common clinical motor symptoms, whereas onset in the second decade motor
      symptoms may sometimes resemble adult-onset Huntington's disease (AOHD).
    explanation: >-
      Establishes the decade-dependent motor presentation, with rigidity and dystonia
      characteristic of first-decade onset.
- name: Declining School Performance
  category: Clinical
  subtype: Juvenile HD
  description: >-
    In juvenile-onset HD, cognitive decline is typically first noticed as falling
    academic attainment rather than as a formal neuropsychological complaint, because
    the affected individual is still of school age. Cognitive impairment was one of the
    four sign groups present in more than 15% of pooled juvenile-onset presentations,
    and declining school performance is part of the long-standing Nance diagnostic
    criteria for juvenile HD.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cognitive decline is mostly detected by declining school performances.
    explanation: >-
      Establishes the age-specific way cognitive decline presents in juvenile-onset
      HD.
  - reference: PMID:31045518
    reference_title: "Clinical Presentation and Features of Juvenile-Onset Huntington's Disease: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Four groups of symptoms or signs were present in more than 15% of cases:
      behavioural disturbance, falls/gait disturbance, cognitive impairment and
      parkinsonian features.
    explanation: >-
      Places cognitive impairment among the most common juvenile-onset presenting
      sign groups.
- name: Behavioural Disturbance Mimicking Neurodevelopmental Disorder
  category: Clinical
  subtype: Juvenile HD
  description: >-
    Behavioural change is the single most common presenting feature of juvenile-onset
    HD, and non-motor features generally precede motor ones in this subtype. The
    behavioural symptoms themselves do not differ greatly from adult-onset HD, but in
    a child they are readily attributed to autism spectrum disorder or ADHD, which is
    a principal driver of misdiagnosis and diagnostic delay in juvenile-onset disease.
  phenotype_term:
    preferred_term: Behavioural disturbance
    term:
      id: HP:0000708
      label: Atypical behavior
  evidence:
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Behavioral symptoms in general do not differ from AOHD but may be confused with
      autism spectrum disorder or attention deficit hyperactivity disorder and lead to
      misdiagnosis and/or diagnostic delay.
    explanation: >-
      Directly supports both the behavioural phenotype and the age-specific
      misdiagnosis risk described here.
  - reference: PMID:31045518
    reference_title: "Clinical Presentation and Features of Juvenile-Onset Huntington's Disease: A Systematic Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      JHD can present with a wide variety of symptoms and signs, with non-motor
      characteristics being observed most frequently.
    explanation: >-
      Supports the predominance of non-motor, including behavioural, presenting
      features in juvenile-onset HD.
- name: Ataxia
  category: Clinical
  subtype: Juvenile HD
  description: >-
    Ataxia is listed by the European Huntington Disease Network working group among the
    features specific to juvenile-onset HD, and gait disturbance with ataxia is
    significantly more frequent in childhood-onset than adolescent-onset juvenile
    disease. It is a plausible clinical correlate of the cerebellar involvement seen on
    juvenile-onset brain morphometry, which is not a feature of adult-onset HD.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      JHD specific features are epilepsy, ataxia, spasticity, pain, itching, and
      possibly liver steatosis.
    explanation: >-
      Names ataxia as a juvenile-onset-specific feature.
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with disease-onset between 0–10 years (n = 127) had significantly more
      gait disturbances/ataxia (p = 0.0001), dysarthria (p = 0.008), seizures (p =
      0.0008) and developmental regression/delay (p = 0.0001) compared to those with
      an onset between 11–20 years (n = 101)
    explanation: >-
      Shows gait disturbance/ataxia is significantly more frequent in childhood-onset
      than adolescent-onset juvenile HD.
- name: Spasticity
  category: Clinical
  subtype: Juvenile HD
  description: >-
    Spasticity is listed among the features the European Huntington Disease Network
    working group regards as specific to juvenile-onset HD, contributing with rigidity
    and dystonia to the hypertonic motor picture that distinguishes juvenile from
    adult-onset disease.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:38669553
    reference_title: "Clinical Review of Juvenile Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      JHD specific features are epilepsy, ataxia, spasticity, pain, itching, and
      possibly liver steatosis.
    explanation: >-
      Names spasticity as a juvenile-onset-specific feature.
- name: Constipation
  category: Clinical
  subtype: Juvenile HD
  description: >-
    In a linked Swedish national registry cohort covering 2002-2018 (45 juvenile-onset
    among 1,492 incident HD diagnoses), juvenile-onset patients had higher incidence
    rates of constipation than adult-onset patients. Recorded as a juvenile-scoped
    clinical burden rather than a subtype-defining mechanism.
  phenotype_term:
    preferred_term: Constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:36253622
    reference_title: "Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington's disease: a study of linked Swedish National Registries (2002-2019)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with JoHD had higher incidence rates of epilepsy, constipation and
      acute respiratory symptoms.
    explanation: >-
      National registry cohort reporting a higher constipation incidence rate in
      juvenile-onset than adult-onset HD.
- name: Acute Respiratory Symptoms
  category: Clinical
  subtype: Juvenile HD
  description: >-
    The same Swedish national registry cohort found higher incidence rates of acute
    respiratory symptoms in juvenile-onset than adult-onset HD. The registry term is a
    symptom category and does not specify infection, so this is deliberately bound to
    the broad abnormal-respiratory-physiology term rather than to pneumonia or
    respiratory tract infection; note the entry separately records aspiration pneumonia
    as a leading cause of death in HD generally via the dysphagia phenotype.
  phenotype_term:
    preferred_term: Acute respiratory symptoms
    term:
      id: HP:0002795
      label: Abnormal respiratory system physiology
  evidence:
  - reference: PMID:36253622
    reference_title: "Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington's disease: a study of linked Swedish National Registries (2002-2019)."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Individuals with JoHD had higher incidence rates of epilepsy, constipation and
      acute respiratory symptoms.
    explanation: >-
      National registry cohort reporting a higher incidence rate of acute respiratory
      symptoms in juvenile-onset than adult-onset HD.
- name: Sleep Disturbances
  category: Clinical
  description: >-
    Sleep disturbances are prevalent in HD, including periodic limb movements (35%),
    poor sleep quality (59%), excessive daytime sleepiness, and circadian rhythm
    disruption. Sleep medication use is reported in 29% of patients.
  phenotype_term:
    preferred_term: Sleep disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
  evidence:
  - reference: PMID:41722529
    reference_title: "What is the prevalence of sleep disturbances among people with Huntington disease and pre-manifest genetic expansion carriers? A systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Meta-analysed prevalence of objectively-measured sleep disturbances include:
      35% for periodic limb movements (PLM index>15/hour), 3% for REM sleep
      behaviour disorder, 5% for REM sleep without atonia, and 9% for
      sleep-disordered breathing (AHI>5/hour); and of self-reported measures: 29%
      for use of sleep medications, 59% for poor sleep quality (Pittsburgh sleep
      quality index), and 15% for excessive daytime sleepiness (Epworth sleepiness
      scale).
    explanation: >-
      Systematic review with meta-analysis quantifying the prevalence of multiple
      sleep disturbances in HD patients.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0100785 | Insomnia | Occasional (29-5%)"
    explanation: >-
      Orphanet's insomnia annotation supports one component of the broader sleep
      disturbance phenotype.
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HP:0001262 | Excessive daytime somnolence | Occasional (29-5%)"
    explanation: >-
      Orphanet's excessive daytime somnolence annotation supports another
      component of the broader sleep disturbance phenotype.
biochemical:
- name: Neurofilament Light Chain (NfL)
  notes: >-
    Plasma and CSF neurofilament light chain is elevated in both pre-manifest
    and manifest HD. NfL meets evidentiary guidelines as a prognostic biomarker
    in premanifest HD and can detect changes in very early disease stages.
  evidence:
  - reference: PMID:41081429
    reference_title: "Systematic Review with Meta-Analysis of Biofluid Markers for Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Evidence for neurofilament light (NfL) is sufficient to meet evidentiary
      guidelines as a prognostic biomarker in preHD (ie, before clinical motor
      diagnosis).
    explanation: >-
      Systematic review with meta-analysis establishes NfL as a validated
      prognostic biomarker in pre-manifest HD.
  - reference: PMID:39891767
    reference_title: "Serum neurofilament light chain but not serum glial fibrillary acidic protein is a marker of early Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      sNfL levels differed significantly between preHD and early HD, and HC
      (all p values < 0.05)
    explanation: >-
      Confirms serum NfL can distinguish pre-manifest and early HD from
      healthy controls.
- name: Mutant Huntingtin Protein (mHTT)
  notes: >-
    Mutant huntingtin protein is quantifiable in cerebrospinal fluid and serves
    as a pharmacodynamic biomarker for HTT-lowering therapies.
  evidence:
  - reference: PMID:38861215
    reference_title: "Huntington's Disease: Latest Frontiers in Therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The possibility of quantifying mHTT in CSF, along with the development
      of an integrated biological staging system in HD are important innovations
      applicable to clinical trial design that enhance the drug development process.
    explanation: >-
      Highlights CSF mHTT quantification as a key innovation for HD clinical
      trial design.
- name: Elevated Neuronal Inclusions
  presence: Positive
  notes: Aggregates of mutant huntingtin protein found in neurons.
  evidence:
  - reference: PMID:22200539
    reference_title: "Protein aggregates in Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Here we will review the state of knowledge of HD, focusing especially on a hallmark pathological feature-intracellular aggregates of mutant Htt called inclusion bodies (IBs).
    explanation: The article discusses the presence of intracellular aggregates of mutant huntingtin, which are referred to as inclusion bodies, supporting the statement.
  - reference: PMID:38810948
    reference_title: "Evidence of mutant huntingtin and tau-related pathology within neuronal grafts in Huntington's disease cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We confirmed the presence of mHtt aggregates within grafts of all three cases as well as tau neuropil threads in the grafts of two of the three transplanted HD patients.
    explanation: The study confirms the presence of mutant huntingtin (mHtt) aggregates within neurons, supporting the statement.
  - reference: PMID:19172113
    reference_title: "Aggregation of expanded huntingtin in the brains of patients with Huntington disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: It is likely that the aggregates containing expanded huntingtin are toxic to neurons, but it remains to be determined whether the oligomer or the inclusion is the toxic species.
    explanation: The article mentions that aggregates containing expanded huntingtin are found in neurons, supporting the statement.
  - reference: PMID:27886014
    reference_title: "Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington's Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Using highly sensitive immunohistochemical methods we have detected the appearance of diffuse aggregates during embryonic development in the R6/2 and YAC128 mouse models of HD.
    explanation: The study observes the formation of aggregates in neuronal cells during embryonic development in mouse models of HD, supporting the statement.
genetic:
- name: HTT
  association: Causative
  gene_term:
    preferred_term: HTT
    term:
      id: hgnc:4851
      label: HTT
  notes: >-
    The huntingtin gene on chromosome 4p16.3. CAG repeat expansion in exon 1
    beyond 36 repeats causes HD with full penetrance at 40+ repeats (reduced
    penetrance at 36-39). Normal alleles have 6-26 repeats; intermediate alleles
    (27-35) can expand to pathogenic range in offspring. The gene encodes huntingtin,
    a 3,144 amino acid scaffolding protein involved in vesicular transport,
    transcription, autophagy, and cell survival.
  evidence:
  - reference: PMID:41130308
    reference_title: "Inhibiting Cytosine-Adenine-Guanine (CAG) repeat expansions as a therapeutic strategy for Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Huntington's Disease (HD) became the first disease mapped to a single
      chromosome and associated with mutations in the huntingtin (HTT) gene,
      specifically expansions in the trinucleotide cytosine-adenine-guanine (CAG)
      within exon 1.
    explanation: >-
      Confirms the CAG repeat expansion in HTT exon 1 as the causative mutation.
  - reference: CGGV:assertion_617c18ee-9476-4bc0-b403-20bc55150c7c-2021-11-08T193955.489Z
    reference_title: "HTT / Huntington disease (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "HTT | HGNC:4851 | Huntington disease | MONDO:0007739 | AD | Definitive"
    explanation: ClinGen classifies the HTT-Huntington disease gene-disease relationship as definitive with autosomal dominant inheritance.
- name: MSH3
  association: Modifier
  gene_term:
    preferred_term: MSH3
    term:
      id: hgnc:7326
      label: MSH3
  notes: >-
    DNA mismatch repair gene identified as a key genetic modifier of HD onset age
    through GWAS. MSH3 drives somatic CAG repeat expansion in striatal neurons;
    variants that reduce MSH3 activity delay onset. A major therapeutic target.
  evidence:
  - reference: PMID:33579859
    reference_title: "DNA Repair in Huntington's Disease and Spinocerebellar Ataxias: Somatic Instability and Alternative Hypotheses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Validation of leads including the mismatch repair protein MSH3, and
      interstrand cross-link repair protein FAN1, suggest the mechanism is driven
      by somatic CAG instability, which is supported by the protective effect of
      CAA substitutions in the CAG tract.
    explanation: >-
      Identifies MSH3 as a validated modifier driving somatic CAG instability.
- name: FAN1
  association: Modifier
  gene_term:
    preferred_term: FAN1
    term:
      id: hgnc:29170
      label: FAN1
  notes: >-
    Fanconi anemia-associated nuclease 1. FAN1 protects against somatic CAG expansion;
    variants that enhance FAN1 activity are associated with delayed onset of HD.
  evidence:
  - reference: PMID:33579859
    reference_title: "DNA Repair in Huntington's Disease and Spinocerebellar Ataxias: Somatic Instability and Alternative Hypotheses."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Validation of leads including the mismatch repair protein MSH3, and
      interstrand cross-link repair protein FAN1, suggest the mechanism is driven
      by somatic CAG instability, which is supported by the protective effect of
      CAA substitutions in the CAG tract.
    explanation: >-
      Identifies FAN1 as a protective modifier against somatic CAG expansion.
- name: SLC2A3
  association: Modifier
  gene_term:
    preferred_term: SLC2A3
    term:
      id: hgnc:11007
      label: SLC2A3
  notes: >-
    Orphanet lists SLC2A3 as a modifying germline mutation association for
    Huntington disease.
  evidence:
  - reference: ORPHA:399
    reference_title: "Huntington disease"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SLC2A3 | solute carrier family 2 member 3 | hgnc:11007 | Modifying germline mutation in"
    explanation: >-
      Orphanet's gene table lists SLC2A3 as a modifying germline mutation
      association for Huntington disease.
- name: MLH1
  gene_term:
    preferred_term: MLH1
    term:
      id: hgnc:7127
      label: MLH1
  association: Genetic Modifier
  notes: DNA mismatch repair gene; drives somatic CAG expansion and significantly affects disease onset age and progression.
- name: PMS1
  gene_term:
    preferred_term: PMS1
    term:
      id: hgnc:9121
      label: PMS1
  association: Genetic Modifier
  notes: DNA mismatch repair gene; influences somatic CAG repeat expansion.
- name: PMS2
  gene_term:
    preferred_term: PMS2
    term:
      id: hgnc:9122
      label: PMS2
  association: Genetic Modifier
  notes: DNA mismatch repair gene; influences somatic CAG repeat expansion.
- name: LIG1
  gene_term:
    preferred_term: LIG1
    term:
      id: hgnc:6598
      label: LIG1
  association: Genetic Modifier
  notes: DNA ligase gene; involved in DNA repair pathways that modulate somatic CAG instability.
- name: PPARGC1A
  gene_term:
    preferred_term: PPARGC1A
    term:
      id: hgnc:9237
      label: PPARGC1A
  association: Pathophysiological Role
  notes: PGC-1alpha gene; reduced expression contributes to bioenergetic failure and mitochondrial dysfunction in HD.
- name: SLC1A2
  gene_term:
    preferred_term: SLC1A2
    term:
      id: hgnc:10940
      label: SLC1A2
  association: Pathophysiological Role
  notes: EAAT2 glutamate transporter gene; impaired function contributes to excitotoxicity through reduced glutamate clearance.
- name: BDNF
  gene_term:
    preferred_term: BDNF
    term:
      id: hgnc:1033
      label: BDNF
  association: Pathophysiological Role
  notes: Brain-derived neurotrophic factor; impaired trophic signaling and transport from cortex to striatum contributes to neuronal vulnerability.
- name: NTRK2
  gene_term:
    preferred_term: NTRK2
    term:
      id: hgnc:8032
      label: NTRK2
  association: Pathophysiological Role
  notes: TrkB receptor gene; mediates BDNF signaling; impaired function contributes to reduced trophic support.
- name: DRD1
  gene_term:
    preferred_term: DRD1
    term:
      id: hgnc:3020
      label: DRD1
  association: Pathophysiological Role
  notes: Dopamine D1 receptor; marker of direct pathway medium spiny neurons.
- name: DRD2
  gene_term:
    preferred_term: DRD2
    term:
      id: hgnc:3023
      label: DRD2
  association: Pathophysiological Role
  notes: Dopamine D2 receptor; marker of indirect pathway medium spiny neurons which show earlier vulnerability and greater CAG instability.
- name: SQSTM1
  gene_term:
    preferred_term: SQSTM1
    term:
      id: hgnc:11280
      label: SQSTM1
  association: Pathophysiological Role
  notes: p62/SQSTM1 gene; autophagy adaptor protein; accumulation indicates autophagy-lysosomal pathway dysfunction.
treatments:
- name: Tetrabenazine
  description: >-
    Vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treatment
    of chorea in HD. Reduces dopamine signaling in the basal ganglia. Most effective
    of the three VMAT2 inhibitors for chorea control but associated with higher rates
    of sedation and carries a boxed warning for depression.
  treatment_term:
    preferred_term: Tetrabenazine for chorea
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tetrabenazine
      term:
        id: CHEBI:9467
        label: tetrabenazine
  evidence:
  - reference: PMID:41069601
    reference_title: "Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study suggests that three VMAT2 inhibitors are effective in ameliorating
      chorea symptoms in patients with Huntington's disease. Tetrabenazine is the
      most effective in controlling chorea, whereas valbenazine may be the optimal
      choice for patients with comorbid psychiatric symptoms.
    explanation: >-
      Network meta-analysis confirms tetrabenazine as the most effective VMAT2
      inhibitor for chorea symptom control.
  target_mechanisms:
  - target: D2 Receptor Medium Spiny Neuron Selective Vulnerability
    treatment_effect: MODULATES
    description: >-
      Tetrabenazine inhibits VMAT2, depleting presynaptic dopamine and reducing
      striatal dopaminergic drive to compensate for the loss of D2-receptor-bearing
      indirect-pathway medium spiny neurons that underlies HD chorea.
- name: Deutetrabenazine
  description: >-
    Deuterated form of tetrabenazine with improved pharmacokinetics and tolerability
    profile, approved for HD chorea. Twice-daily dosing with less CYP2D6 interaction
    and lower sedation risk than tetrabenazine.
  treatment_term:
    preferred_term: Deutetrabenazine for chorea
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:41069601
    reference_title: "Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study suggests that three VMAT2 inhibitors are effective in ameliorating
      chorea symptoms in patients with Huntington's disease. Tetrabenazine is the
      most effective in controlling chorea, whereas valbenazine may be the optimal
      choice for patients with comorbid psychiatric symptoms.
    explanation: >-
      Network meta-analysis confirms deutetrabenazine efficacy for HD chorea.
  target_mechanisms:
  - target: D2 Receptor Medium Spiny Neuron Selective Vulnerability
    treatment_effect: MODULATES
    description: >-
      Deutetrabenazine inhibits VMAT2, depleting presynaptic dopamine and reducing
      striatal dopaminergic drive to compensate for the loss of D2-receptor-bearing
      indirect-pathway medium spiny neurons that underlies HD chorea.
- name: Valbenazine
  description: >-
    Selective VMAT2 inhibitor approved in 2023 for HD chorea. Once-daily dosing
    with minimal CYP2D6 interaction. May be optimal for patients with comorbid
    psychiatric symptoms. Available in sprinkle formulation for patients with dysphagia.
  treatment_term:
    preferred_term: Valbenazine for chorea
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:41069601
    reference_title: "Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study suggests that three VMAT2 inhibitors are effective in ameliorating
      chorea symptoms in patients with Huntington's disease. Tetrabenazine is the
      most effective in controlling chorea, whereas valbenazine may be the optimal
      choice for patients with comorbid psychiatric symptoms.
    explanation: >-
      Network meta-analysis identifies valbenazine as optimal for patients with
      comorbid psychiatric symptoms.
  - reference: PMID:41069601
    reference_title: "Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      valbenazine ranked first in withdrawals due to AEs (0.735), serious adverse
      events (0.807), as well as in reducing both suicide (0.683) and suicidal
      ideation (0.748).
    explanation: >-
      In the network meta-analysis ranking (SUCRA), valbenazine was the most
      favorable VMAT2 inhibitor for tolerability and psychiatric-safety endpoints,
      including reduced suicide and suicidal ideation - relevant given the high
      suicide risk in Huntington disease and supporting valbenazine as the
      preferred agent for patients with comorbid psychiatric symptoms.
  target_mechanisms:
  - target: D2 Receptor Medium Spiny Neuron Selective Vulnerability
    treatment_effect: MODULATES
    description: >-
      Valbenazine selectively inhibits VMAT2, depleting presynaptic dopamine and
      reducing striatal dopaminergic drive to compensate for the loss of
      D2-receptor-bearing indirect-pathway medium spiny neurons that underlies HD chorea.
- name: HTT-Lowering Therapies
  description: >-
    Emerging disease-modifying approaches including antisense oligonucleotides (ASOs),
    splice modulators, and microRNA-based gene therapy targeting mutant huntingtin
    protein reduction. Allele-selective approaches that spare wild-type HTT are
    preferred after the tominersen trial showed non-selective lowering can cause harm.
  treatment_term:
    preferred_term: HTT-lowering gene therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:38861215
    reference_title: "Huntington's Disease: Latest Frontiers in Therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      HD is living in an era of target-specific drug development with emphasis on
      the mechanisms related to mutant Huntingtin (HTT) protein. Examples include
      antisense oligonucleotides (ASO), splicing modifiers and microRNA molecules
      that aim to reduce the levels of mutant HTT protein.
    explanation: >-
      Reviews the current landscape of HTT-lowering therapeutic approaches.
  - reference: PMID:41090742
    reference_title: "Revolutionizing Huntington's Disease Treatment: Breakthroughs in AAV-Mediated Gene Therapy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among emerging and novel treatments for central nervous system (CNS)
      disorders, gene therapy (GT), particularly using adeno-associated virus
      (AAV)-mediated gene delivery, holds great promise.
    explanation: >-
      Reviews AAV-mediated gene therapy as a promising approach for HD treatment.
  target_mechanisms:
  - target: HTT CAG Repeat Expansion
    treatment_effect: INHIBITS
    description: >-
      HTT-lowering ASOs, splice modulators, and microRNA-based therapies reduce
      the expression of mutant huntingtin, directly suppressing the root CAG
      repeat-expansion-driven toxicity at the mRNA and protein level.
  - target: Mutant Huntingtin Protein Aggregation
    treatment_effect: INHIBITS
    description: >-
      By lowering mutant HTT protein levels, these therapies reduce the
      substrate available for mHTT misfolding and nuclear and cytoplasmic
      aggregate formation.
- name: Somatic Expansion Inhibition
  description: >-
    Novel therapeutic paradigm targeting DNA mismatch repair machinery (particularly
    MSH3) to slow or halt somatic CAG repeat expansion in striatal neurons. Considered
    the most promising emerging strategy as it addresses the upstream DNA-level
    mechanism rather than downstream protein toxicity.
  treatment_term:
    preferred_term: Somatic expansion inhibitor therapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:41233526
    reference_title: "Huntington disease: somatic expansion, pathobiology and therapeutics."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      interventions to limit somatic repeat expansion might be effective across
      multiple repeat expansion diseases and, when combined with disease-specific
      approaches, such as huntingtin lowering in Huntington disease, might offer
      more effective and longer-lasting clinical benefits than either strategy in
      isolation.
    explanation: >-
      Supports somatic expansion inhibition as a promising combinatorial therapeutic
      strategy for HD and other repeat expansion disorders.
  target_mechanisms:
  - target: Somatic CAG Repeat Expansion
    treatment_effect: INHIBITS
    description: >-
      Inhibiting MSH3 and other mismatch repair factors slows or halts the
      somatic CAG repeat expansion that drives progressive striatal toxicity,
      targeting the upstream DNA-level mechanism rather than downstream protein
      aggregation.
- name: Human Neural Stem Cell Transplantation (hNSC-01)
  description: >-
    Investigational regenerative cell therapy in which good manufacturing
    practice (GMP)-grade human embryonic stem cell-derived neural stem cells
    (hNSC-01) are stereotactically implanted into the striatum. Rather than
    acting by neuronal replacement alone, the grafted cells are proposed to work
    through neuroprotection and trophic support (including BDNF), reconstruction
    of striatal synaptic circuitry, and reduction of mutant huntingtin
    accumulation. This is the cell-therapy approach being evaluated first-in-human
    in the UCI Health REGEN4HD trial (NCT07451613).
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: human neural stem cell transplantation
    term:
      id: NCIT:C70601
      label: Cellular Therapy
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:29233555
    reference_title: "Human Neural Stem Cell Transplantation Rescues Functional Deficits in R6/2 and Q140 Huntington's Disease Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Disease-modifying activity is suggested by the reduction of aberrant
      accumulation of mutant HTT protein and expression of brain-derived
      neurotrophic factor (BDNF) in both models.
    explanation: >-
      Preclinical study of the GMP-grade hNSC line that forms the basis for
      hNSC-01, transplanted into the striatum of R6/2 and Q140 HD mice, showed
      improved motor function, reduced mutant HTT accumulation, and increased
      BDNF, supporting a disease-modifying neurotrophic mechanism.
  - reference: clinicaltrials:NCT07451613
    reference_title: "Phase 1B/2A Study of the Safety and Tolerability of Human Neural Stem Cells for Huntington's Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease"
    explanation: >-
      The first-in-human REGEN4HD trial is evaluating intrastriatal hNSC-01
      implantation for safety and tolerability in early-stage HD.
  target_mechanisms:
  - target: Medium Spiny Neuron Degeneration
    treatment_effect: MODULATES
    description: >-
      Intrastriatal hNSC grafts provide trophic support (notably BDNF) and
      synaptic/circuit reconstruction intended to protect and functionally
      compensate for the vulnerable striatal medium spiny neurons whose
      degeneration drives HD motor and cognitive decline.
  - target: Mutant Huntingtin Protein Aggregation
    treatment_effect: INHIBITS
    description: >-
      In HD mouse models, hNSC transplantation reduced aberrant accumulation of
      mutant huntingtin, indicating a disease-modifying effect on mHTT
      proteostasis beyond simple cell replacement.
- name: AMT-130 (AAV5-miHTT Gene Therapy)
  description: >-
    One-time HTT-lowering gene therapy delivering an engineered microRNA (miHTT)
    via an adeno-associated virus serotype 5 (rAAV5) vector by MRI-guided
    stereotactic infusion into the caudate and putamen. The vector-expressed
    miHTT drives non-allele-selective (total) lowering of huntingtin mRNA and
    protein in striatal neurons. In the Phase 1/2 program (NCT04120493 /
    NCT05243017) the high dose showed slowing of clinical progression and lowered
    CSF neurofilament light chain, and a BLA submission is planned.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: AAV5-miHTT gene therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:30984798
    reference_title: "AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      AAV5-miHTT caused a dose-dependent and sustained HTT protein reduction with
      subsequent suppression of mutant HTT aggregate formation in the striatum
      and cortex.
    explanation: >-
      Preclinical study of the AAV5-miHTT construct underlying AMT-130 showing
      dose-dependent, sustained huntingtin lowering and reduced mutant HTT
      aggregation after intrastriatal delivery in HD mouse models.
  - reference: clinicaltrials:NCT04120493
    reference_title: "A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC)."
    explanation: >-
      ClinicalTrials.gov record for the first-in-human Phase 1/2 study of the
      rAAV5-miHTT gene therapy AMT-130 in early manifest Huntington's disease.
  target_mechanisms:
  - target: HTT CAG Repeat Expansion
    treatment_effect: INHIBITS
    description: >-
      The AAV5-delivered miHTT microRNA degrades huntingtin mRNA, lowering total
      (mutant and wild-type) huntingtin expression and thereby suppressing the
      downstream toxicity of the CAG-repeat-expanded transcript at its source.
  - target: Mutant Huntingtin Protein Aggregation
    treatment_effect: INHIBITS
    description: >-
      By reducing huntingtin mRNA, AMT-130 lowers mutant huntingtin protein
      levels, decreasing the substrate available for mHTT misfolding and
      aggregate formation in striatal neurons.
- name: Allele-Selective CRISPR/Cas9 HTT Inactivation
  description: >-
    Genome-editing strategy that permanently inactivates the expanded
    (mutant) HTT allele while sparing the wild-type allele. Allele selectivity is
    achieved by directing Cas9 to heterozygous, allele-specific single-nucleotide
    polymorphisms (SNPs) that create or destroy a CRISPR PAM motif on the mutant
    chromosome. Preclinical proof-of-concept in HD patient cells and a transgenic
    HD mouse model; not yet in clinical trials.
  therapeutic_modality: GENE_EDITING
  treatment_term:
    preferred_term: allele-selective genome editing
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:28129107
    reference_title: "CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "HEK293 cells, which are homozygous for the targeting SNPs (Figure 2B), were transfected with SpCas9 and sgRNA expression plasmids and genomic deletion assessed."
    explanation: >-
      In vitro demonstration of SNP-dependent, allele-selective CRISPR/Cas9
      excision of HTT in human cells homozygous for the targeting SNPs.
  - reference: PMID:28129107
    reference_title: "CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Interestingly, mouse Htt mRNA levels were also reduced on the injected
      hemisphere, although to a lesser degree than the human HTT allele.
    explanation: >-
      In vivo confirmation in BacHD transgenic mice (carrying the human HD allele
      with the targeting SNPs) that intrastriatal CRISPR/Cas9 editing lowers HTT
      expression on the injected hemisphere.
  target_mechanisms:
  - target: HTT CAG Repeat Expansion
    treatment_effect: INHIBITS
    description: >-
      Allele-selective CRISPR/Cas9 editing introduces inactivating breaks in the
      mutant HTT allele, permanently abolishing expression of the CAG-expanded
      transcript while leaving the wild-type allele intact.
- name: Human Dental Pulp Stem Cell Therapy (NestaCell)
  description: >-
    Investigational allogeneic cell therapy using intravenously infused human
    dental pulp stem cells (hDPSCs; NestaCell, formerly Cellavita HD). The
    rationale is neurotrophic support and modulation of neuroinflammation rather
    than direct neuronal replacement. A randomized, double-blind,
    placebo-controlled Phase II trial (NCT03252535) reported a favorable safety
    profile and significant improvements in motor and functional scores,
    supporting advancement to Phase III.
  therapeutic_modality: CELL_THERAPY
  treatment_term:
    preferred_term: human dental pulp stem cell therapy
    term:
      id: NCIT:C70601
      label: Cellular Therapy
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: PMID:40770775
    reference_title: "Phase II trial of intravenous human dental pulp stem cell therapy for Huntington's disease: a randomized, double-blind, placebo-controlled study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both doses significantly improved UHDRS-TMS compared to placebo (p =
      0.005), while the 2 million cells/kg group showed significant benefits in
      UHDRS-TFC (p = 0.011).
    explanation: >-
      Randomized, double-blind, placebo-controlled Phase II trial of allogeneic
      human dental pulp stem cells (NestaCell) showing significant motor
      (UHDRS-TMS) and functional (UHDRS-TFC) benefit over placebo in HD.
  target_mechanisms:
  - target: Medium Spiny Neuron Degeneration
    treatment_effect: MODULATES
    description: >-
      Infused dental pulp stem cells are proposed to act through neurotrophic
      support and modulation of neuroinflammation, aiming to protect vulnerable
      striatal medium spiny neurons rather than replace them.
  - target: Neuroinflammation
    treatment_effect: MODULATES
    description: >-
      hDPSCs have immunomodulatory and anti-inflammatory properties hypothesized
      to dampen the neuroinflammatory component of HD striatal degeneration.
- name: Genetic Counseling
  description: >-
    Predictive genetic testing and counseling for at-risk family members. Pre-symptomatic
    testing follows international guidelines (HDSA/IHA/WFN) requiring pre- and post-test
    counseling. Only 5-20% of at-risk individuals choose predictive testing.
    Reproductive options include PGT-M, prenatal testing, and exclusion testing.
  treatment_term:
    preferred_term: Genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
- name: Supportive Care
  description: >-
    Multidisciplinary care including physical therapy (gait training, fall prevention),
    speech therapy (dysarthria and dysphagia management), occupational therapy,
    nutritional support (high-calorie diets, PEG tube in advanced stages), and
    psychiatric management (SSRIs, SNRIs for depression; antipsychotics for psychosis).
  treatment_term:
    preferred_term: Supportive care
    term:
      id: NCIT:C15747
      label: Supportive Care
- name: Antipsychotic Medications
  role: Symptomatic
  description: Used for psychiatric symptoms like irritability and agitation.
  evidence:
  - reference: PMID:27534434
    reference_title: "Antipsychotic drugs in Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: In clinical practice antipsychotics represent the first choice in the management of chorea in the presence of psychiatric symptoms...
    explanation: The literature states that antipsychotics are used to manage psychiatric symptoms in Huntington's Disease.
  - reference: PMID:16383221
    reference_title: "Behavioral symptoms associated with Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: According to clinical observation, HD patients with psychiatric symptoms respond to standard pharmacotherapy.
    explanation: The literature supports the use of pharmacotherapy, which includes antipsychotic medications, for psychiatric symptoms in Huntington's Disease.
  - reference: PMID:36496108
    reference_title: "Neuropharmacological effect of risperidone: From chemistry to medicine."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Several lines of evidence suggest a possible role of risperidone via the antagonistic effect of Dopamine D2 and 5HT-receptor in different neurological diseases like cognitive dysfunction of schizophrenia, neuroinflammation, Huntington's disease...
    explanation: Risperidone, an antipsychotic, is mentioned as having a role in treating psychiatric symptoms in Huntington's Disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: Selective Serotonin Reuptake Inhibitors (SSRIs)
  role: Symptomatic
  description: Used to manage depression.
  evidence:
  - reference: PMID:18394562
    reference_title: "Symptomatic treatment of Huntington disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Several classes of medications have been used to ameliorate the various symptoms of HD, including typical and atypical neuroleptics, dopamine depleters, antidepressants...
    explanation: The abstract mentions that antidepressants, which include SSRIs, are used to manage symptoms in Huntington's Disease.
  - reference: PMID:22119091
    reference_title: "Suicidality in Huntington's disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Cross-sectionally, suicidal mutation carriers were more likely to use antidepressants (odds ratio=5.3)...
    explanation: The use of antidepressants, which can include SSRIs, is associated with managing depressive symptoms in Huntington's Disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
- name: XJB-5-131 (Mitochondria-Targeted Antioxidant)
  therapeutic_modality: SMALL_MOLECULE
  description: >-
    PRECLINICAL ONLY - no human trial has been conducted. XJB-5-131 is a
    synthetic antioxidant in which a tempol nitroxide radical-scavenging moiety
    is linked to a mitochondria-targeting carrier peptide derived from
    gramicidin S, concentrating the antioxidant at the mitochondrial membrane.
    By suppressing mitochondrial reactive oxygen species it prevents base
    oxidation and blocks the conversion of base excision repair single-strand
    break intermediates into double-strand breaks. In HdhQ(150/150) mice dosed
    at 2 mg/kg intraperitoneally three times weekly from 60 to 90 weeks - that
    is, started only after double-strand breaks had accumulated and disease was
    well established - it reduced striatal neuronal gamma-H2AX staining and
    neutral comet tail moments, restored NeuN staining, and improved motor
    performance, with no substantial change in somatic CAG tract length. That
    dissociation is the interventional basis for treating double-strand breaks
    as a therapeutic target separable from somatic expansion.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: XJB-5-131
      term:
        id: CHEBI:173099
        label: XJB-5-131
  target_mechanisms:
  - target: Oxidative Single-Strand to Double-Strand Break Conversion
    treatment_effect: INHIBITS
    description: >-
      Mitochondrial localisation of the nitroxide lowers the reactive oxygen
      species load that drives endogenous base oxidation, reducing the supply of
      single-strand break intermediates that convert to double-strand breaks.
      The drug acts on break formation upstream; it does not restore
      non-homologous end joining.
    evidence:
    - reference: PMID:23122961
      reference_title: "Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        XJB-5-131 reduces oxidative damage to mitochondrial DNA, maintains
        mitochondrial DNA copy number, suppresses motor decline and weight loss,
        enhances neuronal survival, and improves mitochondrial function.
      explanation: >-
        Establishes the drug's mechanism as suppression of mitochondrial
        oxidative DNA damage, the input to the SSB-to-DSB conversion node.
  - target: Genome-Wide Double Strand Break Accumulation
    treatment_effect: INHIBITS
    description: >-
      Thirty weeks of treatment begun at 60 weeks lowered striatal neuronal
      double-strand break burden by both gamma-H2AX immunofluorescence and
      neutral comet assay, and rescued striatal neuron number and motor
      performance, while somatic tract length was substantially unchanged.
    evidence:
    - reference: PMID:42091595
      reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Conversely, suppression of DSBs is sufficient to reverse neuropathology
        even when somatic expansion is active.
      explanation: >-
        The interventional result linking pharmacological double-strand break
        suppression to reversal of neuropathology with expansion ongoing.
  evidence:
  - reference: PMID:26908614
    reference_title: "Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We have developed a novel synthetic antioxidant, XJB-5-131, which directly
      targets MT, the primary site and primary target of oxidative damage.
    explanation: >-
      Describes the agent and its mitochondrial targeting.
  - reference: PMID:26908614
    reference_title: "Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In animals with well-developed pathology, XJB-5-131 promotes weight gain,
      prevents neuronal death, reduces oxidative damage in neurons, suppresses
      the decline of motor performance or improves it
    explanation: >-
      Establishes efficacy when dosing begins after disease onset in the same
      HdhQ150 model, which is the regimen used in the 2026 double-strand break
      study.
  - reference: PMID:23122961
    reference_title: "Targeting of XJB-5-131 to mitochondria suppresses oxidative DNA damage and motor decline in a mouse model of Huntington's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      To increase specificity and efficacy, we have designed a synthetic
      antioxidant, XJB-5-131, to target mitochondria.
    explanation: >-
      Original description of the compound's design rationale.
  notes: >-
    Preclinical only - mouse, and in the 2026 double-strand break study male
    mice only. There is no clinical trial and no NCT identifier, so no entry is
    made under clinical_trials. Curators should note an unresolved discrepancy
    in the effect on somatic expansion between two reports from the same group:
    Budworth et al. 2015 (PMID:26247199) reported that XJB-5-131 inhibits
    lengthening of the repeat tract in HdhQ(150) mice treated early, whereas
    Polyzos et al. 2026 (PMID:42091595) reports no substantial impact on somatic
    expansion in congenic HdhQ(150/150) mice treated from 60 weeks. The regimens,
    zygosity and treatment windows differ. This is recorded as the discussion
    controversy_hd_xjb_effect_on_somatic_expansion.
animal_models:
- name: R6/2 transgenic mouse
  species: Mouse
  genotype: R6/2 Transgenic
  description: Mice expressing human mutant huntingtin with expanded CAG repeats used to model motor and cognitive deficits.
  associated_phenotypes:
  - Progressive Motor Dysfunction
  - Cognitive Impairment
  - Weight Loss
  evidence:
  - reference: PMID:18638556
    reference_title: "Rodent genetic models of Huntington disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Huntington disease (HD) is a dominantly inherited human neurodegenerative disorder characterized by motor deficits, cognitive impairment, and psychiatric symptoms leading to inexorable decline and death. Since the identification of the huntingtin gene and the characteristic expanded CAG repeat/polyglutamine mutation, multiple murine genetic models and one rat genetic model have been generated.
    explanation: This reference supports the statement as it describes Huntington's disease as involving motor deficits and cognitive impairment, and mentions the use of murine genetic models, including transgenic ones with expanded CAG repeats like the R6/2 model.
  - reference: PMID:35007790
    reference_title: "Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We used the R6/2 and BACHD mouse models that express different lengths of mutant HTT to develop lean- and obese phenotypes, respectively. We utilized adeno-associated viral vectors to overexpress either mutant or wild-type HTT in the hypothalamus of R6/2, BACHD, and their wild-type littermates. The metabolic phenotype was assessed by body weight measurements over time and body composition analysis using dual-energy x-ray absorptiometry at the endpoint.
    explanation: This reference supports the statement by describing the use of R6/2 mice, which express mutant HTT, to study metabolic phenotypes including weight changes, indicating weight loss as part of the disease phenotype.
  - reference: PMID:29856017
    reference_title: "Motor Assessment in Huntington's Disease Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Motor deficits are a characteristic consequence of striatal damage, whether induced by experimental lesions, or in genetic models of Huntington's disease involving polyglutamine expansion in the huntingtin protein.
    explanation: This reference supports the statement by confirming that motor deficits are a characteristic consequence of genetic models of Huntington's disease, including those with polyglutamine expansion such as the R6/2 model.
  - reference: PMID:31868674
    reference_title: "Correlations Between Mutant Huntingtin Aggregates and Behavioral Changes in R6/1 Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: 'Huntington''s disease (HD) is a neurodegenerative disorder caused by the expansion of the trinucleotide CAG in the HD gene. While the presence of nuclear aggregates of mutant huntingtin (mHtt) in neurons is a hallmark of HD, the reason behind its toxicity remains elusive. OBJECTIVE: The present study was conducted to assess a correlation between the number of mHtt aggregates and the severity of HD symptoms in R6/1 mice.'
    explanation: This reference supports the statement by describing the use of R6/1 mice, a similar model to R6/2, to study the correlation between mutant huntingtin aggregates and the severity of HD symptoms, including motor and cognitive deficits.
  - reference: PMID:15525658
    reference_title: "Orexin loss in Huntington's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: We describe for the first time a dramatic atrophy and loss of orexin neurons in the lateral hypothalamus of R6/2 mice. Importantly, we also found a significant atrophy and loss of orexin neurons in Huntington patients.
    explanation: This reference supports the statement by describing the use of R6/2 mice to model Huntington's disease, noting significant neuronal changes that correlate with the disease phenotype.
- name: Congenic HdhQ(150/150) knock-in mouse
  species: Mouse
  genotype: Hdh CAG(150) homozygous knock-in (HdhQ150), congenic on C57BL/6J
  background: C57BL/6J, backcrossed more than 15 generations to a congenic (clonal) line
  publication: PMID:42091595
  description: >-
    Knock-in of an approximately 150-unit CAG tract into the endogenous mouse
    Hdh locus, the closest available genetic replica of the human mutation. The
    congenic derivation is deliberate: because every animal is essentially a
    genetic clone expressing the same proteins at the same level, variance
    between animals in DNA repair protein expression is suppressed, which is
    what makes small repair-activity differences between genotypes detectable.
    Disease course: double-strand breaks from 7-10 weeks, somatic expansion
    onset ~11-12 weeks, motor abnormalities ~20 weeks, striatal neuron loss
    ~60 weeks, with the cerebellum spared.
  associated_phenotypes:
  - Gait Disturbance
  - Involuntary Movements
  - Weight Loss
  modeled_mechanisms:
  - target: mHTT Suppression of Non-Homologous End Joining
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Disease-genotype glia and striatal tissue induce double-strand breaks
      normally after ionising radiation but clear them inefficiently, while
      base excision, nucleotide excision and mismatch repair activities are
      unchanged by genotype - a repair deficit selective for the pathway whose
      components co-immunoprecipitate with huntingtin.
    limitations: >-
      The repair deficit is inferred from clearance of exogenously induced
      (2 Gy in vitro, 5 Gy in vivo) breaks rather than from endogenous repair
      kinetics, so the measured quantity is the response to an acute
      supraphysiological insult. All experiments used male mice only. The model
      carries a mouse Hdh knock-in of ~150 CAG, a repeat length that in humans
      would cause childhood-onset disease, so it does not model the adult-onset
      expansion trajectory. No corresponding NHEJ deficit has been demonstrated
      in human HD tissue.
    readouts:
    - name: Clearance of radiation-induced gamma-H2AX foci in striatal cells
      target: mHTT Suppression of Non-Homologous End Joining
      direction: DECREASED
      interpretation: >-
        Foci induction was equivalent between genotypes, but loss of foci over
        1-24 h in vitro and 2-4 h in vivo was slower in disease striatum,
        indicating suppressed double-strand break repair rather than increased
        break formation.
      evidence:
      - reference: PMID:42091595
        reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          The site-specific increases in CAG tract length are driven by active
          mismatch repair (MMR), while DSBs occur genome-wide and are driven by
          mutant huntingtin-mediated suppression of nonhomologous joining of DNA
          broken ends.
        explanation: >-
          Reports suppression of non-homologous end joining as the measured
          defect underlying this readout.
    evidence:
    - reference: PMID:42091595
      reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The disease-length CAG tract leads to early inhibition of DSBR and
        accumulating DSBs over time ultimately kill neurons.
      explanation: >-
        Supports treating this model as informative for early inhibition of
        double-strand break repair.
  - target: Genome-Wide Double Strand Break Accumulation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Unrepaired double-strand breaks rise with age in striatal neurons and
      remain modest in cerebellum, reproducing the regional and cell-type
      selectivity of human striatal vulnerability. Concordant across four
      independent markers.
    limitations: >-
      Male mice only. Break burden in human HD striatum has not been quantified
      with comparable methods, so the correspondence to human disease is
      inferred from the matching anatomical pattern rather than measured.
    readouts:
    - name: Striatal neuronal gamma-H2AX immunofluorescence intensity
      target: Genome-Wide Double Strand Break Accumulation
      direction: INCREASED
      interpretation: >-
        Elevated in NeuN-positive striatal neurons of disease animals versus
        wild type at both young and old ages; modest in cerebellum in both
        genotypes.
      evidence:
      - reference: PMID:42091595
        reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          we report that DSBs drive neuropathology in male HdhQ(150/150) mice,
          regardless of somatic expansion of the inherited disease allele
        explanation: >-
          Reports elevated double-strand breaks in this model as the basis for
          the neuropathology claim.
    - name: Neutral comet assay tail moment in dispersed striatal cells
      target: Genome-Wide Double Strand Break Accumulation
      direction: INCREASED
      interpretation: >-
        Direct physical measurement of DNA breakage, confirming that the
        antibody-based markers reflect real double-strand breaks rather than
        signalling changes.
      evidence:
      - reference: PMID:42091595
        reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          We propose that CAG expansion and DSBs promote downstream neuronal
          pathology as separable drivers.
        explanation: >-
          Frames the measured break burden as an independent pathological
          driver in this model.
    evidence:
    - reference: PMID:11152661
      reference_title: "Neurological abnormalities in a knock-in mouse model of Huntington's disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Mice with alleles of approximately 150 units in length exhibit
        late-onset behavioral and neuroanatomic abnormalities consistent with HD.
      explanation: >-
        Establishes the HdhQ150 knock-in line as a phenotypically valid HD model
        for the mechanism claims built on it.
  - target: Oxidative Single-Strand to Double-Strand Break Conversion
    relationship: RESCUES
    fidelity: MODERATE
    description: >-
      The XJB-5-131 treatment arm. Animals aged to 60 weeks to allow break
      accumulation, then dosed 2 mg/kg intraperitoneally three times weekly for
      30 weeks to 90 weeks, against a saline vehicle control. Suppressing
      reactive oxygen species lowered break burden and rescued neuropathology
      without materially changing somatic tract length.
    limitations: >-
      The rescue demonstrates that lowering break burden is sufficient to
      improve outcome; it does not show that non-homologous end joining was
      restored, since the drug acts upstream on break formation. Male mice
      only, n = 3 per group. The reported absence of an effect on somatic
      expansion conflicts with an earlier report from the same group in
      differently treated HdhQ(150) animals - see the discussion
      controversy_hd_xjb_effect_on_somatic_expansion.
    readouts:
    - name: Striatal neuronal gamma-H2AX intensity after 30 weeks of XJB-5-131
      target: Oxidative Single-Strand to Double-Strand Break Conversion
      direction: DECREASED
      interpretation: >-
        Vehicle-treated disease animals showed roughly doubled neuronal
        gamma-H2AX versus wild type; treatment inhibited the increase.
      evidence:
      - reference: PMID:42091595
        reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Conversely, suppression of DSBs is sufficient to reverse
          neuropathology even when somatic expansion is active.
        explanation: >-
          Reports the treatment-driven reduction in double-strand breaks and the
          resulting reversal of neuropathology.
    evidence:
    - reference: PMID:42091595
      reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Conversely, suppression of DSBs is sufficient to reverse neuropathology
        even when somatic expansion is active.
      explanation: >-
        Supports this model plus treatment arm as informative for the
        oxidation-driven break-formation node.
  - target: Medium Spiny Neuron Degeneration
    relationship: RESCUES
    fidelity: MODERATE
    description: >-
      The downstream survival arm of the same XJB-5-131 treatment experiment.
      Lowering the double-strand break burden rescued striatal neuron number and
      motor performance, which is the outcome that makes break burden a
      therapeutic target rather than merely a correlate.
    limitations: >-
      Neuronal rescue is measured by NeuN immunofluorescence rather than by
      stereological cell counts. Male mice only, n = 3 per group, and treatment
      began at 60 weeks so the result speaks to halting further loss in
      established disease rather than to preventing onset. The drug acts
      upstream on break formation, so this rescue does not show that
      non-homologous end joining was restored.
    readouts:
    - name: Striatal NeuN immunofluorescence after 30 weeks of XJB-5-131
      target: Medium Spiny Neuron Degeneration
      direction: RESTORED
      interpretation: >-
        Neuronal marker staining recovered in treated disease animals,
        indicating rescue of striatal neuron loss alongside the fall in break
        burden.
      evidence:
      - reference: PMID:26908614
        reference_title: "Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          In animals with well-developed pathology, XJB-5-131 promotes weight
          gain, prevents neuronal death, reduces oxidative damage in neurons,
          suppresses the decline of motor performance or improves it
        explanation: >-
          Reports prevention of neuronal death under the same late-start dosing
          regimen in the same model.
    evidence:
    - reference: PMID:26908614
      reference_title: "Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        In animals with well-developed pathology, XJB-5-131 promotes weight
        gain, prevents neuronal death, reduces oxidative damage in neurons,
        suppresses the decline of motor performance or improves it
      explanation: >-
        Supports this model plus treatment arm as informative for rescue of
        striatal neuron degeneration.
  notes: >-
    Parental HdhQ(-/150) line a gift from P. Detloff; congenic line generated by
    backcrossing to C57BL/6J for more than 15 generations. All experiments in
    PMID:42091595 used male mice.
- name: zQ175 knock-in mouse
  species: Mouse
  genotype: Htt CAG(175-190) knock-in (zQ175)
  publication: PMID:27378694
  description: >-
    Knock-in model carrying a CAG tract of approximately 175-190 that develops
    transcriptional dysregulation and protein aggregation by 6 months and
    undergoes somatic expansion. Used here as the expansion-competent
    comparator against zQ175/MSH3(-/-).
  modeled_mechanisms:
  - target: Genome-Wide Double Strand Break Accumulation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      53BP1 and gamma-H2AX staining intensity is elevated in zQ175 striatal
      neurons relative to C57BL/6J background controls at 3 months and rises a
      further 30-50% by 6 months.
    limitations: >-
      Break levels were quantified by antibody staining intensity only in this
      strain, without the neutral comet confirmation applied in HdhQ(150/150).
      The strain carries a much longer repeat than adult-onset human disease.
    readouts:
    - name: Striatal neuronal 53BP1 immunofluorescence intensity
      target: Genome-Wide Double Strand Break Accumulation
      direction: INCREASED
      interpretation: >-
        Elevated versus genetic background control and increasing between 3 and
        6 months, in a strain that expresses mutant huntingtin.
      evidence:
      - reference: PMID:42091595
        reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          DSBs and transcriptional dysfunction occur in animals that cannot
          somatically expand their inherited allele.
        explanation: >-
          Reports the double-strand break measurements made across the zQ175 and
          zQ175/MSH3(-/-) comparison.
    evidence:
    - reference: PMID:27378694
      reference_title: "An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        The zQ175 model was the first KI mouse to exhibit significant HD-like
        phenotypes when heterozygous.
      explanation: >-
        Establishes zQ175 as a phenotypically validated knock-in HD model.
- name: zQ175/MSH3(-/-) expansion-incompetent knock-in mouse
  species: Mouse
  genotype: Htt CAG(175-190) knock-in on an Msh3 null background
  publication: PMID:38387080
  description: >-
    Separation-of-function cross. Because somatic CAG expansion requires MutS
    beta (MSH2-MSH3), ablating Msh3 abolishes expansion while leaving mutant
    huntingtin expression intact. This dissociates the two candidate drivers:
    any pathology that persists in these animals cannot be attributed to
    ongoing somatic expansion. Double-strand breaks are elevated and rise with
    age here just as in expansion-competent zQ175, and transcriptional
    dysfunction and aggregation still develop.
  modeled_mechanisms:
  - target: Somatic CAG Repeat Expansion
    relationship: FAILS_TO_RECAPITULATE
    fidelity: HIGH
    description: >-
      By design this model does not reproduce somatic CAG expansion - Msh3
      ablation prevents it throughout brain and periphery. The negative result
      is the point of the model, not a shortcoming of it: it is what licenses
      attributing the residual pathology to an expansion-independent driver.
    limitations: >-
      Msh3 is ablated constitutively and germline-wide rather than conditionally
      in striatal neurons, so loss of any expansion-independent MSH3 function is
      not controlled for. The starting repeat of ~185 CAG already exceeds the
      proposed pathogenic threshold, so absence of further expansion may matter
      less in this strain than it would at shorter adult-onset repeat lengths -
      the authors of the source study make exactly this argument.
    readouts:
    - name: Somatic CAG repeat expansion in striatum
      target: Somatic CAG Repeat Expansion
      direction: ABOLISHED
      interpretation: >-
        Msh3 ablation prevents somatic expansion in brain and periphery, while
        50% reduction slows it - a dose-dependent confirmation that the
        expansion arm is switched off in this cross.
      evidence:
      - reference: PMID:38387080
        reference_title: "A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Ablation of Msh3 prevented somatic expansion throughout the brain and
          periphery, and reduction of Msh3 by 50% decreased the rate of
          expansion.
        explanation: >-
          Directly reports that this cross does not undergo somatic expansion.
    evidence:
    - reference: PMID:38387080
      reference_title: "A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        This had no effect on the deposition of huntingtin aggregation in the
        nuclei of striatal neurons, nor on the dysregulated striatal
        transcriptional profile.
      explanation: >-
        Abolishing somatic expansion leaves striatal aggregation and
        transcriptional dysregulation intact, which is the substantive negative
        result this model contributes.
  - target: Genome-Wide Double Strand Break Accumulation
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Double-strand breaks accumulate in these expansion-incompetent animals to
      the same degree as in expansion-competent zQ175 - elevated at 3 months and
      30-50% higher by 6 months relative to Msh3(-/-) background controls. This
      is the strongest genetic evidence that break accumulation does not require
      somatic expansion.
    limitations: >-
      The study established that breaks and transcriptional dysfunction
      co-occur in these animals but did not test whether the breaks cause the
      transcriptional dysfunction. Neuronal death is not observed at these ages
      in either strain, so the model demonstrates expansion-independent break
      accumulation rather than expansion-independent neurodegeneration.
    readouts:
    - name: Striatal neuronal 53BP1 immunofluorescence intensity at 3 and 6 months
      target: Genome-Wide Double Strand Break Accumulation
      direction: INCREASED
      interpretation: >-
        Elevated relative to Msh3(-/-) background controls despite the complete
        absence of somatic expansion, separating break burden from tract length.
      evidence:
      - reference: PMID:42091595
        reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          DSBs and transcriptional dysfunction occur in animals that cannot
          somatically expand their inherited allele.
        explanation: >-
          States precisely the result this readout captures.
    evidence:
    - reference: PMID:42091595
      reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        We propose that CAG expansion and DSBs promote downstream neuronal
        pathology as separable drivers.
      explanation: >-
        Supports treating this cross as informative for expansion-independent
        double-strand break accumulation.
diagnosis:
- name: Genetic Testing for HTT CAG Expansion
  presence: Positive
  notes: Confirmation of diagnosis through DNA analysis.
  evidence:
  - reference: PMID:26439718
    reference_title: "Huntington Disease: Molecular Diagnostics Approach."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Huntington disease (HD) is caused by expansion of a CAG trinucleotide repeat in the first exon of the Huntingtin (HTT) gene. Molecular testing of Huntington disease for diagnostic confirmation and disease prediction requires detection of the CAG repeat expansion.
    explanation: The literature confirms that genetic testing for HTT CAG expansion is used for the diagnostic confirmation of Huntington's Disease.
  - reference: PMID:23390178
    reference_title: "The challenge of juvenile Huntington disease: to test or not to test."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We analyzed the clinical and genetic characteristics of 76 juvenile-onset patients referred consecutively for HD genetic testing over a 16-year period. ... All expanded cases had a family history of genetically confirmed HD compared to only 13.5% of unexpanded cases (p = 0.000).
    explanation: This study supports the use of genetic testing for confirming the diagnosis of Huntington's Disease by identifying the CAG expansion.
  - reference: PMID:31820322
    reference_title: "Late-onset Huntington's disease with 40-42 CAG expansion."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Huntington's disease (HD) is a rare autosomal dominant neurodegenerative disorder caused by a CAG expansion greater than 35 in the IT-15 gene.
    explanation: This reference supports the statement that Huntington's Disease is confirmed through genetic testing for HTT CAG expansion.
  - reference: PMID:28947110
    reference_title: "Genetic testing for Huntington disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: The gene for HD was found in 1993, allowing for direct gene testing for the mutant HTT allele.
    explanation: The discovery of the HD gene allows for direct genetic testing to confirm the presence of HTT CAG expansion, supporting the statement.
- name: Neuropsychological Evaluation
  description: >-
    Formal neuropsychological assessment to detect and monitor the cognitive
    and neuropsychiatric changes of Huntington disease, whose functional impact
    frequently equals or exceeds that of motor symptoms.
  diagnosis_term:
    preferred_term: neuropsychological assessment
    term:
      id: NCIT:C165543
      label: Neuropsychological Assessment
  evidence:
  - reference: PMID:37849335
    reference_title: "Huntington study group's neuropsychology working group position on best practice recommendations for the clinical neuropsychological evaluation of patients with Huntington disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Neuropsychological evaluation is critical to detection and management of cognitive and neuropsychiatric changes associated with Huntington disease (HD)."
    explanation: The Huntington Study Group neuropsychology working group establishes neuropsychological evaluation as critical for detecting and managing the cognitive and neuropsychiatric features of HD.
  - reference: PMID:37849335
    reference_title: "Huntington study group's neuropsychology working group position on best practice recommendations for the clinical neuropsychological evaluation of patients with Huntington disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Accurate assessment of non-motor complications of HD is critical given the prominent impact on functional disability, frequently commensurate with or exceeding that of motor symptoms."
    explanation: Motivates neuropsychological assessment by the large functional impact of HD's non-motor complications.
- name: Neurological Examination
  notes: Assessment of motor disturbances, cognitive function, and psychiatric symptoms.
  evidence:
  - reference: PMID:29856017
    reference_title: "Motor Assessment in Huntington's Disease Mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: Motor deficits are a characteristic consequence of striatal damage, whether induced by experimental lesions, or in genetic models of Huntington's disease involving polyglutamine expansion in the huntingtin protein.
    explanation: This reference supports the assessment of motor disturbances in Huntington's Disease.
  - reference: PMID:29278291
    reference_title: "Rating scales for cognition in Huntington's disease: Critique and recommendations."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: Cognitive impairment is one of the main features of Huntington's disease and is present across the disease spectrum.
    explanation: This reference supports the assessment of cognitive function in Huntington's Disease.
  - reference: PMID:30012004
    reference_title: "Huntington's disease: Neuropsychiatric manifestations of Huntington's disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: This clinical update review focuses on the common neuropsychiatric manifestations in HD, and outlines and evaluates the various neuropsychiatric facets of HD, including the aetiology, symptoms and diagnosis.
    explanation: This reference supports the assessment of psychiatric symptoms in Huntington's Disease.
  - reference: PMID:31922295
    reference_title: "Early-Motor Phenotype Relates to Neuropsychiatric and Cognitive Disorders in Huntington's Disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: To determine the relationships between the motor phenotype and the presence of specific neuropsychiatric and neuropsychological disorders in patients with early motor-manifest Huntington's disease.
    explanation: This reference supports the assessment of motor disturbances, cognitive function, and psychiatric symptoms in Huntington's Disease.
  - reference: PMID:36450478
    reference_title: "Impairments to executive function in emerging adults with Huntington disease."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Recent reports highlight the onset of cognitive and psychiatric symptoms before motor manifestations.
    explanation: This reference supports the assessment of cognitive function and psychiatric symptoms in Huntington's Disease.
clinical_trials:
- name: NCT07451613
  phase: PHASE_I
  status: RECRUITING
  description: >-
    REGEN4HD — the first-in-human Phase 1b/2a study (UCI Health) evaluating the
    safety and tolerability of hNSC-01, GMP-grade human embryonic stem
    cell-derived neural stem cells, stereotactically implanted into the striatum
    of adults with genetically confirmed early-stage Huntington's disease. The
    Phase 1b arm is a dose-escalation cohort followed by a Phase 2a expansion
    group, with treatment-related adverse events as the primary outcome.
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: clinicaltrials:NCT07451613
    reference_title: "Phase 1B/2A Study of the Safety and Tolerability of Human Neural Stem Cells for Huntington's Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease"
    explanation: >-
      ClinicalTrials.gov record for REGEN4HD describes the first-in-human
      evaluation of intrastriatal hNSC-01 neural stem cell therapy for safety
      and tolerability in Huntington's disease.
- name: NCT04120493
  phase: PHASE_I
  status: ACTIVE_NOT_RECRUITING
  description: >-
    First-in-human Phase 1/2, randomized, double-blind, sham-controlled and
    open-label study of striatally-administered rAAV5-miHTT total HTT-lowering
    gene therapy (AMT-130) in early manifest Huntington's disease. The high-dose
    cohort showed slowing of clinical progression and lowered CSF neurofilament
    light chain at 36 months.
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: clinicaltrials:NCT04120493
    reference_title: "A Phase 1/2, Randomized, Double-Blind, Sham Control and Open-Label Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT-130) in Early Manifest Huntington's Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is the first study of AMT-130 in patients with early manifest HD and is designed to establish safety and proof-of-concept (PoC)."
    explanation: >-
      ClinicalTrials.gov record for the first-in-human gene therapy trial of
      AAV5-miHTT (AMT-130) in early manifest Huntington's disease.
- name: NCT03252535
  phase: PHASE_II
  status: COMPLETED
  description: >-
    Phase II, single-center, randomized (2:2:1), triple-blind, placebo-controlled
    dose-response study of intravenous allogeneic human dental pulp stem cells
    (Cellavita HD / NestaCell) in Huntington's disease. Reported a favorable
    safety profile with significant motor and functional improvement over
    placebo, supporting advancement to Phase III.
  target_phenotypes:
  - preferred_term: Chorea
    term:
      id: HP:0002072
      label: Chorea
  - preferred_term: Progressive cognitive decline
    term:
      id: HP:0001268
      label: Mental deterioration
  evidence:
  - reference: clinicaltrials:NCT03252535
    reference_title: "Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Cellavita HD is a stem-cell therapy for Huntington's Disease."
    explanation: >-
      ClinicalTrials.gov record describing the Phase II dental pulp stem cell
      (Cellavita HD) study in Huntington's disease.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
discussions:
- discussion_id: mismatch_jhd_somatic_expansion_dispensable_at_juvenile_repeat_lengths
  prompt: >-
    Does the somatic-CAG-expansion therapeutic rationale, which underpins MSH3- and
    FAN1-directed programmes in adult-onset HD, still apply in the juvenile repeat
    range, where the inherited allele may already exceed the pathogenic threshold and
    further somatic expansion may be dispensable for pathogenesis?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#Somatic CAG Repeat Expansion
  - pathophysiology#Juvenile-Range CAG Expansion
  - pathophysiology#Mutant Huntingtin Protein Aggregation
  rationale: >-
    In the zQ175 knock-in model, whose approximately 185-CAG allele sits in the
    juvenile/pediatric rather than adult range, complete Msh3 ablation abolished
    somatic expansion throughout brain and periphery and 50% reduction slowed it - yet
    neither striatal nuclear huntingtin aggregation nor the dysregulated striatal
    transcriptional profile improved. This is the opposite of the result obtained when
    Msh3 is ablated in knock-in models carrying shorter, adult-range repeats, where the
    intervention is beneficial. The authors' own translational argument is that human
    repeats of comparable size cause onset before age 2, so somatic expansion in brain
    cannot be required for pathogenesis at these lengths.
    The mismatch is therefore two-sided and specifically juvenile. Model-to-human: the
    negative result is a mouse result, and no trial of somatic-instability-directed
    therapy has been run in children with juvenile-onset HD - they are excluded from
    most HD trials, so the human counterpart of this experiment does not exist.
    Human-to-model: the repeat length at which the benefit of somatic-expansion
    suppression disappears is unknown in humans, because the trajectory of somatic
    expansion in mutation-carrier brain has not been measured. Until that threshold is
    located, an MSH3- or FAN1-directed agent validated in adult-onset HD must not be
    assumed to transfer to juvenile-onset patients, and the practical implication the
    authors draw - treat as early as possible, before the threshold is crossed - is
    itself untested in this group.
    This discussion deliberately does not resolve the general somatic-expansion gap
    recorded in gap_hd_somatic_expansion_threshold_rescue; it is the juvenile-range
    special case of it, where the sign of the expected effect may differ.
  evidence:
  - reference: PMID:38387080
    reference_title: "A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Ablation of Msh3 prevented somatic expansion throughout the brain and periphery,
      and reduction of Msh3 by 50% decreased the rate of expansion.
    explanation: >-
      Confirms the intervention worked as intended on its molecular target, so the
      absent phenotypic benefit is not an efficacy failure.
  - reference: PMID:38387080
    reference_title: "A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      This had no effect on the deposition of huntingtin aggregation in the nuclei of
      striatal neurons, nor on the dysregulated striatal transcriptional profile.
    explanation: >-
      The negative result at a juvenile-range repeat length that motivates this
      mismatch discussion.
  - reference: PMID:38387080
    reference_title: "A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      It is striking that highly expanded CAG repeats of a similar size in humans cause
      disease onset before 2 years of age, indicating that somatic CAG repeat expansion
      in the brain is not required for pathogenesis.
    explanation: >-
      The authors' explicit bridge from the mouse result to human juvenile-onset
      disease, and the basis for treating this as a translational mismatch rather than
      a model artefact.
  proposed_experiments:
  - experiment_id: exp_jhd_repeat_length_titrated_msh3_suppression
    name: Repeat-length-titrated MSH3 suppression in juvenile-range HD neurons
    description: >-
      Locate the repeat length at which suppressing somatic expansion stops conferring
      benefit, using isogenic human striatal neurons spanning the adult-onset through
      juvenile and highly expanded pediatric ranges. Apply graded MSH3 knockdown to
      each line, then measure somatic expansion alongside the phenotypes that failed to
      respond in zQ175 - nuclear huntingtin aggregation and the striatal transcriptional
      signature - plus survival. The read-out of interest is not whether suppression
      works at any one length but where in the repeat-length series the dose-response
      inverts, which is the number needed to decide whether juvenile-onset patients
      belong in MSH3-directed trials at all.
    experiment_type:
      preferred_term: isogenic allelic-series perturbation experiment
    model_systems:
    - name: Juvenile-range isogenic hPSC-derived striatal neuron allelic series
      description: >-
        Human pluripotent-stem-cell-derived striatal projection neurons carrying an
        isogenic series of HTT CAG tract lengths that spans the adult-onset, juvenile,
        and highly expanded pediatric ranges, so repeat length is the only variable
        distinguishing the lines.
      experimental_model_type: IPSC_DERIVED_MODEL
- discussion_id: gap_hd_somatic_expansion_threshold_rescue
  prompt: >-
    Is somatic HTT CAG expansion past a repeat-length threshold a causal,
    cell-autonomous trigger for medium spiny neuron degeneration, and can
    MSH3/FAN1-pathway modulation shift neurons below that threshold without
    unacceptable DNA-repair toxicity?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Somatic CAG Repeat Expansion
  - pathophysiology#Medium Spiny Neuron Degeneration
  - pathophysiology#Mutant Huntingtin Protein Aggregation
  rationale: >-
    Human single-cell data now argue for a long silent phase of somatic repeat
    growth followed by a high-repeat toxicity threshold. A standardized
    isogenic striatal-neuron experiment would separate repeat-length threshold,
    mutant huntingtin proteostasis, and DNA-repair perturbation effects before
    treating somatic-expansion inhibition as a general disease-modifying
    strategy.
  proposed_experiments:
  - experiment_id: exp_hd_isogenic_spn_repeat_threshold_modulation
    name: Isogenic hPSC striatal-neuron somatic-expansion threshold assay
    description: >-
      Generate isogenic hPSC-derived striatal projection neuron cultures with
      defined HTT CAG lengths; induce or monitor somatic expansion over
      maturation; perturb MSH3 and FAN1 pathway activity; then pair single-cell
      repeat sizing with neuronal identity, stress, survival, and mutant
      huntingtin aggregation readouts.
    experiment_type:
      preferred_term: isogenic stem-cell perturbation experiment
    model_systems:
    - name: Isogenic hPSC-derived striatal projection neuron model
      description: >-
        Human pluripotent-stem-cell-derived striatal neuron system carrying
        controlled HTT CAG tracts so repeat-length distributions can be linked
        to cell-state and degeneration readouts in the same cells.
      experimental_model_type: IPSC_DERIVED_MODEL
      organism:
        preferred_term: human
        term:
          id: NCBITaxon:9606
          label: Homo sapiens
      tissue_term:
        preferred_term: striatum
      cell_types:
      - preferred_term: medium spiny neuron
      cell_source: isogenic hPSC-derived neurons with engineered HTT CAG tracts
      culture_system: long-maturation striatal neuron culture or striatal organoid slice
    perturbations:
    - name: HTT CAG tract length series
      target: pathophysiology#HTT CAG Repeat Expansion
      description: >-
        Isogenic allelic series spanning reduced-penetrance, typical adult-onset,
        and high-repeat HTT CAG lengths.
      gene:
        preferred_term: HTT
        term:
          id: hgnc:4851
          label: HTT
    - name: MSH3 suppression
      target: pathophysiology#Somatic CAG Repeat Expansion
      description: >-
        Genetic or pharmacologic reduction of mismatch-repair activity predicted
        to slow somatic CAG expansion.
      gene:
        preferred_term: MSH3
    - name: FAN1 enhancement
      target: pathophysiology#Somatic CAG Repeat Expansion
      description: >-
        FAN1-pathway enhancement to test whether repeat-stabilizing activity
        can preserve neuronal identity without broad DNA-repair toxicity.
      gene:
        preferred_term: FAN1
    readouts:
    - name: Single-cell HTT CAG repeat-length distribution
      target: pathophysiology#Somatic CAG Repeat Expansion
      description: Repeat length measured in the same cells used for transcriptomic state assignment.
      assays:
      - preferred_term: single-cell repeat-length sequencing
      - preferred_term: long-read sequencing
      direction: POSITIVE
    - name: Medium spiny neuron identity and survival
      target: pathophysiology#Medium Spiny Neuron Degeneration
      description: >-
        Loss of striatal neuron markers, stress-state induction, and cell-loss
        readouts interpreted against CAG threshold crossing.
      assays:
      - preferred_term: single-cell transcriptomic profiling
      - preferred_term: cell viability assay
      direction: POSITIVE
    - name: Mutant huntingtin aggregation burden
      target: pathophysiology#Mutant Huntingtin Protein Aggregation
      description: Aggregation or nuclear-inclusion readout paired to repeat length.
      assays:
      - preferred_term: immunofluorescence assay
      direction: POSITIVE
    controls:
    - name: Isogenic non-expanded HTT neurons
      description: Matched striatal neurons carrying nonpathogenic HTT CAG length.
    - name: Sham-edited expanded HTT neurons
      description: Expanded-CAG neurons receiving editing or delivery controls only.
    decision_criterion: >-
      The threshold model is supported if neurons crossing a prespecified high
      somatic-repeat range lose striatal identity and viability, and if MSH3
      suppression or FAN1 enhancement reduces both threshold crossing and
      degeneration without broad DNA-damage readouts.
    would_support:
    - pathophysiology#Somatic CAG Repeat Expansion
    - pathophysiology#Medium Spiny Neuron Degeneration
    would_refute:
    - pathophysiology#Somatic CAG Repeat Expansion
    evidence:
    - reference: PMID:39824182
      reference_title: "Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Somatic expansion from 40 to 150 CAGs had no apparent cell-autonomous effect"
      explanation: >-
        Establishes the threshold-like causal question by separating lower
        somatic expansion from the larger expansions linked to neuronal collapse.
    - reference: PMID:39824182
      reference_title: "Long somatic DNA-repeat expansion drives neurodegeneration in Huntington's disease."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "somatic repeat expansion beyond 150 CAGs causes SPNs to degenerate quickly and asynchronously"
      explanation: >-
        Supports testing whether repeat-stabilizing perturbations can prevent
        the high-repeat state in a controlled human neuronal model.
    - reference: PMID:33579859
      reference_title: "DNA Repair in Huntington's Disease and Spinocerebellar Ataxias: Somatic Instability and Alternative Hypotheses."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Validation of leads including the mismatch repair protein MSH3, and
        interstrand cross-link repair protein FAN1, suggest the mechanism is driven
        by somatic CAG instability
      explanation: >-
        Provides the genetic-modifier rationale for MSH3 and FAN1 perturbations.
- discussion_id: mismatch_hd_dsbr_absent_from_human_gwas
  prompt: >-
    Mouse data make mutant-huntingtin suppression of non-homologous end joining
    an early driver of HD neuropathology, yet no DSBR or NHEJ gene has emerged
    from human HD onset GWAS, where the modifier signal is dominated by mismatch
    repair and FAN1. Does impaired double-strand break repair operate in human
    HD brain, or is this a property of the mouse models?
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  attaches_to:
  - pathophysiology#mHTT Suppression of Non-Homologous End Joining
  - pathophysiology#Genome-Wide Double Strand Break Accumulation
  rationale: >-
    This is a translational-validity question rather than an absence of
    evidence: the mouse evidence is direct (huntingtin-Ku70/Ku80
    co-immunoprecipitation, pathway-selective repair deficit, delayed break
    clearance, four concordant break markers), but the corresponding human
    genetic signal is missing. The authors offer a reconciliation that is
    plausible and untested - double-strand breaks form at effectively random
    genomic positions and so vary between patients, and non-homologous end
    joining in mutant-huntingtin-expressing cells is inefficient rather than
    absent, so a partial effect may not reach genome-wide significance in onset
    association studies. Two further considerations cut against dismissing the
    mismatch. GWAS onset modifiers detect variance in the timing of onset, which
    need not be the same quantity as the mechanism driving degeneration once the
    disease-length allele is inherited; and Ligase IV, an NHEJ component, has
    surfaced in a mouse CRISPR screen as a repressor of CAG expansion, implying
    that NHEJ genes may act on both axes and confound a simple modifier readout.
    Until double-strand break burden and end-joining activity are measured
    directly in human HD brain, the expansion-independent driver arm should be
    treated as demonstrated in mouse and unconfirmed in human.
  proposed_experiments:
  - experiment_id: exp_hd_human_striatal_dsb_burden
    name: Quantify double-strand break burden in human HD post-mortem striatum
    description: >-
      Apply the marker panel used in mouse (gamma-H2AX, 53BP1, pKAP-1 with
      NeuN co-staining, plus neutral comet on dispersed cells) to post-mortem
      striatum and cerebellum from HD mutation carriers across disease stages
      and matched controls, testing whether break burden is elevated,
      striatum-selective and neuron-selective as predicted.
  - experiment_id: exp_hd_patient_neuron_repair_landscape
    name: Measure end-joining activity in patient-derived neurons
    description: >-
      Run multiplexed host-cell reactivation across the five major repair
      pathways in isogenic patient-derived and CAG-corrected striatal neurons,
      testing whether the deficit is selective for double-strand break repair
      as it is in mouse glia and whether it scales with repeat length.
  - experiment_id: exp_hd_targeted_dsbr_gene_burden
    name: Targeted DSBR gene burden testing in HD onset cohorts
    description: >-
      Rather than relying on genome-wide significance, test a pre-specified set
      of NHEJ and DSBR genes for association with residual age of onset in
      existing HD GWAS cohorts, which has the power to detect the partial effect
      the authors predict would be missed by an unbiased scan.
  evidence:
  - reference: PMID:42091595
    reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The site-specific increases in CAG tract length are driven by active
      mismatch repair (MMR), while DSBs occur genome-wide and are driven by
      mutant huntingtin-mediated suppression of nonhomologous joining of DNA
      broken ends.
    explanation: >-
      The mouse claim whose human counterpart is unconfirmed.
- discussion_id: gap_hd_dsb_transcriptional_causality
  prompt: >-
    Do accumulating double-strand breaks cause the transcriptional dysfunction
    seen in HD striatal neurons - through error-prone end-joining variants and
    transcription blockade at unrepaired breaks - or do the two simply arise in
    parallel from mutant huntingtin?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Genome-Wide Double Strand Break Accumulation
  - pathophysiology#Transcriptional Dysregulation
  rationale: >-
    The source study is explicit that this was not tested: double-strand break
    accumulation was shown to coincide with transcriptional dysfunction in both
    zQ175 and zQ175/MSH3(-/-) mice regardless of somatic expansion, but no
    experiment established the causal direction. The authors also note a
    tension in their own model - transcriptional changes in HD are reproducible
    between studies, which is difficult to derive from breaks distributed at
    random across the genome. Their proposed resolution is that repair at
    preferred sites (clustered single-strand breaks at neuronal gene enhancers,
    where SAR-seq peaks co-localise with PARP and XRCC1) yields recurrent
    variants while random breaks elsewhere contribute undetectably. The edge
    from Genome-Wide Double Strand Break Accumulation to Transcriptional
    Dysregulation is therefore curated with causal_link_type
    INDIRECT_UNKNOWN_INTERMEDIATES and PARTIAL evidence.
  proposed_experiments:
  - experiment_id: exp_hd_dsb_transcriptome_time_course
    name: Temporal ordering of break burden and transcriptome change
    description: >-
      Dense time-course sampling of matched striatal tissue for break markers
      and RNA-seq in HdhQ(150/150) mice, testing whether break burden rises
      before the transcriptional signature diverges.
  - experiment_id: exp_hd_xjb_transcriptome_endpoint
    name: Break suppression as a transcriptome intervention
    description: >-
      Repeat the XJB-5-131 late-start regimen with striatal RNA-seq as the
      primary endpoint, testing whether lowering break burden corrects the
      transcriptional signature and not only neuron number and motor score.
  - experiment_id: exp_hd_repair_junction_mapping
    name: Map repair junctions against dysregulated genes
    description: >-
      Sequence end-joining repair junctions genome-wide in aged disease striatum
      and test whether somatic variants are enriched at the regulatory elements
      of the genes that are transcriptionally dysregulated, as the clustered-SSB
      hypothesis predicts.
  evidence:
  - reference: PMID:42091595
    reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      DSBs and transcriptional dysfunction occur in animals that cannot
      somatically expand their inherited allele.
    explanation: >-
      Establishes co-occurrence, which is what makes the causal direction an
      open question rather than a settled edge.
- discussion_id: controversy_hd_xjb_effect_on_somatic_expansion
  prompt: >-
    Does XJB-5-131 suppress somatic CAG expansion? Two reports from the same
    laboratory in the same mouse model disagree.
  kind: CONTROVERSY
  status: OPEN
  attaches_to:
  - pathophysiology#Somatic CAG Repeat Expansion
  - pathophysiology#Oxidative Single-Strand to Double-Strand Break Conversion
  rationale: >-
    Budworth et al. 2015 reported that XJB-5-131 inhibits lengthening of the
    repeat tract in HdhQ(150) mice and that this correlated with rescue of motor
    decline, framing the drug as an expansion suppressor. Polyzos et al. 2026
    reports that in congenic HdhQ(150/150) mice the same compound rescues
    neuropathology with no substantial impact on somatic expansion, and uses
    that dissociation as a central argument for double-strand breaks being an
    expansion-independent driver. The two studies differ in zygosity, in the
    congenic background, and above all in treatment window - early dosing in the
    2015 study versus dosing begun at 60 weeks in the 2026 study, by which point
    most expansion has already occurred. A treatment that slows the rate of
    expansion would look effective when started early and ineffective when
    started late, which would reconcile the reports without either being wrong.
    This matters beyond bookkeeping: if XJB-5-131 does suppress expansion under
    some regimens, then the late-start experiment is the only one that cleanly
    separates the two drivers, and the separability argument rests on it alone.
    Curators should not assert either effect as settled.
  evidence:
  - reference: PMID:26247199
    reference_title: "Suppression of Somatic Expansion Delays the Onset of Pathophysiology in a Mouse Model of Huntington's Disease."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      a pharmacological inhibitor, XJB-5-131, inhibits the lengthening of the
      repeat tracks, and correlates with rescue of motor decline in these animals
    explanation: >-
      The 2015 claim that XJB-5-131 inhibits repeat lengthening.
  - reference: PMID:42091595
    reference_title: "Double strand breaks drive toxicity in a Huntington's disease mouse model with or without somatic expansion."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Conversely, suppression of DSBs is sufficient to reverse neuropathology
      even when somatic expansion is active.
    explanation: >-
      The 2026 position that rescue occurs while somatic expansion continues,
      which is in tension with XJB-5-131 acting as an expansion suppressor under
      this regimen.
references:
- reference: PMID:20301482
  title: "Huntington Disease."
  tags:
  - GeneReviews
  findings:
  - statement: >-
      HD manifests typically in adult life but childhood onset does occur, with a median
      survival of 15 to 18 years after onset.
    supporting_text: >-
      HD typically manifests in adult life with mean age of onset around 40-50 years,
      although childhood onset and late onset do occur.
  - statement: >-
      Expansion of the HTT CAG repeat is strongly biased toward paternal transmission,
      while contraction is biased toward maternal transmission. This is the general-HD
      basis of the roughly 80% paternal transmission seen in juvenile-onset disease.
    supporting_text: >-
      Expansion and contraction of CAG repeat length can occur with maternal or
      paternal transmission; however, expansion occurs far more commonly in paternal
      transmission and contraction occurs more commonly in maternal transmission.
datasets:
- accession: ega:EGAS00001006472
  title: Multiple Tissue Monitoring in Huntington disease - RNAseq fibroblasts
  description: We examined whether peripheral tissues can serve as a source of readily accessible biological signatures at the RNA and protein level in Huntington disease (HD) patients. Under the MTM-HD study we generated large, high-quality human datasets from skeletal muscle, skin and adipose tissue, as well as primary human fibroblast lines to probe molecular changes in human pre-manifest and early manifest HD patients. We document the involvement of inflammation, energy metabolism and extracellular vesicle homeostasis. This demonstrates the potential to identify biological signatures from peripheral tissues in HD suitable as biomarkers in clinical trials.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Huntington Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001006473
  title: Multiple Tissue Monitoring in Huntington disease - RNAseq adipose tissue
  description: We examined whether peripheral tissues can serve as a source of readily accessible biological signatures at the RNA and protein level in Huntington disease (HD) patients. Under the MTM-HD study we generated large, high-quality human datasets from skeletal muscle, skin and adipose tissue, as well as primary human fibroblast lines to probe molecular changes in human pre-manifest and early manifest HD patients. We document the involvement of inflammation, energy metabolism and extracellular vesicle homeostasis. This demonstrates the potential to identify biological signatures from peripheral tissues in HD suitable as biomarkers in clinical trials.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Huntington Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001006474
  title: Multiple Tissue Monitoring in Huntington disease - RNAseq skeletal muscle
  description: We examined whether peripheral tissues can serve as a source of readily accessible biological signatures at the RNA and protein level in Huntington disease (HD) patients. Under the MTM-HD study we generated large, high-quality human datasets from skeletal muscle, skin and adipose tissue, as well as primary human fibroblast lines to probe molecular changes in human pre-manifest and early manifest HD patients. We document the involvement of inflammation, energy metabolism and extracellular vesicle homeostasis. This demonstrates the potential to identify biological signatures from peripheral tissues in HD suitable as biomarkers in clinical trials.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Huntington Disease"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: metabolomics_workbench:ST002442
  title: Alterations in CSF Urea Occur in Late Manifest Stage Huntington Disease
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Huntington Disease"). Retrieved 2026-08-02.
- accession: massive:MSV000079178
  title: Integration-independent Transgenic Huntington Disease Fragment Mouse Models
  organism:
    preferred_term: mouse
    term:
      id: NCBITaxon:10090
      label: Mus musculus
  data_type: PROTEOMICS
  description: Data from Integration-independent Transgenic Huntington Disease Fragment Mouse Models Reveal Distinct Phenotypes and Life Span in Vivo CoIP of HTT full length and fragment proteins from mouse cortical lysates. Controlled with preimmune mouse IgG IP.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Huntington Disease"). Retrieved 2026-08-02.
- accession: dbgap:phs000222
  title: PREDICT-HD Huntington Disease Study
  description:  The purpose of this project is to make clinical measurements from the PREDICT-HD consortium available through the dbGaP mechanism. The phenotype data will first be converted into a community open standard and subsequently exported to dbGaP for archival and open access distribution of the results of the studies. This will permit members of the scientific community to utilize a permanent resource for investigating the interactions of phenotypes upon an international cohort of early Huntington Disease.   In  version 2  cut of the data we provided HD CAG repeat lengths for both allele
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Huntington Disease"). Retrieved 2026-08-02.

📚

References & Deep Research

References

1

PMID:20301482

Huntington Disease.

2 findings

HD manifests typically in adult life but childhood onset does occur, with a median survival of 15 to 18 years after onset.

"HD typically manifests in adult life with mean age of onset around 40-50 years, although childhood onset and late onset do occur."

Expansion of the HTT CAG repeat is strongly biased toward paternal transmission, while contraction is biased toward maternal transmission. This is the general-HD basis of the roughly 80% paternal transmission seen in juvenile-onset disease.

"Expansion and contraction of CAG repeat length can occur with maternal or paternal transmission; however, expansion occurs far more commonly in paternal transmission and contraction occurs more commonly in maternal transmission."

Deep Research

1

OpenScientist ▸

Huntington Disease: Comprehensive Disease Characteristics Report

openscientist-autonomous 25 citations 2026-04-07T09:05:30.235049

Huntington Disease: Comprehensive Disease Characteristics Report

Executive Summary

Huntington Disease (HD) is a devastating, autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion (≥36 repeats; full penetrance ≥40) in exon 1 of the huntingtin gene (HTT) on chromosome 4p16.3. The expanded polyglutamine tract in the huntingtin protein — a 3,144 amino acid multifunctional scaffold essential for vesicular transport, transcription, autophagy, and neuronal survival — causes misfolding, aggregation, and toxic gain-of-function, preferentially destroying GABAergic medium spiny neurons (MSNs) in the striatum through eight converging pathogenic mechanisms. HD manifests as a clinical triad of progressive motor dysfunction (chorea evolving to rigidity), cognitive decline progressing to dementia, and psychiatric disturbances, with detectable premanifest changes beginning 15-20 years before motor onset. With a prevalence of approximately 5-7 per 100,000 in Western populations (~30,000 affected in the US), HD remains without disease-modifying therapy, though three VMAT2 inhibitors provide symptomatic chorea relief. The therapeutic landscape is undergoing a paradigm shift following the tominersen trial failure, with the most promising emerging strategies being somatic CAG expansion inhibitors (targeting MSH3/FAN1), allele-selective HTT lowering, and AAV-mediated gene therapy, supported by HD's uniquely organized global research infrastructure.

This report covers 21 sections: genetics, disease identifiers, epidemiology, huntingtin protein biology, molecular pathogenesis, neuropathology, clinical features, premanifest phase, differential diagnosis, diagnosis, current treatment, therapeutic pipeline, animal models, emerging concepts, genetic counseling, psychosocial impact, intermediate alleles, treatment comparison, clinical trial lessons, research infrastructure, and future directions.

1. Genetic Basis

1.1 The HTT Gene and CAG Repeat Expansion

Gene: HTT (Huntingtin), located on chromosome 4p16.3
Mutation: Expansion of a polymorphic CAG trinucleotide repeat in exon 1
Protein product: Huntingtin (HTT), a large ~348 kDa scaffolding protein with roles in vesicular transport, transcriptional regulation, and cell survival
Inheritance: Autosomal dominant with complete penetrance at ≥40 CAG repeats

1.2 CAG Repeat Length Categories

Category	CAG Length	Clinical Significance
Normal	6–26	No risk of HD; stable across generations
Intermediate (mutable normal)	27–35	No HD risk, but may expand in offspring (especially paternal transmission)
Reduced penetrance	36–39	Some individuals develop HD; incomplete penetrance
Full penetrance	≥40	Will develop HD if normal lifespan
Juvenile onset	≥60	Onset typically before age 20; more rigid/akinetic phenotype

1.3 CAG Length and Age of Onset

The CAG repeat length is inversely correlated with age of motor onset and accounts for approximately 50–70% of the variance in onset age. However, the remaining variance is influenced by:

Genetic modifiers: DNA mismatch repair genes (MSH3, FAN1, MLH1, PMS1, PMS2, LIG1)
Somatic CAG expansion: Progressive lengthening of the CAG repeat in somatic cells, particularly in striatal neurons
Environmental factors: Exercise, cognitive reserve, and other lifestyle factors (less well-characterized)

1.4 Anticipation

HD shows genetic anticipation, particularly with paternal transmission. The CAG repeat is unstable during spermatogenesis, leading to potential intergenerational expansions. This explains why juvenile HD cases are more commonly paternally inherited.

2. Disease Identifiers

Database	Identifier
OMIM	143100
MONDO	MONDO:0007739
Orphanet	ORPHA:399
MeSH	D006816
ICD-10	G10
DOID	DOID:12858

3. Epidemiology

3.1 Prevalence

Population	Prevalence per 100,000
North America (Caucasian)	~7.33
Western Europe	~5.70
Australia	~5.63
Finland	~2.12
South America	~1.57
Japan	~0.72
East Asia	~0.40
Sub-Saharan Africa	~0.02

Global estimate: ~2.7 per 100,000 overall
United States: ~30,000 affected individuals; ~200,000 at risk
Trend: Prevalence appears to be increasing in Western countries due to improved diagnosis, genetic testing, longer survival with supportive care, and new mutations from intermediate alleles

3.2 Incidence

Approximately 0.4–0.5 per 100,000 per year in Western populations
Higher in populations with European ancestry

3.3 Population Variation

The marked ethnic/geographic variation in prevalence correlates with the distribution of intermediate and high-normal CAG alleles. Western European populations have a higher proportion of alleles near the pathogenic threshold, providing a reservoir for new mutations through intergenerational expansion.

4. Huntingtin Protein Biology

4.1 Protein Structure

Huntingtin is a large (3,144 amino acids, ~348 kDa) scaffold protein containing: - Polyglutamine (polyQ) tract: Encoded by the CAG repeat in exon 1; normally 6-26 Qs - Proline-rich domain (PRD): Adjacent to polyQ; modulates aggregation propensity - HEAT repeats: Four clusters of α-helical repeat domains forming a solenoid structure; mediate protein-protein interactions - Subcellular localization: Nucleus, cytoplasm, axons, dendrites, perikaryon, and associated with vesicles and organelles

4.2 Normal Functions of Wild-Type Huntingtin

Function	Mechanism	Relevance to HD
Vesicular transport	Scaffold for dynein/kinesin motors on microtubules	mHTT impairs BDNF transport cortex→striatum
Transcription regulation	Interacts with REST/NRSF, CBP, Sp1, TFIID	mHTT sequesters transcription factors → gene silencing
Autophagy	Scaffold for autophagy initiation and cargo recognition	mHTT aggregates overwhelm and impair autophagy
Anti-apoptotic signaling	Sequesters caspase-3; blocks pro-apoptotic HIP-1	Loss of function removes survival signaling
Embryonic development	Essential for gastrulation	HTT knockout is embryonic lethal (E7.5)
Synaptic function	Vesicle recycling and neurotransmitter release	Synaptic dysfunction is an early HD feature

4.3 Key Post-Translational Modifications

Modification	Site	Function	HD Relevance
Phosphorylation	S421 (Akt/SGK)	Neuroprotective; promotes BDNF transport	Lowest in striatum → vulnerability factor (PMID: 18992820)
Phosphorylation	S13/S16	Regulates mHTT clearance	Phospho-mimetic reduces toxicity
Acetylation	K444	Promotes autophagic clearance	Impaired acetylation → mHTT accumulation
Caspase cleavage	D513, D552, D586	Generates N-terminal fragments	Fragments with expanded polyQ are highly toxic
Palmitoylation	C214 (HIP14-mediated)	Membrane targeting/trafficking	Reduced in HD → altered protein trafficking
SUMOylation	K6, K9, K15	Competes with ubiquitination	Alters aggregation and clearance dynamics

Key Insight: The finding that S421 phosphorylation is naturally lowest in striatal neurons provides a molecular explanation for selective vulnerability — these neurons have the least protective modification of HTT, making them most susceptible to mHTT toxicity.

4.4 Signaling Pathways Involving HTT

Wikidata pathway analysis reveals HTT participates in multiple critical signaling cascades: MAPK, Wnt, insulin, TGF-beta, VEGF, apoptosis, PDGF, p38 MAPK, ErbB, toll-like receptor, and inflammatory (IL-1, IL-6, TNF-alpha) pathways. This broad involvement explains why mHTT disruption has such pleiotropic effects.

5. Molecular Pathogenesis

5.1 Mutant Huntingtin Protein (mHTT) Toxicity

The expanded polyglutamine (polyQ) tract causes huntingtin to: 1. Misfold and aggregate → forms intranuclear inclusions and cytoplasmic aggregates 2. Sequester essential proteins → disrupts proteostasis, transcription, and transport 3. Undergo aberrant proteolytic cleavage → generates toxic N-terminal fragments

5.2 Key Pathogenic Mechanisms

Protein aggregation and proteostasis failure: mHTT overwhelms the ubiquitin-proteasome system and autophagy pathways
Transcriptional dysregulation: mHTT interacts with and sequesters transcription factors (CBP, Sp1, TFIID, REST/NRSF), leading to widespread gene expression changes, including downregulation of BDNF and PGC-1α
Mitochondrial dysfunction: Impaired Complex II/III activity, reduced ATP production, increased oxidative stress, defective mitochondrial dynamics (fission/fusion)
Excitotoxicity: Enhanced sensitivity of MSNs to glutamate via NMDA receptors, leading to calcium overload and cell death
BDNF depletion: mHTT impairs BDNF transcription in cortical neurons and disrupts vesicular transport of BDNF along the corticostriatal pathway
Somatic CAG repeat expansion: DNA mismatch repair (MMR) machinery drives progressive lengthening of the CAG repeat in post-mitotic neurons, particularly in the striatum; this is now recognized as a critical determinant of disease onset
Synaptic dysfunction: Altered neurotransmitter release, impaired synaptic plasticity, and progressive corticostriatal circuit disruption
Neuroinflammation: Microglial activation, reactive astrocytosis, and elevated inflammatory cytokines (IL-6, IL-8, TNF-α) in both CNS and periphery

5.3 Selective Neuronal Vulnerability

Medium spiny neurons (MSNs) in the caudate nucleus and putamen are preferentially affected due to: - High excitatory glutamatergic input from cortex - Dependence on BDNF from cortical projections - High metabolic demand and vulnerability to energy deficits - Greater somatic CAG expansion in striatal vs. other brain regions - Expression pattern of DNA repair enzymes promoting instability

The indirect pathway MSNs (D2 receptor-expressing, enkephalin-positive) are affected earliest, followed by direct pathway MSNs (D1 receptor-expressing, substance P-positive), correlating with the clinical progression from chorea to rigidity.

6. Neuropathology

6.1 Vonsattel Grading System

Grade	Pathological Features
Grade 0	No gross atrophy; microscopic neuronal loss in caudate head
Grade 1	Mild caudate atrophy; up to 50% neuronal loss in caudate
Grade 2	Moderate caudate atrophy; striatal atrophy visible grossly
Grade 3	Severe striatal atrophy; marked neuronal loss with astrogliosis
Grade 4	Very severe atrophy; >95% neuronal loss in caudate; cortical atrophy

6.2 Brain Regions Affected (in order of severity)

Caudate nucleus (earliest and most severe)
Putamen
Globus pallidus
Cerebral cortex (layers III, V, VI)
Thalamus, subthalamic nucleus
Hippocampus, cerebellum (later stages)

7. Clinical Features

7.1 The Clinical Triad

Motor Symptoms

Chorea (most characteristic): Involuntary, irregular, non-repetitive movements
Dystonia: Sustained abnormal postures, increases as disease progresses
Bradykinesia/rigidity: Increasingly prominent in later stages
Gait disturbance: Wide-based, unsteady gait; falls are common
Oculomotor abnormalities: Saccade initiation difficulties (often earliest motor sign)
Dysphagia: Swallowing difficulty; aspiration pneumonia is a leading cause of death
Dysarthria: Progressive speech deterioration

Cognitive Symptoms

Executive dysfunction: Impaired planning, mental flexibility, multitasking (earliest cognitive change)
Psychomotor slowing: Reduced processing speed
Visuospatial deficits
Memory impairment: Primarily retrieval-based (vs. encoding-based in Alzheimer's)
Progressive dementia: Inevitable in later stages; subcortical pattern
Cognitive changes may precede motor onset by 10-15 years

Psychiatric Symptoms (often precede motor onset)

Depression: 33–69% of patients; suicide risk elevated 5-10x
Irritability/aggression: Common and distressing for families
Anxiety: 34–61% of patients
Apathy: Increases with disease progression; distinct from depression
Obsessive-compulsive behaviors: 10–52%
Psychosis: Relatively rare (<10%)
Disinhibition and impulsivity

7.2 Other Clinical Features

Weight loss: Progressive, multifactorial (increased energy expenditure, dysphagia, hypothalamic dysfunction)
Sleep disturbances: Circadian rhythm disruption, insomnia, increased sleep latency (prevalence systematically studied; PMID: 41722529)
Autonomic dysfunction: Bowel/bladder issues
Peripheral manifestations: Skeletal muscle wasting, cardiac dysfunction, immune dysregulation

7.3 Disease Stages (Shoulson-Fahn Total Functional Capacity)

Stage	TFC Score	Duration	Key Features
I	11–13	~8 years	Subtle motor/cognitive changes; fully functional
II	7–10	~3 years	Chorea more evident; reduced work capacity
III	3–6	~3 years	Cannot work; needs assistance with finances
IV	1–2	~3 years	Requires substantial assistance with daily living
V	0	Variable	Total dependence; nursing care required

Mean age of motor onset: ~45 years (range: childhood to >70 years) Mean disease duration: 15–20 years from motor onset to death Cause of death: Most commonly aspiration pneumonia, followed by cardiovascular disease and suicide

7.4 Juvenile Huntington Disease (JHD)

Onset before age 20 (approximately 5-10% of cases)
More commonly paternally inherited (CAG expansion during spermatogenesis)
Phenotype differs from adult-onset: rigidity and bradykinesia predominate (vs. chorea)
Additional features: seizures (25-40%), rapid cognitive decline, cerebellar ataxia
Faster progression; mean duration ~8-10 years

8. The Premanifest Phase: A Window for Intervention

HD is unique among neurodegenerative diseases in that gene-positive individuals can be identified decades before clinical onset, enabling detailed characterization of the premanifest phase.

8.1 Timeline of Premanifest Changes

Years Before Motor Onset	Change Detectable
~20 years	Plasma NfL begins to rise above controls
~15-20 years	Subtle striatal (caudate) atrophy on volumetric MRI
~10-15 years	Executive dysfunction and processing speed deficits detectable on neuropsychological testing
~5-10 years	Psychiatric symptoms (depression, irritability, anxiety) may appear
~2-5 years	Subtle motor signs (oculomotor abnormalities, finger tapping irregularities)
0 years	Clinical motor diagnosis (UHDRS Diagnostic Confidence Level 4)

8.2 Key Observational Studies

PREDICT-HD: Demonstrated that cognitive and brain imaging changes are detectable up to 15+ years before motor diagnosis
TRACK-HD/TRACK-ON: Longitudinal study showing progressive striatal atrophy, white matter changes, and cognitive decline in premanifest carriers
ENROLL-HD: World's largest observational study of HD families (>20,000 participants); provides natural history data and machine-learning progression models (PMID: 34870344)

8.3 Therapeutic Implications

The extended premanifest phase, combined with genetic predictability and measurable biomarkers (NfL, volumetric MRI), makes HD uniquely suited for preventive clinical trials. Intervening before irreversible neuronal loss could maximize therapeutic benefit. Current trials (e.g., HD-DCI) are enrolling premanifest carriers based on biomarker-predicted proximity to onset.

9. Differential Diagnosis

9.1 Genetic HD Phenocopies (HTT-Negative)

Approximately 2-40% of patients presenting with an HD-like phenotype test negative for HTT CAG expansion (PMID: 41612618). Key phenocopies include:

Condition	Gene/Mutation	Inheritance	Distinguishing Features
HDL1	PRNP octapeptide repeat insertion	AD	Personality changes, seizures; prion disease
HDL2	JPH3 CTG/CAG expansion	AD	Virtually indistinguishable from HD; common in African ancestry
SCA17	TBP CAG expansion	AD	Prominent ataxia alongside chorea and dementia
C9orf72	GGGGCC repeat expansion	AD	FTD/ALS spectrum features; increasingly recognized HD phenocopy
Chorea-acanthocytosis	VPS13A mutations	AR	Lip/tongue biting, acanthocytes on blood smear
McLeod syndrome	XK gene mutations	X-linked	Acanthocytes, cardiomyopathy, elevated CK
DRPLA	ATN1 CAG expansion	AD	Epilepsy, ataxia; more common in Japan
Benign hereditary chorea	NKX2-1 (TITF1) mutations	AD	Non-progressive; thyroid/lung involvement

9.2 Acquired Causes of Chorea

Condition	Key Diagnostic Features
Sydenham chorea	Post-streptococcal; children; anti-basal ganglia antibodies
SLE/antiphospholipid syndrome	Young women; anti-phospholipid antibodies
Tardive dyskinesia	History of dopamine receptor blocker exposure
Wilson disease	Kayser-Fleischer rings; low ceruloplasmin; liver disease
Anti-NMDAR encephalitis	Young women; psychiatric onset; ovarian teratoma
Polycythemia vera	Elderly; elevated hematocrit
Thyrotoxicosis	Thyroid function abnormalities; reversible

9.3 Diagnostic Algorithm

For patients presenting with chorea ± cognitive/psychiatric features: 1. First-line: HTT CAG repeat testing (definitive for HD) 2. If HTT-negative: Blood smear (acanthocytes), ceruloplasmin/copper (Wilson), thyroid function, ANA/antiphospholipid antibodies 3. If still undiagnosed: Gene panel for HD phenocopies (JPH3, TBP, ATN1, C9orf72, PRNP, VPS13A, XK, NKX2-1) 4. Consider: Brain MRI (caudate atrophy pattern), anti-neuronal antibodies

10. Diagnosis

10.1 Clinical Diagnosis

Based on unequivocal motor signs (chorea or other movement disorder) in the setting of a positive family history
Unified Huntington Disease Rating Scale (UHDRS) for standardized assessment
Diagnostic Confidence Level (DCL) of 4 = motor abnormalities unequivocal and characteristic of HD

10.2 Genetic Testing

Diagnostic testing: PCR-based CAG repeat sizing from blood DNA; ≥36 CAGs confirms genetic diagnosis
Predictive testing: Available for at-risk individuals (50% risk if one parent affected); requires genetic counseling per international guidelines
Prenatal testing: Available via chorionic villus sampling or amniocentesis
Preimplantation genetic testing (PGT): Option for IVF to select unaffected embryos

10.3 Neuroimaging

MRI: Caudate nucleus atrophy (progressive loss of caudate head convexity); measurable years before motor onset
Volumetric MRI: Quantitative striatal volume loss is a sensitive progression biomarker
PET/SPECT: Reduced D2 receptor binding in striatum; reduced glucose metabolism
MR spectroscopy: Altered metabolite profiles (reduced NAA, elevated myo-inositol) in striatum

10.4 Fluid Biomarkers

Biomarker	Specimen	Clinical Utility
Mutant huntingtin (mHTT)	CSF	Pharmacodynamic marker for HTT-lowering therapies
Neurofilament light (NfL)	Plasma/CSF	Neurodegeneration marker; elevated in premanifest HD; tracks progression
GFAP	Plasma/CSF	Not a reliable early marker (PMID: 39891767)
Inflammatory cytokines	Plasma	IL-6, IL-8, TNF-α elevated; correlate with disease burden

11. Current Treatment

11.1 Approved Symptomatic Therapies

Drug	Mechanism	Indication	Year Approved
Tetrabenazine (Xenazine)	VMAT2 inhibitor	Chorea	2008 (FDA)
Deutetrabenazine (Austedo)	Deuterated VMAT2 inhibitor	Chorea	2017 (FDA)
Valbenazine (Ingrezza)	Selective VMAT2 inhibitor	Chorea	2023 (FDA)

11.2 Off-Label and Supportive Treatments

Antipsychotics (olanzapine, risperidone): For chorea, psychosis, aggression
Antidepressants (SSRIs, SNRIs): For depression and anxiety
Benzodiazepines: For anxiety and myoclonus
Physical therapy: Gait training, fall prevention, exercise programs
Speech therapy: For dysarthria and dysphagia management
Occupational therapy: Adaptive strategies for daily living
Nutritional support: High-calorie diets; PEG tube in advanced stages
Palliative care: Increasingly important in advanced disease

11.3 No Disease-Modifying Therapy Is Currently Approved

12. Therapeutic Pipeline and Emerging Strategies

12.1 HTT-Lowering Approaches

Therapy	Type	Status	Notes
Tominersen	Non-selective ASO (intrathecal)	Phase III halted (2021)	Higher doses worsened outcomes; dose-dependent toxicity concerns
WVE-003	Allele-selective ASO (SNP-targeting)	Phase I/II	Targets mHTT-linked SNP; spares wild-type HTT
AMT-130	AAV5-delivered miRNA	Phase I/II	uniQure; one-time striatal injection; targets both HTT alleles
PTC518	Oral splice modulator	Phase II	Promotes HTT exon skipping; oral bioavailability

12.2 Somatic Expansion Inhibitors (Novel Paradigm)

Target: MSH3 (MutSβ complex) — the DNA mismatch repair component that drives somatic CAG expansion
Rationale: GWAS modifier studies show MSH3 variants alter onset age; reducing MSH3 could slow somatic expansion
Status: Multiple preclinical programs; considered the most promising emerging therapeutic approach
FAN1 activation: FAN1 nuclease protects against somatic expansion; activation strategies in development

12.3 Other Approaches

CRISPR gene editing: Direct correction of expanded CAG repeats (preclinical)
Immunotherapy: Targeting extracellular mHTT aggregates
Neuroprotection: BDNF supplementation, mitochondrial enhancers (CoQ10 trials negative)
Cell replacement therapy: iPSC-derived MSN transplantation (very early stage)

13. Animal Models

Model	Type	CAG Length	Key Features
R6/2	Transgenic (exon 1 fragment)	~150	Rapid progression; 12-16 week lifespan; robust phenotype
R6/1	Transgenic (exon 1 fragment)	~115	Slower progression than R6/2
YAC128	Transgenic (full-length)	128	Full-length mHTT; striatal-specific neurodegeneration
BACHD	Transgenic (BAC, full-length)	97	Metabolic phenotype; slower progression
zQ175	Knock-in	~175	Somatic expansion; closest to human genetics
HdhQ111	Knock-in	111	Endogenous promoter; somatic instability
OVT73 sheep	Transgenic	73	Large animal model; closer to human brain size
HD minipig	Knock-in	~124	Large animal; long lifespan for longitudinal studies

14. Key Emerging Concepts

14.1 HD as a Developmental Disorder

Recent evidence suggests mHTT affects brain development, with subtle abnormalities in cortical and striatal organization present from early life, years before clinical onset (PMID: 41252373). This challenges the traditional view of HD as purely a late-onset neurodegenerative disease.

14.2 Somatic Instability as the Central Disease Driver

The recognition that somatic CAG expansion in striatal neurons may be the rate-limiting step in disease onset has fundamentally shifted the therapeutic paradigm. The inherited CAG length sets the stage, but it is the ongoing somatic expansion that ultimately triggers neuronal death.

14.3 Peripheral Pathology

HD is increasingly recognized as a systemic disease, with pathology in skeletal muscle, heart, immune system, and endocrine organs, challenging the CNS-centric view.

14.4 Biomarker-Driven Clinical Trials

NfL in plasma has emerged as a powerful, minimally invasive biomarker that can detect disease-related changes in premanifest HD carriers and may serve as a surrogate endpoint in clinical trials.

15. Genetic Counseling and Predictive Testing

15.1 Predictive Testing Framework

Eligibility: At-risk individuals (typically ≥18 years) with a first-degree relative with confirmed HD
Uptake: Only ~5-20% of at-risk individuals choose predictive testing
International guidelines (HDSA/IHA/WFN) require pre- and post-test genetic counseling
Protocol: Minimum two counseling sessions; psychological assessment; neurological exam; waiting period between sessions; post-result follow-up
"Right not to know": Must be respected; testing of minors is generally discouraged unless medically indicated

15.2 Reproductive Options

Option	Description	Considerations
Natural conception	Accept 50% risk	Informed choice with genetic counseling
Prenatal testing	CVS at 10-12 wks or amniocentesis at 15-18 wks	Requires decision about potential termination
Exclusion testing	Tests linkage without revealing parent's status	Preserves parental autonomy; complex
PGT-M (PGD)	IVF with embryo selection	Avoids termination; costly; not universally available
Gamete donation	Donor egg/sperm from non-carrier	Eliminates genetic risk entirely
Adoption	Non-biological parenting	No genetic risk; availability varies

15.3 Ethical and Legal Considerations

Genetic Information Nondiscrimination Act (GINA, US): Protects against discrimination in health insurance and employment based on genetic information, but does NOT cover life, disability, or long-term care insurance
Duty to warn: Genetic counselors face ethical tensions between patient confidentiality and potential duty to inform at-risk relatives
Incidental findings: Expanded testing panels may reveal HD risk incidentally
Psychological impact of results: Both positive AND negative results can cause psychological distress (survivor guilt, altered family dynamics)

16. Psychosocial Impact and Family Burden

16.1 Impact on Patients

Suicide: Risk 5-10x general population; highest around time of diagnosis and in early-mid stages when awareness is preserved
Depression: Affects 33-69% of patients; both reactive and neurobiological components
Employment: Progressive inability to work; mean retirement ~5-8 years after motor onset
Driving cessation: Usually required within first few years of motor onset
Decision-making capacity: Progressively impaired; advance care planning essential early

16.2 Impact on Families and Caregivers

Caregiver burden: Averages 40-70 hours/week in advanced stages (PMID: 26688844)
Multi-generational impact: Children witness parent's decline while potentially carrying the gene
Relationship strain: Behavioral changes (apathy, irritability, disinhibition) challenge partnerships
Financial impact: Estimated $50,000-$100,000+/year in advanced stages (US); loss of income compounds costs
Caregiver health: Elevated rates of depression, anxiety, and physical health problems

16.3 Support Resources

Huntington's Disease Society of America (HDSA): Centers of Excellence, support groups, social services
European Huntington's Disease Network (EHDN): Research and care coordination
HD Youth Organization (HDYO): Resources specifically for young people impacted by HD
ENROLL-HD: Global observational study providing community and research connection

17. Intermediate Alleles and New Mutations

17.1 Population Genetics of Intermediate Alleles

~2-7% of the general population carries intermediate alleles (27-35 CAGs)
Prevalence varies by ethnicity, highest in Western European populations
Meiotically unstable, especially during spermatogenesis (paternal transmission)
~6-10% chance of expansion into disease range per paternal transmission
Alleles at 33-35 CAGs carry the highest expansion risk

17.2 Clinical Significance

Intermediate allele carriers themselves do NOT develop HD
However, a scoping review (PMID: 41406155) found some evidence of subtle phenotypic features in carriers:
Possible mild cognitive or psychiatric symptoms
Subtle motor signs in some individuals
Clinical significance remains debated; most carriers are fully asymptomatic
Accounts for ~1-3% of HD cases presenting without family history ("sporadic" or "de novo" HD)

17.3 Evolutionary Implications

Intermediate alleles represent a mutation-selection balance: new mutations continuously arise from the intermediate allele pool, maintaining HD in the population despite the reduced reproductive fitness of affected individuals. This also explains why HD prevalence is higher in populations (Western European) with larger proportions of high-normal/intermediate alleles.

18. VMAT2 Inhibitor Treatment Comparison

Based on a Bayesian network meta-analysis (PMID: 41069601):

Feature	Tetrabenazine	Deutetrabenazine	Valbenazine
FDA Approval	2008	2017	2023
Dosing	TID (3x/day)	BID (2x/day)	QD (1x/day)
CYP2D6 metabolism	Significant interaction	Reduced	Minimal
Chorea reduction (UHDRS-TMS)	~5 points	~4.4 points	~3.2 points
Sedation/fatigue	Common (>30%)	Less common	Less common
Depression risk	Boxed warning	Lower risk	Lower risk
Key advantage	Most clinical experience	Better tolerability	Once daily; sprinkle formulation
Formulations	Tablets	Tablets	Capsules + sprinkle (PMID: 41215526)

Clinical Pearl: All three VMAT2 inhibitors are symptomatic only (reduce chorea severity); none modify disease progression. Treatment choice should be individualized based on patient comorbidities, polypharmacy, and tolerance.

19. Lessons from Clinical Trials

19.1 The Tominersen Pivotal Moment

The Phase III GENERATION-HD1 trial of tominersen (Roche/Ionis) — a non-selective antisense oligonucleotide targeting both mutant and wild-type HTT via intrathecal delivery — was halted in March 2021 after an independent monitoring committee found that higher doses worsened clinical outcomes compared to placebo. Key lessons:

Non-selective HTT lowering is risky: Wild-type HTT has essential functions; reducing it below a critical threshold may cause harm
Neuroinflammation from intrathecal delivery: The procedure and drug itself may trigger CNS inflammation independent of target engagement
Dose-response is not linear: Higher doses ≠ better outcomes; there may be a narrow therapeutic window
Patient stratification matters: Younger patients with lower disease burden may respond differently than advanced patients
Biomarker dissociation: mHTT lowering in CSF did not translate to clinical benefit, questioning CSF mHTT as a surrogate endpoint

19.2 Reshaping the Therapeutic Paradigm

Post-tominersen, the field has shifted toward: - Allele-selective ASOs (WVE-003): Target mHTT-linked SNPs to lower only mutant HTT, preserving wild-type function - One-time gene therapy (AMT-130): AAV-delivered miRNA for sustained local HTT lowering in the striatum - Oral small molecules (PTC518): Splice modulators offering non-invasive, titratable dosing - Somatic expansion inhibitors: An entirely different approach that doesn't require HTT protein lowering — targets the upstream DNA instability mechanism - Combination strategies: Multiple complementary mechanisms may ultimately be needed

19.3 Clinical Trial Design Evolution

Composite endpoints (combining motor, cognitive, and functional measures) now preferred over single-domain endpoints
Enrichment designs using biomarker-defined populations (e.g., NfL-stratified)
Longer trial durations to capture disease-modifying effects vs. symptomatic changes
Adaptive platform designs allowing multiple therapies to be tested simultaneously
Digital and remote assessments to reduce patient burden and increase data granularity

20. Research Infrastructure and Community

20.1 Major Research Platforms

Platform	Description	Scale
ENROLL-HD	Global observational study; natural history data	>20,000 participants, 20+ countries
HDSA Centers of Excellence	Specialized multidisciplinary HD clinics	50+ centers in the US
EHDN	European HD clinical research network	Pan-European coordination
CHDI Foundation	Private foundation dedicated to HD drug discovery	>$100M/year funding
HD Clarity	Multi-site CSF biomarker collection	Global CSF repository
HDClarity	Biofluid collection for biomarker research	Standardized protocols
HDYO	HD Youth Organization	Youth-specific resources and support

20.2 Why HD is Uniquely Positioned for Breakthroughs

HD occupies a uniquely favorable position among neurodegenerative diseases for therapeutic development:

Genetic clarity: Single-gene cause with 100% penetrance at ≥40 CAGs — no diagnostic ambiguity
Predictable trajectory: CAG-based onset prediction enables premanifest intervention
Measurable biomarkers: NfL, mHTT, volumetric MRI provide quantitative tracking
Organized community: Global patient registries, advocacy organizations, and research networks
Paradigm disease: Insights benefit all 45+ trinucleotide repeat disorders and neurodegeneration broadly
Animal models: Well-characterized transgenic and knock-in models spanning mice to large animals

21. Limitations and Future Directions

21.1 Limitations of This Report

Prevalence estimates vary across studies and meta-analyses; some regional data may be outdated
The therapeutic pipeline is rapidly evolving; clinical trial statuses change frequently
Mechanistic understanding continues to evolve, particularly regarding the relative contributions of gain-of-function vs. loss-of-function
Psychosocial burden estimates are based primarily on Western healthcare systems
This report relies on published literature and database queries; unpublished clinical trial data may alter some conclusions

21.2 Key Unanswered Questions

Why are striatal MSNs selectively vulnerable despite ubiquitous HTT expression? (Partial answers: S421-P levels, somatic expansion rates, BDNF dependence — but full picture remains unclear)
What somatic CAG expansion threshold triggers neuronal death? This critical question could define therapeutic targets
Can allele-selective HTT lowering avoid tominersen's toxicity while preserving efficacy?
Is there an optimal therapeutic window in the premanifest phase for disease modification?
What is the contribution of wild-type HTT loss-of-function to HD pathogenesis?
Can somatic expansion be therapeutically stopped or reversed in already-expanded neurons?
Do peripheral manifestations (muscle, heart, immune) require separate therapeutic attention?
Can digital biomarkers provide more sensitive and continuous outcome measures than current clinical scales?

21.3 Future Directions

Direction	Timeline	Potential Impact
Somatic expansion inhibitors (MSH3)	2-5 years to clinical trials	Transformative — addresses root cause
Allele-selective ASOs	3-5 years (Phase II/III data)	High — preserves wild-type HTT
Gene therapy (AAV)	3-7 years (Phase II/III)	High — one-time treatment potential
Combination therapies	5-10 years	Highest — multi-mechanism targeting
Precision medicine	5-10 years	Moderate — CAG + modifier genotyping
Digital biomarkers	1-3 years (adoption)	Moderate — continuous monitoring
Cell replacement therapy	10+ years	Uncertain — circuit replacement challenge
Prevention trials in premanifest carriers	5-10 years	Very high — prevent neurodegeneration

References (Selected Key Publications)

Genetics & Pathogenesis

Donaldson et al. (2026) "Huntington disease: somatic expansion, pathobiology and therapeutics." PMID: 41233526
Shin & Hefti (2025) "Huntington's as a developmental disorder." PMID: 41252373
Maiuri et al. (2021) "DNA Repair in HD: Somatic Instability and Alternative Hypotheses." PMID: 33579859
Warby et al. (2009) "Phosphorylation of huntingtin reduces accumulation of nuclear fragments." PMID: 18992820
Ehrnhoefer et al. (2011) "Posttranslational modifications and function of huntingtin." PMID: 21311053

Biomarkers & Natural History

Paulsen et al. (2025) "Systematic Review with Meta-Analysis of Biofluid Markers for HD." PMID: 41081429
Heim et al. (2025) "Serum NfL but not GFAP is a marker of early HD." PMID: 39891767
Rodrigues et al. (2020) "Mutant huntingtin and NfL have distinct longitudinal dynamics." PMID: 33328328
Wild et al. (2015) "Quantification of mHTT in CSF from HD patients." PMID: 25844897
Mohan et al. (2022) "Machine-Learning Derived HD Progression Model." PMID: 34870344

Therapeutics & Clinical Trials

Saade & Mestre (2024) "HD: Latest Frontiers in Therapeutics." PMID: 38861215
Winquist & Church (2025) "Inhibiting CAG repeat expansions as therapeutic strategy." PMID: 41130308
Huang et al. (2025) "VMAT2 inhibitors for HD chorea: network meta-analysis." PMID: 41069601
Giri et al. (2025) "Valbenazine Sprinkle formulation for dysphagia." PMID: 41215526
Rodrigues et al. (2025) "Cholinesterase inhibitors and memantine for HD cognition." PMID: 40791064

Clinical Features & Phenocopies

van Hofslot et al. (2026) "Clinical phenotype of intermediate allele carriers." PMID: 41406155
Cardoso et al. (2026) "Non-Huntington's disease chorea: expanding universe." PMID: 41612618
Schneider & Bird (2016) "HD, HD Look-Alikes, and Benign Hereditary Chorea." PMID: 30713928
Sneddon et al. (2026) "Sleep disturbances in HD and premanifest carriers." PMID: 41722529

Psychosocial & Epidemiology

van Walsem et al. (2022) "Quality of life, utilization, and costs in HD (Norway)." PMID: 36517848
Domaradzki (2015) "Impact of HD on Family Carers." PMID: 26688844

Emerging Science

Maimon (2026) "Huntington's disease is the best investment in neuroscience today." PMID: 41690900
Gavgani & García-Domínguez (2025) "Breakthroughs in AAV-Mediated Gene Therapy for HD." PMID: 41090742
Gulzar et al. (2026) "Therapeutic strategies for HD: current approaches and future." PMID: 40874597
Louessard et al. (2024) "HTT roles in striatal development and neuronal functions." PMID: 38427495

Report compiled: April 2026 | Based on 69+ literature sources, Wikidata SPARQL queries, and domain knowledge 13 confirmed findings recorded in knowledge graph across 5 iterations

Ask OpenScientist

OpenScientist Report

Classifications

Mappings

Definitions

Inheritance

Subtypes

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

External Assertions

Medical Actions

Biochemical Markers

Diagnosis

Progression

Prevalence

Related Datasets

Clinical Trials

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Huntington Disease: Comprehensive Disease Characteristics Report

Executive Summary

1. Genetic Basis

1.1 The HTT Gene and CAG Repeat Expansion

1.2 CAG Repeat Length Categories

1.3 CAG Length and Age of Onset

1.4 Anticipation

2. Disease Identifiers

3. Epidemiology

3.1 Prevalence

3.2 Incidence

3.3 Population Variation

4. Huntingtin Protein Biology

4.1 Protein Structure

4.2 Normal Functions of Wild-Type Huntingtin

4.3 Key Post-Translational Modifications

4.4 Signaling Pathways Involving HTT

5. Molecular Pathogenesis

5.1 Mutant Huntingtin Protein (mHTT) Toxicity

5.2 Key Pathogenic Mechanisms

5.3 Selective Neuronal Vulnerability

6. Neuropathology

6.1 Vonsattel Grading System

6.2 Brain Regions Affected (in order of severity)

7. Clinical Features

7.1 The Clinical Triad

Motor Symptoms

Cognitive Symptoms

Psychiatric Symptoms (often precede motor onset)

7.2 Other Clinical Features

7.3 Disease Stages (Shoulson-Fahn Total Functional Capacity)

7.4 Juvenile Huntington Disease (JHD)

8. The Premanifest Phase: A Window for Intervention

8.1 Timeline of Premanifest Changes

8.2 Key Observational Studies

8.3 Therapeutic Implications

9. Differential Diagnosis

9.1 Genetic HD Phenocopies (HTT-Negative)

9.2 Acquired Causes of Chorea

9.3 Diagnostic Algorithm

10. Diagnosis

10.1 Clinical Diagnosis

10.2 Genetic Testing

10.3 Neuroimaging

10.4 Fluid Biomarkers

11. Current Treatment

11.1 Approved Symptomatic Therapies

11.2 Off-Label and Supportive Treatments

11.3 No Disease-Modifying Therapy Is Currently Approved

12. Therapeutic Pipeline and Emerging Strategies

12.1 HTT-Lowering Approaches

12.2 Somatic Expansion Inhibitors (Novel Paradigm)

12.3 Other Approaches

13. Animal Models